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The field of Palladium-catalyzed C-H activation/functionazation has advanced rapidly in 
the past decade. Owing to unique properties of palladium catalysis, a number of novel 
transformations have been discovered, providing access to various useful synthetic building 
blocks. Meanwhile, the utilities of palladium catalysis have also been demonstrated in the 
synthesis of many biologically and pharmaceutically important molecules, particularly 
polyarylated aromatic and heteroaromatic compounds from readily available materials. 
Moreover, recent years have witnessed an explosive growth in the field of iminium and 
enamine catalysis. A number of novel transformations have been discovered to provide the 
access to various heterocylces. This dissertation describes several novel reactions including 
the palladium-catalyzed reactions via the C-H activation and the enamine catalysis in [3+2] 
cycloaddition reactions.  
Chapter 1 gave a brief introduction to transition metal catalysis in a wide range of 
organic transformations. An evaluation of the current research progress of the palladium-
catalyzed C-H activations and their applications in different synthesis transformations was 
subsequently elucidated with selected examples illustrating the state of the art in this research 
field. 
        Chapter 2 described the coupling of coumarins with alkynes, which proceeded through a 
palladium-catalyzed cascade sequence. This process provided a new route to the synthesis of 
highly substituted cyclopentadiene fused chromones. Postulated reaction pathway was 
explored to elucidate the roles of palladium catalysis in the observed transformation. 
        Chapter 3 disclosed an efficient method of synthesizing benzazepine heterocycles. It 
utilized simple and readily available isatins and alkynes, and employed a direct Pd (II)-
x 
 
catalyzed oxidative cycloaddition. These heterocycles were well tolerated in the reaction, 
which allowing access to a number of unique molecular structures.  
Chapter 4 presented a brief overview of organocatalysis, especially on the development 
of aminocatalysis via iminium and enamine activation.  Morover, the 1,3-dipolar 
cycloaddition reaction  transformed via the iminium and enamine catalysis was specially 
emphasized. Some selected examples were illustrated this development in detailed. 
Chapter 5 showed a general, organocatalytic inverse-electron-demand [3+2] 
cycloaddition reaction between various carbonyls and diazoacetates. The reaction was 
catalyzed by second amines via the enamine activation model to generate substituted 
pyrazoles with high levels of regioselectivity. 
Chapter 6 documented an enamine catalyzed strategy to fully promote the Huisgen [3+2] 
cycloaddition with a broad spectrum of carbonyls and azides to access the efficient assembly 
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Chapter 1 Introduction of Transition Metal Catalysis and Recent 
Research Progress of Palladium-catalyzed C-H Activations 
 
1.1 Transition Metal Catalysis and Related Cross-coupling Reactions 
        Transition metal refers to the group of metals in the middle section of the periodic 
table. The transition metal ions outermost d orbitals are incompletely filled with electrons 
so they can easily give and take electrons. This makes transition metals prime candidates 
for catalysis, either as the metal itself or as a compound based on bonding ability, 
variability of oxidation state and variability of co-ordination number. So the transition 
metal catalysts take an important role in modern organic synthesis (Table 1.1). They 
allow apparently impossible reactions to occur easily. This chemistry complements 
traditional functional-group-based chemistry and significantly broadens the scope of 
organic chemistry. 
        Among the myriad of transition metal catalyzed synthetic transformations, 
transition-metal catalysts catalyzed cross-coupling reactions are particularly valuable 
tools in synthetic chemistry, they are the most convenient ways to install important motif 
in many pharmaceutical relevant and biological active compounds.  The term cross-
coupling reaction refers to the metal-catalyzed coupling of aryl or vinyl halides/triflates 
with organometallic partners (Scheme 1.1). This cross-coupling reaction has been widely 
used both in research laboratories and industrial procedures for the formation of biaryl 
building blocks of complex molecules.
1 
So, the 2010 Nobel Prize in chemistry was 
awarded to Richard F. Heck, Ei-ichi Negishi and Akira Suzuki for their great contribution 
2 
 
to the transition-metal (palladium) catalyzed carbon-carbon bond formation by cross-
coupling reaction.
2
 In the next section, palladium catalyzed cross-coupling reactions are 
specially emphasized and discussed in detail. 
 
Table 1.1 Transition metals catalyzed cross-coupling reactions.
3-16
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1.2 Palladium Catalyzed Cross-coupling Reactions 
                                               
Scheme 1.1 General cross-coupling reaction 
        Palladium-catalyzed cross-coupling of aryl halides and boronic acids (Suzuki 
coupling), organostannanes (Stille), organosiloxanes (Hiyama), organozinc compounds 
(Negishi), Grignard reagents (Kumada-Corriu), alkynes (Sonogashira) or olefins (Heck) 
have found widespread popularity in synthetic chemistry.
6-15
 These reactions involve 
developing methods for connecting aromatic carbon atoms together and developing 
synthetic transformations for making bi(hetero)aryl compounds under mild reaction 
conditions and with high degrees of selectivity. However, despite the structural simplicity 
of biaryl scaffolds and their wide abundance in medicinal agents, natural products and 
electronic materials, the preparation of pre-functional partners still appears to be the a 
challenge in academic and industrial levels.
17-19 
The installation of these pre-functional 
groups such as in Kumada, Negishi, Suzuki-Miyaura and similar cross-coupling reactions 
still involves extra synthetic steps.  The factors, such as the generation of waste after the 
C–C bond formation, the cost associated with undesired reaction byproducts, waste 
disposal from the reagents
 
limit the application scopes of these palladium catalyzed cross-
couping processes.
 
In order to improve the efficiency and atom economy of the process, 
palladium catalyzed C–H bond fuctionalization/activation is developed for the direct 
conversion of C–H bonds into carbon-oxygen, carbon-halogen, carbon-nitrogen, carbon-
4 
 
sulfur, and carbon-carbon bonds, 
20-22 
which has been broadly explored for the past 30 
years.  
 
1.3 Palladium-catalyzed C-H Fuctionalization/Activation 
        In order to demonstrate how the transition-metal can react with C–H bonds to 
produce C–M bonds in the process called C–H fuctionalization/activation and how to 
overcome the high bond dissociation energies (i.e.110 kcal/mol for the H–C6H5), four 
types of mechanisms promoted by transition-metal catalysts will be initially introduced. 
These formed C–M bonds are more active than their C–H counterparts, and they can be 
easily converted to different functional groups.
 23, 24 
Although metal-free C–H 
functionalization is more widely known than the transition-metal counterparts, the 
transition-metal mediated transformations of saturated and unsaturated C–H bonds have 
emerged as a very powerful tool in synthetic chemistry. Model studied reactions of 
unactivated C–H bonds with stoichiometric amounts of transition-metal were identified 
as four main mechanisms for the transformation of C–H bonds into C–M bonds: 
oxidative addition, σ-bond metathesis, electrophilic substitution and 1, 2-addition 
(Scheme 1.2).
 25-29 
                
5 
 
                  
                   
 
Scheme 1.2 Proposed C–H activation mechanisms 
        Different transition metals have been used in the reactions for about one hundred 
years, however, its catalytic version of C–H fuctionalization/activation has only been 
explored for the past several decades, especially the use of palladium catalysis for this 
type of transformation based on its compatibility with different oxidants and ability to 
selectively functionalize cyclopalladated intermediates. These abilities make them 
exceptionally practical for applications in the C–H fuctionalization/activation reactions. 
So, in next section, a brief summary of the palladium-catalyzed C–H 
fuctionalization/activation in recent years are summarized. Direct fuctionalization/ 
activation of alkenyl reactions have been specially emphasized in our investigation and 





1.3.1 Recent Development of Palladium Catalyzed C-H   
Fuctionalization/Activation reactions 
        Various approaches have been used in palladium-catalyzed C-H activation/C-C 
bond formation. In this part, A summary of recent development on palladium-catalyzed 
coupling of C-H bonds with organometallic reagents to form C(sp
2





) – C(sp3) bonds was summarized. A lot of mechanism has been used to 
explain the process of these reactions which could be summarized into four types 






) – H Activation Reactions: PdII/Pd0 and  
Olefination Cycle 
 
Scheme 1.3 Proposed mechanism of C–H bond activation Pd II/Pd0 - catalytic cycle 
7 
 
        The noticeable progress had been made in the development of palladium-catalyzed 
C–H activation/C–C bond forming process in the past several years. Researches in this 
field have largely focused on the discovery of new modes of catalysis and the expansion 
of substrate scope. Currently, C–H bonds activation via PdII/Pd0 catalytic cycle was 
successfully established. Yu and co-workers reported that treated oxazoline 1-1 as a 
directing group can promote C–H activation during an unprecedented coupling process 








Scheme 1.4 Palladium (II)-catalyzed C–H activation with organotin reagents 
        This potential generality of palladium (II)-catalyzed C–H activation by directing 




 catalytic cycle has been further demonstrated by Shi’s research 
group in the coupling of anilides 1-3 with arylsilanses 1-4 (Scheme 1.5). Arylboronic 
acids 1-5 were also explored under similar strategy with these highly reactive anilide 
substrates (Scheme 1.5). 
34, 35
 The versatility and practicality of this model was then 
further explored and improved by using carboxylic acid 1-7 as the directing group and 
potassium aryltrifluoroborates 1-8 as the coupling partners. The use of O2 or air as the 







Scheme 1.5 Palladium (II)-catalyzed C–H activation with organosilane and organoborone      
                    reagents  
 
 
Scheme 1.6 Palladium (II)-catalyzed C–H activation using carboxylic acid as directing     
                    group 
 
        Then more coupling partner was explored, especially focusing on the olefination 
transformations (Scheme 1.7). One of the earliest examples concerns C–H activation of 
benzene 1-10 by Pd(OAc)2 and subsequent carbopalladation and β-hydride elimination to 
afford olefinated arenes 1-12 by Moritani (Scheme 1.8).
 37 
Because of the regioselectivity 
problem of the substrate, the concept of directing group was firstly introduced by de 
Vries and coworker to overcome the problem of regioselectivity (Scheme 1.9).
 38
 The 
usage of the anilide 1-3 substrate afforded high ortho selectivity, benzoquinone is 
9 
 
believed to be crucial for the C–C bond forming step in the reaction, and the usage of 
TsOH was also found to be beneficial in the transformation.
 
 
Scheme 1.7 Proposed mechanism of C–H bonds activation - olefin insertion 
 
                            




               
Scheme 1.9 Palladium (II)-catalyzed ortho olefination of arenes 
 
Scheme 1.10 Palladium (II)-catalyzed olefination of indoles 
        Moreover, different types of substrates were also applied to this type of C–H 
activation such as the indoles. Although the first case of catalytic olefination of indoles 1-




 salts as the reoxidant was reported by Itahara et al 
(Scheme 1.10), several recent studies have advanced this chemistry.
 39
 Notably, the work 
of Ma and Yu, in which allylic acetate 1-19 is cleverly used as the olefin partner and 
avoided the need for an oxidant (Scheme 1.11), 
40 







Scheme 1.11 Palladium (II)-catalyzed oxidant-free olefination of indoles 
        To expand the synthetic utility of directed C–H activation/olefination. A concise and 
general route for the preparation of pyridine ortho-olefination compounds 1-23 from 




Scheme 1.12 Palladium (II)-catalyzed olefination of pyridine N- oxides 
                  
Scheme 1.13 Palladium (II)-catalyzed olefination of quinoline N- oxides 
        Moreover, a recent report by Wu and co-worker described a useful olefination of 
quinoline N–oxides 1-24 (scheme 1.13). 42 The use of the quinoline N–oxides itself was 
crucial for C–H activation in which the N–oxides group was a key element for 
introducing a functional group at the position ortho to the nitrogen atom. Recently, based 
12 
 
on the challenges of selectivity when multiple inequivalent C–H bonds presented in the 
target molecule, Yu and co-worker made great contribution in this area by designing a 
class of easily removable nitrile-containing templates that direct the activation of distal 
meta-C–H bonds (more than ten bonds away) of a tethered arene 1-27. This new mode of 
C–H activation to a weak ‘end-on’ interaction between the linear nitrile group and the 
metal centre made only the meta-C–H activation possible. This new strategy for directing 
remote C–H activation provided a novel route for the preparation of toluene derivatives, 
hydrocinnamic acids, 2-biphenylcarboxylic acids, unnatural amino acids, and drug 
molecules with sophisticated substitution patterns that are difficult to access using 
conventional C–H activation methods. 43 
 


















as the intermediates. In contrast, the involvement of Pd
IV
 complexes as the 





 The first case that involved the Pd
IV
 complexes 1-32 as the 
intermediate was reported by the Tremont and Rhaman. They described the first 
intriguing methylation of ortho C–H bonds in anilide 1-3 (Scheme 1.16). In this work, the 





mechanism was presented .
48 
             
Scheme1.15 Plausible mechanism of C–H bonds activation - PdIV/PdII catalytic cycle 
        The proposed oxidation of palladium (II) to palladium (IV) by MeI was indicated by 
X-ray crystallography. The first case 1-35 was obtained by Canty and co-worker (Scheme 
1.17).
 49
 Recently, Sanford and co-worker got the palladium (IV) complex crystal 1-36 in 





Scheme 1.16 Palladium (II) - catalyzed methylation of anilides and proposed mechanism 
 
Scheme 1.17 X-ray crystallographic structure of palladium (IV) complex 




 cycle mechanism, Sanford and co-worker and Dauglis et al., 
independently designed a more general approach using directed C–H activation and 









cycles, where the 1-38 and 1-41 
took the similar role as the MeI mentioned as above. 
                             
Scheme 1.18 Arylation of C–H bonds by PdII/PdIV cycle 
       Extensively, Daugulis and co-worker discovered that the arylation of C–H bonds can 
be performed via cheap and practical ArI 1-43 under neat conditions or using TFA as the 
solvent (Scheme 1.19).
53





cycle. This conditions also had been applied to the arylation of 
C–H bonds by linkage of pyridyl group to carboxylic acid 1-49/1-51 as the directing 
group (Scheme 1.20) and mechanistic studies to date had been conducted with benzoic 





                      
Scheme 1.19 Arylation of C–H bonds using ArI via PdII/PdIV cycle 
 









1.3.1.3 Palladium (II)-catalyzed C(sp
2
) –H activation: Allylic C–H activation 
       As mentioned above, significant advances in directed C–H arylations and alkylations 
have been made, but non-directed C–H to C–C bond forming processes are more scare.55 
Herein, the recent progress about this research area had been summarized here. The first 
case that mentioned this type of reaction catalyzed by palladium (II) salt 1-54a to activate 
the allylic C(sp
2
) –H bond was reported by White and co-worker (Scheme 1.21-22).56 In 
the palladium (II)-mediated reaction, the DMSO was always considered promoting the 
re-oxidation of Pd (0) with O2.  
 
Scheme 1.21 Mechanism of C–H bonds activation - nucleophilic attack 
        However, in this reaction the authors deduced a crucial role of DMSO that it not 
only altered the reaction pathway selectivity but controlled the reaction regioselectivity. 
18 
 
In seeking to explain the observed reactivity, the π-allypalladium species were described 
as the intermediates in direct allylic alkylation based on the research results.  
 
Scheme 1.22 Pd (II)-catalyze oxidation of terminal olefination to allylic acetate 
 
Scheme 1.23 Pd (II)-catalyze intermolecular allylic allylation 
         Based on this interesting reaction process, Shi and co-worker (Scheme 1.23)
 
surveyed other different types of nucleophiles 1-56 and considered that the π-
allypalladium species was the crucial intermediate in the reaction as well as the BQ 
which was indicated as the vital factor in promoting the reaction via taking role as the 
proton acceptor and an oxidant.
 55
 To expand the synthetic utility of undirected allylic C–
H activation, a range of carbon nucleophiles 1-59 were investigated and the excellent 
yields were got if the substrates had the low pKa value and DMSO still took the crucial 
role in the reaction. This transformation cannot be promoted without the DMSO 
existence in the reaction system (Scheme 1.24).
57 
A recent report by White and co-
workers described a novel nucleophile 1-60 activation strategy for promoting 
19 
 
intermolecular allylic C–H aminaiton that operated via electrophilic Pd (II) catalysis with 
acidic N-tosylcarbamate nucleophiles (pKa<4) (Scheme 1.25).
58 
This strategy employed 
exogenous catalytic amine base to elevate the concentration of anionic carbamate 
nucleophile that is not associated with the Pd counterion, resulting in one of the most 
mild and selective C-H activation.   
 
Scheme 1.24 Pd (II)-catalyze intermolecular allylic C–H alkylation reaction 
 
Scheme 1.25 Intermolecular allylic C–H alkylation reaction with base additives 
         Finally, efforts in establishing different type of ligands to promote the allylic C–H 
activation had yielded unprecedented reactivity (Scheme 1.26).
59 
The usage of a serial of 
designed ligand 1-64 was crucial for the allylic C–H activation especially in absence of 
DMSO, which were previously found to be unreacted without DMSO.  Mechanistic 
studies indicated that the new ligand supported aerobic BQ-free catalytic turnover. It is 
deduced that ancillary ligands facilitate reductive elimination from Pd (II) and thereby 




Scheme 1.26 Pd (II)-catalyze intermolecular aerobic allylic C–H acetoxylation 
 
1.3.2 Recent Development of Palladium Catalyzed C–H Alkynylation 
         C–H fuctionalization/activation reactions presents an attractive and powerful 
strategy for the generation of different types of heteroaromatic compounds, such as 
indoles, carbazoles, benzothiazoles, pyridines and so on. 
60, 61
However, directly C–H 
alkynylatoin and cycloaromatization of alkynes with arenes through C–H bond activation 
forming aromatic rings still consider as challenges. Although Rh-catalyzed annulations of 
phenylazoles with internal alkynes via dual C–H cleavage directed by an ortho-azole 
group using Cu(OAc)2 as an oxidant was successfully established by Miura et al, 
62
 the 
first example of palladium-catalyzed C–H alkynylation to date involved the reaction of 
anilides 1-65 with the bromoalkynes 1-66. A number of substituted anilides could be 
ortho-alkynylated 1-67 in high yield when combined together with silyl-protected 





Scheme 1.27 Pd (II)-catalyzed directed C–H alkynylation 
Subsequently, several highly substituted naphthalenes have been synthesized in 
moderated yields by Wu and co-worker via treatment of electron-rich arenes 1-68 with 
alkynes 1-69 using Pd(OAc)2 as catalyst and AgOAc as oxidant.
64
 This transformation 
promoted via invoking a tetraphenylcyclopentadiened Pd 
IV
 complex 1-71 and following 
by two alkyne insertions, cylization, and Pd
0
 recycling to generate substituted 
naphthalenes (Scheme 1.28).  
         Later, in 2010, Wu’s research group developed an efficient method for the direct 
aromatic ring construction of amides with alkynes catalyzed by Pd(OAc)2 under mild 
conditions. This observation enlarged the methods to construct useful luminescent 
materials (Scheme 1.29).
65 
Recently, Jiao and co-workers described a Pd-catalyzed 
cycloaromatization of biaryls 1-74 with alkynes through dual C–H activation applying O2 
as oxidant 
[34]
.  This method not only provides a new way to construct aromatic ring from 
biaryls and internal alkynes, but also supply an efficient approach for synthesizing 







Scheme 1.28 Palladium-catalyzed sythesis of highly substituted naphthalenes 
 





Scheme 1.30 Palladim-catalyzed cycloaromatization of biaryls with alkynes 
         Within the same year, Jiao et al reported an unprecedented palladium-catalyzed ring 
expansion of indoles with alkynes using O2 as oxidant leading to tetrahydroquinoline 
derivatives 1-78 with highly substituted cyclopentadienyl cores. This transformation 
involves dual C–H activation, one C–C bond cleavage, five new C–C bond formation and 





Scheme 1.31 Palladium-catalyzed ring expansion reactions of indoles with alkynes 
         Although, great progresses in construction of aromatic rings have been reported, 
cycloaromatization of alkynes with different substrates through C–H activation to build 
synthetic and medicinal important polycyclic aromatic compounds still has limited the 
24 
 
scopes and has attracted considerable attention based on their increasing applications in 
related fields. 
 
1.4 Project Objective 
        Huge advances have been made in the field of  palladium catalyzed C–H 
activation/functionalization over the two past decades, Owing to the unique properties of 
palladium catalysis, both the development of novel reactions and the mechanistic study of 
the transformation of C–H to C–C, C–O, C–X, C–N, C–S have been greatly explored. A 
number of novel transformations, as described above, have been discovered, providing 
access to various useful synthetic building blocks. The utilities of palladium catalysis 
have also been demonstrated in the synthesis of many biologically and pharmaceutically 
important molecules, particularly polyarylated aromatic and heteroaromatic compounds 
from readily available materials. 
        Despite great advances in the development of palladium catalyzed C–H activation, 
there are still many challenges that remain to be addressed: a) regioselective arene C–H 
activation. The scope of C–C bond formation via C–H activation reactions would be 
greatly expanded by designing novel ligands to promote C–H activation of 
monosubstituted benzene regioselectively at the meta- or para-positions.  b) The 
application of palladium catalyzed C–H activation to form complex, multifunctional 
substrates, especially directly C–H alkynylation, also remains a key future objective.      
25 
 
        Challenges still exist in these fields, if solved successful, these strategies would pave 
the way for the widespread application of this C–H activation chemistry for late stage 
derivatization of biological, pharmaceutical compounds and advanced materials. 
Therefore, in light of this, how to form complex, multifunctional substrates from 
available materials via the C–H alkynylation will be the aim for further investigation. 
         The main purpose of this project is to explore significant palladium-catalyzed 
methodologies to overcome the mentioned challenges. The specific aspect of this project 
is to use different types of available starting materials via directly alkynylation activation 
to form many potential biologically and pharmaceutically important molecules, 
particularly polyarylated aromatic and heteroaromatic compounds. 
         These results of this project should provide a concise way to synthesize different 
types of important molecules which contain potential biological and pharmaceutical 
activity. Some of these molecules can be treated as functional materials. It may also pave 
the way to explore more detail information of how the palladium catalyst behaves in the 
catalytic cycle during promoting the reactions. 
        Two different types of reactions to form different types of polyarylated aromatic and 
heteroaromatic compounds are explored. There are cyclopentadiene fused chromones, 
and azepine fused isatin. More specifically information will be listed in later two chapters. 
In chapter 2, palladium-catalyzed cascade reactions of coumarins with alkynes will be 







Chapter 2 Palladium-catalyzed Cascade Reactions of 
Coumarins with Alkynes: Synthesis of Highly Substituted 





The coupling of coumarins with alkynes is described, which proceeds through a 
palladium-catalyzed cascade sequence. This process provides a new route to the 






        Polyarylated aromatic compounds are commonly found in functional materials, such 
as semiconductors, fluorescent and luminescent tools and materials.
68
 Owing to the 
importance of such framework, their synthesis has attracted considerable attention in the 
field of material chemistry. Alkynes, an important building block for organic 
transformations, have been utilized to construct polycyclic aromatic compounds via 
conventional synthetic methodologies involving transition metal-catalyzed  ring 
formation reaction.
69,70 
These conventional synthetic methodologies involve transitional 
metal-catalyzed ring construction of an aromatic substrate with two alkynes. However, 
mono- or di- functionalized aromatic substrates, such as aryl halides and aryl boronates 
were required for such reaction. Most recently, C–H activation initiated cyclization 
reactions of alkynes has become an impressive and powerful tool for the construction of 
synthetically useful building blocks, such as indoles, isoquinolines, benzothiazoles, 
pyridines, naphthalenes and other heteroaromatic rings.
71
 Herein, we document a 
palladium-catalyzed cascade reaction of coumarins with alkynes involving C–H bond 
activation process,
72
 which could lead to highly substituted cyclopentadiene fused 
chromone framework. To the best of my knowledge, this is the first report to synthesize 
polysubstituted cyclopenta[b]chromen-9(3H)-one via this novel method. 
        In particular, chromones have been widely employed as important intermediates in 
the synthesis of many natural products and medicinal agents.
73
 They have been found to 











 and antioxidant activities.
79
 Interestingly, they also can serve 
28 
 
as a family of diet medicine because of their health-promoting effects found in the diet of 
humans.
80
 Despite the several existing methods for the synthesis of chromone 
derivatives,
80c 
there still is demand for diverse strategies which can efficiently provide 
variously substituted chromone systems. In this context, the significance of this synthetic 
methodology is highlighted by its correlation to the protocols for the preparation of 
chromone systems. 
 
2.2 Results and Discussion 
2.2.1 Reaction Optimization 
        During our investigation of Pd(OAc)2 (20 mol%) catalyzed cascade reacton of 4-
hydroxy-2H-chromen-2-one (2-1a) with diphenylacetylene (2-2a) in the presence of CuI 
as oxidant in dimethylacetamide (DMA) at 130 
o
C for 24 h,  Cs2CO3  was discovered as 
the most efficient base and it could promote the yield of 2-3a from 24% to 52% (Table 
2.1, entries 1–5).  Subsequently, we examined other reaction parameters by varying 
oxidants, temperatures and the influence of the solvents in order to improve the reaction 
yield. The results were summarized in Table 2.1 and 2-2. In general, the higher reaction 
yields were obtained with CuII oxidants (Table 2.1, entries 10 and 12, 61% and 63%, 
respectively). The presence of other common oxidants, such as oxone, benzoquinone 
(BQ), and K2S2O8, did not favour this process (Table 2.1, entries 16–18, 17–29%). 
Gratifyingly, the best result with regard to reaction yield and time was obtained through 
the condition of 10 mol% Pd(OAc)2 and 5.0 equivalent diphenylacetylene 2-2a (Table 2.1, 
29 
 
entry 13, 79% yield). Changing of the organic solvents from non-polar to polar did not 
show any improvement in the reaction yield and reaction rate (Table 2.2, entries 1–6, 12–
67%). When the reaction was conducted in lower temperature, it proceeded smoothly 
with a lower reaction yield (Table 2.1, entry 14, 110 °C, 69%). Surprisingly, a higher 
reaction temperature did not increase the yield (Table 2.1, entry 14, 150 °C, 77%). 
Table 2.1 Conditions optimization of palladium-catalyzed cascade reactions of 









 CuI 34 
2 KOH CuI 24 
3 NaOAc CuI 25 
4 K2CO3 CuI 34 
5 Cs2CO3 CuI 52 
6 Cs2CO3 AgI 37 
7 Cs2CO3 AgOAc 10 
8 Cs2CO3 CuCl 28 
9 Cs2CO3 CuBr 31 
10 Cs2CO3 CuCl2 61 




        a
 Reaction conditions: 2-1a (0.2 mmol, 1.0 equiv.), 2-2a (0.3 mmol, 1.5 equiv.), 20     
mol% Pd(OAc)2, base (0.4 mmol, 2.0 equiv.), oxidant (0.4 mmol, 2.0 equiv.), DMA (2 mL), 
130 °C, 24 h. 
b
 None of base. 
c
 Isolated yield. 
d
 2-2a (1.0 mmol, 5.0 equiv.), 10 mol% 
Pd(OAc)2. 
e
 110 °C. 
f
 150 °C. 
 




12 Cs2CO3 CuBr2 63 
13
[d]
 Cs2CO3 CuBr2 79 
14
[d, e]
 Cs2CO3 CuBr2 69 
15
[d, f]
 Cs2CO3 CuBr2 77 
16 Cs2CO3 Oxone 29 
17 Cs2CO3 BQ 17 






 Toluene 15 
2
[b]
 DCE 17 
3
[b]
 CH3CN 12 




        a
 Reaction conditions: 2-1a (1.0 equiv.), 2-2a (5.0 equiv.), 10 mol% Pd(OAc)2, 
Cs2CO3 (2.0 equiv.), CuBr2 (2.0 equiv.), solvent (2 mL), 130 
o







2.2.2 Substrate Scope 
        With the optimized conditions in hand, we decided to explore the scope of this 
unprecedented cascade reaction. The substrate scope of Pd(OAc)2 catalyzed cascade 
process of coumarins 2-1b to 2-1o with diphenylacetylene 2-2a was shown in Table 2.3 
and it was found that a wide range of coumarines bearing electron-donating group or 
electron-withdrawing group, as well as naphthalene ring, afforded the desired highly 
substituted cyclopentadiene fused chromones 2-3b to 2-3o in moderate to good yields 
(Table 2.3, 49–86%). Extension of substrate scope was examined using a wide range of 
symmetric and asymmetric diarylacetylenes, as well as heterocyclic ring involved 
asymmetric alkynes (Table 2.4). Moderate to high yields was observed within 24 h 
(Table 2.4, 47–88%). Notably, electron-donating group involved diarylacetylenes gave 
higher yields (Table 2.4, 2-3p to 2-3u and 2-3y, 63–88%). On the other hand, electron-
withdrawing group involved diarylacetylenes led to lower yields (Table 2.4, 2-3v to 2-3x, 
47–62%). 
5 DMSO 56 
6 NMP 67 
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        a
 Reaction conditions: 2-1b to 2-1o (1.0 equiv.), 2-2a (5.0 equiv.), 10 mol% Pd(OAc)2, 














         
a
 Reaction conditions: 2-1a (1.0 equiv.), 2-2b to 2-2k (5.0 equiv.), 10 mol% 




         Moreover, heterocyclic ring tolerated alkyne 2-2z was also proved to be a good 
substrate to afford desired product 2-3z (Table 2.4, 60%, 20 h). Regarding to the 
substrates of asymmetric diarylacetylene (Table 2.4), two regioisomers were obtained 
with ca. 1 : 1 ratio (Table 2.4, 2-3r, 2-3s to 2-3v, and 2-3x to 2-3z). Interestingly, if 
phenyl ring bearing two CF3 groups on meta position or TMS group on para position, an 
excellent ratio of regioisomers could be achieved (Table 2.4, 2-3s and 2-3w, ratio of 
regioisomers: 92:8 and 93:7, respectively). Further investigations on this type of π-
conjugated system for the usage in functional liminescent materials, however, are still in 
progress. 
 
2.2.3 Mechanistic Investigations  
        Postulated reaction pathway is summarized in Scheme 2.1. In the initial step, a 
regioselective direct electrophilic aromatic palladation at the 3-position of the coumarin 
forms a palladium complex I. The subsequent insertion of two diphenylacetylene 
molecules forms a dienylpalladium intermediate III, which will then undergo 
intramolecular 6-exo-dig insertion into coumarin leads to a polycyclic palladium 
intermediate IV. Subsequent trapping by OH group from coumarin generated 
intermediate V. Intermediate V undergoes a set of rearrangements to offer a 
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cyclopentadiene fused intermediate VII. The intermediate VII is transferred to 
intermediate VIII via reductive elimination and Pd
0
 is reoxidized by CuBr2 to regenerate 
the Pd
II 
catalyst for next catalytic cycle. Finally, the desired product 2-3a is obtained via a 
phenyl ring migration. The configuration of the compound was determined by X-ray 









        In summary, we have disclosed an unprecedented palladium-catalyzed cascade 
reaction between coumarins and alkynes. The coupling of coumarins with alkynes in the 
presence of Pd(OAc)2 enabled us to trigger a cascade process to furnish highly substituted 
cyclopentadiene fused chromone framework in moderate to high chemical yields (47–
88%). Studies directed to clarify the functionalities of these compounds as well as the 
extension of this cascade strategy to other substrates is currently underway. 
 
2.4 Experimental Section 
2.4.1 Material and General Methods 





C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or a 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26), carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) was 
used as a reference. Multiplicity was indicated as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). Coupling 
constants were reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in ESI mode and API 3000™ in APCI (Heated 
Nebulizer) mode. All high resolution mass spectra were obtained on a Finnigan/MAT 
95XL-T spectrometer. For thin layer chromatography (TLC), Merck pre-coated TLC 
plates (Merck 60 F254) were used, and compounds were visualized with a UV light at 
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254 nm. Further visualization was achieved by staining with iodine. Flash 
chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh silica 
gel.  






























, 2-2f to 2-2l
83
 were prepared according to literature, respectively. 
 
2.4.2 Representative Procedure for Palladium-catalyzed Reaction    
 
        To a solution of diphenylacetylene 2-2a (178 mg, 1 mmol) and 4-hydroxycoumarin 2-1a 
(32.4 mg, 0.2 mmol) in 2 ml of dimethylacetamide, then Copper (II) bromide (89.2 mg, 0.4 mmol) 
as an oxidant and cesium carbonate (130.3 mg, 0.4 mmol) as an additive were added. The 
reaction mixture was stirred at 130
o
C for 24h. The crude product was purified by column 
chromatography on silica gel, eluted by hexane/EtOAc = 25:1 then 10:1 to afford 70.0 mg (79% 






2.4.3 Analytical Data of Palladium-catalyzed Reaction   
1,2,3,3-tetraphenylcyclopenta[b]chromen-9(3H)-one (2-3a)  
 
1
H NMR (500 MHz, CDCl3): δ  8.31 – 8.19 (m, 1H), 7.55 (dd, J = 11.3, 4.2, 1H), 7.43 – 
7.33 (m, 8H), 7.25 (ddd, J = 14.1, 7.1, 2.2, 9H), 7.01 (t, J = 7.3, 1H), 6.94 (t, J = 7.5, 2H), 
6.83 – 6.75 (m, 2H).; 13C NMR (125 MHz, CDCl3): δ 177.10, 173.36, 155.77, 142.68, 
138.78, 137.52, 134.57, 134.25, 132.78, 130.61, 130.30, 128.91, 128.48, 127.81, 127.43, 
127.35, 126.97, 126.23, 125.29, 125.21, 120.91, 118.22, 69.49.; HRMS (ESI) calcd for 
C36H25O2 [M+H]
+





HNMR (500 MHz, CDCl3) δ 7.96 (s, 1H), 7.32 (ddd, J = 9.6, 7.7, 3.3 Hz, 7H), 7.25 – 
7.16 (m, 10H), 6.95 (t, J =7.4 Hz, 1H), 6.88 (t, J =7.6 Hz, 2H), 6.75–6.67 (m, 2H), 2.35 (s, 
3H).; 
13
C NMR (125 MHz, CDCl3): δ = 177.61, 174.00, 154.57, 142.98, 139.34, 138.11, 
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135.68, 135.13, 134.77, 134.46, 131.12, 130.85, 129.42, 128.96, 128.43, 128.28, 127.93, 
127.87, 127.82, 127.44, 126.11, 125.43, 121.18, 118.49, 69.92, 21.43.; HRMS (ESI) 
calcd for C37H27O2 [M+H]
+





HNMR (500 MHz, CDCl3) δ 8.34 – 7.99 (m, 1H), 7.50 (dd, J =8.6, 2.2 Hz, 1H), 7.47 – 
7.40 (m, 6H), 7.40 – 7.35 (m, 1H), 7.35 (s, 9H), 7.06 (t, J =7.3 Hz, 1H), 6.99 (t, J=7.6, 
2H), 6.86 (dd, J =19.2, 8.0 Hz, 2H), 3.04 (hept, J = 6.8 Hz, 1H), 1.30 (d, J = 6.9 Hz, 6H).; 
13
C NMR (126 MHz, CDCl3) δ 177.20, 173.70, 154.32, 146.25, 142.54, 138.97, 137.70, 
134.71, 134.42, 131.84, 130.70, 130.41, 128.99, 128.53, 127.84, 127.49, 127.42, 127.39, 
127.00, 125.10, 123.06, 120.78, 118.14, 69.53, 33.79, 23.98.; HRMS  (ESI) calcd for 
C39H31O2 [M+H]
+







H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.47–7.38 (m, 6H), 7.36–7.28 (m, 11H), 7.05 
(t, J = 7.4 Hz, 1H), 6.98 (t, J = 7.6 Hz, 2H), 6.81 (d, J = 7.3, 2H), 2.75 (q, J = 7.6 Hz, 2H), 
1.27 (t, J = 7.6 Hz, 3H).; 
13
C NMR (125 MHz, CDCl3) δ 177.63, 174.08, 154.73, 143.00, 
142.03, 139.40, 138.14, 135.17, 134.83, 133.49, 131.15, 130.86, 129.44, 128.97, 128.44, 
128.28, 127.94, 127.87, 127.83, 127.45, 125.57, 124.93, 121.23, 118.58, 69.97, 28.82, 
15.98.; HRMS (ESI) calcd for C38H29O2 [M+H]
+





H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H), 7.45 – 7.38 (m, 6H), 7.34 – 7.27 (m, 9H), 
7.22 (s, 1H), 7.09 – 7.02 (m, 1H), 6.98 (dd, J = 10.4, 4.7, 2H), 6.85 – 6.78 (m, 2H), 2.35 
(s, 6H).; 
13
C (125 MHz, CDCl3) δ 177.33, 174.02, 154.83, 143.63, 142.81, 139.50, 138.23, 
135.24, 134.91, 134.85, 131.16, 130.89, 129.43, 128.94, 128.23, 127.93, 127.84, 127.80, 
127.40, 126.39, 123.56, 121.09, 118.94, 69.90, 20.71, 19.85; HRMS (ESI) calcd for 
C38H29O2 [M+H]
+






H NMR (500 MHz, CDCl3) δ 8.13 (dd, J = 7.9 Hz, 1.1, 1H), 7.46 – 7.39 (m, 7H), 7.34–
7.27 (m, 10H), 7.06 (ddd, J = 6.6, 3.8, 1.2 Hz, 1H), 6.99 (dd, J = 10.4, 4.8 Hz,2H), 6.85 
(dd, J = 5.1, 3.4 Hz, 2H), 2.36 (s, 3H).; 
13
C NMR (125 MHz, CDCl3) δ 177.13, 174.17, 
154.76, 142.89, 139.50, 138.49, 135.14, 134.77, 134.31, 131.16, 130.82, 129.37, 128.91, 
128.26, 128.08, 127.90, 127.86, 127.81, 127.42, 125.63, 125.17, 124.38, 120.97, 77.69, 
77.44, 77.19, 70.13, 15.92.; HRMS (ESI) calcd for C37H27O2 [M+H]
+






H NMR (500 MHz, CDCl3): δ 7.59 (d, J = 3.0 Hz, 1H), 7.33 (ddd, J = 9.6, 7.6, 2.5 Hz, 
6H), 7.28 – 7.18 (m, 10H), 7.10 (dd, J = 9.1, 3.0 Hz, 1H), 6.96 (t, J = 7.3 Hz, 1H), 6.89 (t, 
J = 7.6 Hz, 2H), 6.73 (d, J = 7.4 Hz, 2H), 3.78 (s, 3H).; 
13
C NMR (125 MHz, CDCl3) δ 
177.60, 173.70, 157.54, 151.05, 143.07, 139.31, 138.13, 135.11, 134.82, 131.13, 130.84, 
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129.43, 128.99, 128.31, 127.95, 127.88, 127.83, 127.47, 126.45, 123.12, 120.72, 120.07, 
106.04, 69.89, 56.31.; HRMS (ESI) calcd for C37H27O2 [M+H]
+






H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.9 Hz, 1H), 7.39 (td, J =7.6, 2.7 Hz, 6H), 
7.33 – 7.24 (m, 9H), 7.02 (t, J =7.3 Hz, 1H), 6.94 (dd, J =13.5, 5.9 Hz, 3H), 6.82 – 6.77 
(m, 3H), 3.82 (s, 3H).; 
13
C NMR (125 MHz, CDCl3) δ 177.15, 173.60, 163.97, 157.99, 
142.98, 139.39, 138.11, 135.15, 134.85, 131.14, 130.84, 129.43, 128.99, 128.29, 127.94, 
127.87, 127.84, 127.43, 121.27, 119.51, 114.93, 101.17, 69.86, 56.24.; HRMS (EI) calcd 
for [M+H]
+







H NMR (500 MHz, CDCl3) δ  7.88 (dd, J =8.4, 3.1 Hz, 1H), 7.40–7.36 (m, 7H), 7.31–
7.25 (m, 10H), 7.03 (t, J = 7.4 Hz, 1H), 6.95 (t, J = 7.6 Hz, 2H), 6.79 – 6.76 (m, 2H).; 13C 
NMR (125 MHz, CDCl3) δ 177.97, 172.99, 161.17, 159.21, 152.42, 143.51, 138.97, 
137.85, 134.90, 134.57, 131.10, 130.78, 129.39, 129.06, 128.43, 128.03, 127.99, 127.92, 
127.59, 127.18, 127.12, 121.48, 121.27, 120.91, 120.77, 120.70, 111.76, 111.57, 70.00; 
HRMS (ESI) calcd for C36H24O2F [M+H]
+





H NMR (500 MHz, CDCl3): δ 8.21 (d, J = 8.6, 1H), 7.48–7.35 (m, 8H), 7.35–7.26 (m, 
9H), 7.06 (t, J = 7.3 Hz, 1H), 6.98 (t, J = 7.6 Hz, 2H), 6.81 (d, J = 7.7 Hz, 2H).; 
13
C NMR 
(125 MHz, CDCl3): δ 177.17, 172.68, 155.88, 143.17, 138.88, 138.53, 137.30, 134.44, 
134.13, 130.65, 130.34, 128.92, 128.63, 128.02, 127.62, 127.58, 127.55, 127.47, 127.16, 
126.11, 123.91, 121.29, 118.42, 69.58.; HRMS (ESI) calcd for C36H24O2Cl [M+H]
+
 







H NMR (500 MHz, CDCl3): δ 8.19 (t, J = 4.7 Hz, 1H), 7.51 (dd, J = 8.9, 2.6 Hz, 1H), 
7.39 – 7.33 (m, 7H), 7.31 – 7.24 (m, 9H), 7.05 – 7.00 (m, 1H), 6.95 (dd, J = 10.5, 4.8 Hz, 
2H), 6.77 (t, J = 1.5 Hz, 2H).; 
13
C NMR (125 MHz, CDCl3) δ 177.87, 172.66, 154.62, 
143.66, 138.99, 137.81, 134.93, 134.54, 133.49, 131.80, 131.14, 130.83, 129.42, 129.11, 
128.49, 128.09, 128.03, 127.95, 127.65, 126.91, 126.24, 121.53, 120.45, 70.09.; 
HRESIMS calcd for C36H24O2Cl [M+H]
+






H NMR (500 MHz, CDCl3 ) δ 8.39 (d, J = 2.4 Hz, 1H), 7.69 (dd, J = 8.9, 2.5 Hz, 1H), 
7.39 (qd, J = 5.5, 3.4 Hz, 7H), 7.34 – 7.28 (m, 10H), 7.09 – 7.04 (m, 1H), 6.98 (dd, J = 
10.5, 4.7 Hz, 2H), 6.79 (dd, J = 5.2, 3.4 Hz, 2H).; 
13
C NMR (125 MHz, CDCl3 ) δ 177.82, 
172.50, 155.10, 143.69, 139.02, 137.82, 136.25, 134.96, 134.53, 131.16, 130.83, 129.50, 
129.43, 129.10, 128.48, 128.08, 128.02, 127.93, 127.65, 127.31, 121.63, 120.67, 119.28, 
70.12.; HRESIMS calcd for C36H24O2Br [M+H]
+







H NMR (500 MHz, CDCl3) δ 8.52 (s, 1H), 7.87 – 7.84 (m, 1H), 7.64 (d, J = 7.1 Hz, 2H), 
7.54 – 7.39 (m, 9H), 7.36 – 7.27 (m, 10H), 7.07 (t, J = 7.3 Hz, 1H), 6.99 (t, J = 7.5 Hz, 
2H), 6.83 (d, J = 7.2 Hz, 2H).; 
13
C NMR (125 MHz, CDCl3) δ 177.72, 173.95, 155.72, 
143.28, 139.90, 139.26, 138.91, 138.02, 135.08, 134.73, 132.16, 131.15, 130.87, 129.45, 
129.04, 128.37, 128.26, 127.98, 127.88, 127.61, 127.53, 125.95, 124.66, 121.46, 119.27, 
70.04; HRESIMS calcd for C42H29O2 [M+H]
+





H NMR (500 MHz, CDCl3 ) δ 8.33 (d, J = 8.3 Hz, 1H), 8.26 (d, J  = 8.7 Hz, 1H), 7.91 (d, 
J = 8.0 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.63 – 7.58 (m, 1H), 7.53 
– 7.47 (m, 6H), 7.39 – 7.30 (m, 9H), 7.12 – 7.07 (m, 1H), 7.02 (dd, J = 10.3, 4.7 Hz, 2H), 
6.89 (dd, J = 5.2, 3.4 Hz, 2H).; 
13
C NMR (125MHz, CDCl3 ) δ 176.54, 173.92, 153.47, 
143.55, 139.47, 138.37, 136.07, 135.13, 134.71, 131.24, 130.93, 129.43, 129.11, 128.42, 
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128.01, 127.90, 127.60, 127.53, 125.73, 124.65, 122.58, 122.09, 121.90, 70.23; 
HRESIMS calcd for C20H27O2 [M+H]
+





H NMR (500 MHz, CDCl3) δ 10.17 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 9.1Hz, 1H), 7.89 (d, 
J = 7.9 Hz, 1H), 7.70 (t, J = 7.4 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1H), 7.46 (ddd, J =10.8, 6.8, 
6.1 Hz, 7H), 7.35 – 7.30 (m, 9H), 7.09 – 7.02 (m, 1H), 6.99 (t, J = 7.6 Hz, 2H), 6.82 (d, J 
= 7.4 Hz, 2H).; 
13
C NMR (125 MHz, CDCl3) δ 176.20, 174.81, 157.38, 143.92, 139.78, 
138.14, 135.25, 135.21, 134.98, 131.67, 131.32, 131.22, 130.84, 129.47, 129.33, 129.03, 
128.48, 128.34, 127.97, 127.93, 127.48, 126.95, 123.80, 119.02, 118.30, 69.63; 
HRESIMS calcd for C40H27O2  [M+H]
+







H NMR (500 MHz, CDCl3) δ 8.27 (dd, J =7.9, 1.4 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.40 
(dd, J = 10.4, 6.1 Hz, 2H), 7.33 – 7.29 (m, 6H), 7.13 (m, 6H), 6.81 (d, J = 8.1 Hz, 2H), 
6.75 (d, J = 8.1 Hz, 2H), 2.37 (s, 3H), 2.36 (s, 6H), 2.21 (s, 3H).; 
13
C NMR (125 MHz, 
CDCl3) δ 177.89, 173.91, 156.33, 142.91, 138.56, 137.87, 137.32, 136.88, 135.29, 133.06, 
132.30, 132.24, 130.97, 130.70, 129.64, 129.43, 128.90, 128.68, 128.66, 127.89, 126.79, 
125.97, 125.55, 121.47, 118.72, 69.21, 21.86, 21.58, 21.5.; HRESIMS calcd for C40H33O2 
[M+H]
+





H NMR (500 MHz, CDCl3 ) δ 8.26 (dd, J = 8.0, 1.5 Hz, 1H), 7.60 – 7.54 (m, 1H), 7.41 – 
7.26 (m, 8H), 6.85 – 6.79 (m, 6H), 6.78 – 6.74 (t, J = 9.3 Hz, 2H), 6.54 (t, J = 9.3Hz, 2H), 
3.81 (s, 3H), 3.78 (s, 6H), 3.68 (s, 3H); 
13
C NMR (125 MHz, CDCl3 ) δ 177.96, 173.94, 
159.44, 159.17, 158.68, 156.13, 142.44, 137.35, 133.07, 132.12, 130.47, 130.32, 130.11, 
127.62, 127.34, 126.61, 125.76, 125.52, 121.01, 118.60, 114.26, 113.77, 113.42, 113.33, 
68.32, 55.57, 55.48, 55.31.; HRESIMS (complex as standard) calcd for C40H33O6 [M+H]
+
 




bis(4- methoxyphenyl)-1,3-diphenylcyclopenta[b]chromen-9(3H)-one (2-3r) 
 
                                             a                                                  b 
Ratio of regioisomers 55:45; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.28 
(dd, J = 8.0, 1.6 Hz, 1H), 7.61 – 7.58 (m, 1H), 7.45 – 7.38 (m, 7H), 7.35 – 7.29 (m, 7H), 
6.88 – 6.85 (m, 2H), 6.78 – 6.74 (m, 2H), 6.55 – 6.52 (m, 2H), 3.82 (s, 3H), 3.69 (s, 3H).; 
13
C NMR (125 MHz, CDCl3) δ 177.72, 173.92, 159.65, 158.90, 156.31, 143.13, 138.52, 
138.18, 135.17, 133.19, 132.24, 130.88, 130.68, 129.84, 129.40, 128.98, 128.22, 127.93, 
127.78, 127.43, 126.78, 125.88, 125.65, 121.36, 118.74, 114.42, 113.48, 69.22, 55.72, 
55.44.; HRESIMS (complex as standard) calcd for C38H29O4 [M+H]
+




H NMR (500 MHz, CDCl3 ) δ 8.31 (dd, J = 7.9, 1.5 Hz, 1H), 7.64 – 7.57 (m, 1H), 7.47 – 
7.30 (m, 12H), 7.10 – 6.99 (m, 3H), 6.90 – 6.83 (m, 5H), 3.83 (s, 3H), 3.82 (s, 3H).; 13C 
NMR (125 MHz, CDCl3) δ 177.97, 174.02, 159.60, 159.36, 156.24, 142.57, 138.61, 
138.43, 135.43, 133.22, 132.19, 131.13, 130.62, 129.75, 129.34, 128.92, 128.19, 127.98, 
127.33, 127.07, 126.73, 125.84, 125.67, 121.19, 118.70, 114.36, 113.36, 69.22, 55.66, 
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55.56; HRESIMS (complex as standard) calcd for C38H29O4 [M+H]
+




diphenyl -1,3-bis(4-(trimethylsilyl)phenyl)cyclopenta[b]chromen-9(3H)-one (2-3s) 
 
                                                a                                                b 
Ratio of regioisomers 53:47; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.30 
(dd, J = 8.0, 1.5 Hz, 1H), 7.61 – 7.56 (m, 1H), 7.49 – 7.36 (m, 12H), 7.31 – 7.29 (m, 3H), 
7.06 (t, J = 7.4 Hz, 1H), 6.99 (t, J = 7.6 Hz, 2H), 6.81 (d, J = 1.1Hz, 2H), 0.28 (s, 6H), 
0.28 (s, 6H); 
13
C NMR (125 MHz, CDCl3) δ 177.68, 173.88, 156.28, 143.20, 140.62, 
139.73, 139.32, 138.45, 138.07, 135.19, 135.03, 133.97, 133.25, 132.80, 131.22, 130.03, 
129.44, 129.05, 128.95, 128.78, 128.26, 127.93, 127.44, 126.78, 125.84, 125.70, 121.45, 
118.76, 70.00, -0.59, -0.67.; HRESIMS (complex as standard) calcd for C42H41O2 
Si2[M+H]
+





H NMR (500 MHz, CDCl3 ) δ 8.26 (td, J = 7.7, 1.4 Hz, 1H), 7.58 (ddd, J = 8.6, 7.2, 1.6 
Hz,  1H), 7.47 – 7.36 (m, 11H), 7.34 – 7.28 (m, 5H), 7.12 (d, J = 8.1 Hz, 2H), 6.79 (d, J = 
8.0 Hz, 2H), 0.27 (s, 9H), 0.16 (s, 9H); 
13
C NMR (125 MHz, CDCl3 ) δ 177.65, 173.88, 
156.32, 143.07, 140.62, 139.43, 139.38, 138.47, 138.09, 135.33, 135.08, 133.98, 133.24, 
133.05, 132.86, 130.79, 130.20, 129.52, 128.96, 128.86, 128.46, 128.26, 127.95, 127.90, 
126.77, 125.85, 125.69, 121.49, 118.79, 69.74, -0.67, -0.74; HRESIMS (complex as 
standard) calcd for C42H41O2 Si2[M+H]
+
 633.2640, found 633.2670. 
 
1,3-bis(3,4-dimethylphenyl)-2,3-diphenylcyclopenta[b]chromen-9(3H)-one or 2,3-
bis(3,4-dimethyl phenyl)-1,3-diphenylcyclopenta[b]chromen-9(3H)-one (2-3t) 
 
                                               a                                           b 
Ratio of regioisomers 59:41; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.18 
(dd, J = 8.0, 1.4 Hz, 1H), 7.51 – 7.46 (m, 1H), 7.30 (ddd, J = 8.3, 6.9, 5.4 Hz, 4H), 7.22 – 
7.17 (m, 4H), 6.95 – 6.84 (m, 7H), 6.80 (s, 1H), 6.73 – 6.68 (m, 2H), 2.16 (s, 6H), 2.15 (s, 
6H).; 
13
C NMR (125 MHz, CDCl3) δ 177.67, 173.88, 156.33, 143.00, 139.34, 138.40, 
138.37, 137.83, 137.01, 135.38, 134.76, 133.13, 131.18, 129.97, 129.62, 129.52, 128.87, 
128.49, 128.13, 127.72, 127.23, 126.81, 125.95, 125.58, 121.71, 118.79, 69.89, 21.94, 
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21.84.; HRESIMS (complex as standard) calcd for C40H33O2 [M+H]
+




H NMR (500 MHz, CDCl3 ) δ 8.27 – 8.25 (m, 1H), 7.58 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 
7.43 – 7.37 (m, 6H), 7.29 – 7.26 (m, 7H), 6.98 – 6.95 (m, 3H), 6.66 (s, 1H), 6.32 (s, 1H), 
2.25 (s, 6H), 1.98 (s, 6H); 
13
C NMR (125 MHz, CDCl3 ) δ 177.65, 173.98, 156.38, 
143.70, 138.77, 138.45, 138.30, 137.93, 136.86, 135.15, 134.82, 133.17, 131.27, 130.88, 
130.76, 129.96, 129.67, 129.50, 129.26, 128.99, 128.91, 128.82, 128.15, 127.88, 127.76, 
127.72, 127.40, 127.21, 126.78, 125.94, 125.63, 121.53, 118.81, 69.82, 21.93, 21.64.; 
HRESIMS (complex as standard) calcd for C40H33O2 [M+H]
+
 545.2475, found 545.2486. 
 
1,3-bis(4-ethylphenyl)-2,3-bis(4-hexylphenyl)cyclopenta[b]chromen-9(3H)-one or 2,3-
bis(4-ethyl- phenyl)-1,3-bis(4-hexylphenyl)cyclopenta[b]chromen-9(3H)-one (2-3u) 
 




Ratio of regioisomers 61:39; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.31 
(dd, J = 8.0, 1.6 Hz, 1H), 7.61 – 7.59 (m, 1H), 7.45 – 7.32 (m, 8H), 7.19 – 7.13 (m, 6H), 
6.84 (d, J = 8.2 Hz,  2H), 6.76 (d, J = 8.2Hz, 2H), 2.72 – 2.62 (m, 8H), 2.56 – 2.50 (m, 
2H), 1.42 – 1.25 (m, 18H), 1.19 – 1.14 (m, 2H), 1.01 – 0.89 (m, 6H).; 13C NMR (125 
MHz, CDCl3) δ 178.00, 173.98, 156.31, 144.09, 143.12, 143.07, 142.88, 142.28, 138.52, 
135.46, 135.41, 133.05, 132.61, 132.37, 131.03, 130.72, 129.51, 129.41, 128.88, 128.36, 
127.91, 127.28, 126.76, 125.93, 125.54, 121.44, 118.76, 69.19, 36.32, 36.04, 32.24, 32.17, 
31.66, 31.61, 29.50, 28.88, 28.83, 23.12, 23.07, 15.70, 15.49, 14.58, 14.55; HRESIMS 
(complex as standard) calcd for C52H57O2 [M+H]
+
 713.4353, found 713.4369. 
 
Spectrum data of a and b as complex;
 1
H NMR (500 MHz, CDCl3) δ 8.34 – 8.28 (m, 1H), 
7.58 (m, 2H), 7.45 – 7.32 (m, 7H), 7.24 – 7.06 (m, 6H), 6.94 – 6.89 (m, 1H), 6.83 (d, J = 
8.1 Hz, 2H), 6.76 (d, J = 8.1 Hz, 2H), 2.75 – 2.46 (m, 12H), 1.41 – 1.21 (m, 18H), 0.97 – 
0.87 (m, 6H). 
13
C NMR (125 MHz, CDCl3 ) δ 177.98, 173.96, 171.55, 166.89, 161.64, 
161.54, 156.36, 156.30, 144.60, 144.52, 144.08, 143.49, 143.39, 143.29, 143.21, 142.87, 
142.09, 141.80, 138.45, 135.74, 135.61, 135.49, 135.44, 134.55, 133.05, 132.82, 132.67, 
132.55, 132.48, 132.32, 130.99, 130.84, 130.77, 130.66, 130.31, 130.22, 129.69, 129.49, 
129.39, 129.35, 129.26, 128.86, 128.38, 128.34, 128.27, 128.19, 127.92, 127.85, 127.55, 
127.29, 126.85, 126.76, 126.44, 125.94, 125.54, 125.45, 121.46, 118.75, 118.54, 69.28, 
67.41, 36.04, 35.94, 32.21, 32.17, 32.13, 31.66, 31.64, 31.36, 29.54, 29.49, 29.19, 29.16, 
28.88, 23.09, 23.07, 15.70, 14.56, 14.54, 14.52; HRESIMS (complex as standard) calcd 
for C52H57O2 [M+H]
+




fluoro- phenyl)-1,3-diphenylcyclopenta[b]chromen-9(3H)-one (2-3v) 
 
                                                     a                                       b 
Ratio of regioisomers 51:49; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.27 
(dd, J = 8.0, 1.4 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.43 – 7.29 (m, 11H), 7.08 (t, J = 7.4 Hz, 
1H), 7.02 – 6.94 (m, 6H), 6.78 – 6.75 (m, 2H). ; 13C NMR (125 MHz, CDCl3) δ 176.96, 
173.51, 163.24, 161.37, 161.28, 155.83, 142.86, 137.89, 137.36, 134.34, 133.15, 133.06, 
132.22, 132.16, 130.67, 130.63, 130.61, 130.00, 128.96, 128.80, 128.70, 128.57, 128.10, 
127.74, 127.34, 126.32, 125.47, 125.28, 120.63, 118.29, 115.62, 115.44, 114.57, 114.40, 
68.97; HRESIMS (complex as standard) calcd for C36H23O2F2[M+H]
+




H NMR (500 MHz, CDCl3 ) δ 8.27 (dd, J = 7.9, 1.3 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.44 – 
7.28 (m, 13H), 7.00 (dd, J = 14.5, 5.9 Hz, 2H), 6.79 – 6.74 (m, 2H), 6.69 (t, J = 8.7 Hz, 
2H); 
13
C NMR (125 MHz, CDCl3 ) δ 176.85, 173.38, 163.37, 162.78, 161.39, 160.81, 
155.84, 153.19, 141.50, 139.25, 137.33, 133.95, 133.11, 133.02, 132.30, 132.24, 130.63, 
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130.57, 130.49, 130.30, 128.91, 128.78, 128.76, 128.66, 128.16, 127.71, 127.57, 126.38, 
125.45, 125.34, 120.81, 118.26, 115.71, 115.54, 114.82, 114.65, 68.94; HRESIMS 
(complex as standard) calcd for C36H23O2F2[M+H]
+
 525.1661, found 525.1665. 
 
1,3-bis (4-fluorophenyl)-2,3-diphenylcyclopenta[b]chromen-9(3H)-one or 2,3-bis (3,5-bis 
(trifluoromethyl)phenyl)-1,3-diphenylcyclopenta[b]chromen-9(3H)-one (2-3w) 
 
                                                    a                                  b 
Ratio of regioisomers 73:27; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.34 
(dd, J = 8.2, 1.4 Hz, 1H), 7.87 (s, 1H), 7.85 (s, 2H), 7.79 (s, 3H), 7.72 – 7.69 (m, 1H), 
7.50 – 7.43 (m, 5H), 7.34 – 7.31 (m, 2H), 7.21 (t, J = 7.5 Hz, 1H), 7.11 (t, J = 7.7 Hz, 2H), 
6.70 – 6.67 (m, 2H). ; 13C NMR (125 MHz, CDCl3) δ 175.67, 173.77, 156.34, 144.86, 
140.34, 137.78, 136.30, 135.76, 134.23, 133.09, 132.59, 132.32, 131.33, 131.22, 130.96, 
129.91, 129.53, 129.06, 128.99, 128.93, 127.07, 126.49, 125.50, 124.83, 124.54, 122.66, 
122.37, 121.95, 120.72, 118.74, 70.04.; HRESIMS (complex as standard) calcd for 
C40H21O2F12 [M+H]
+





H NMR (500 MHz, CDCl3 ) δ 8.30 (dd, J = 8.2, 1.5 Hz, 1H), 7.90 (s, 3H), 7.71 – 7.67 
(m, 1H), 7.59 (s, 1H), 7.48 (dd, J = 9 .6, 5.3 Hz, 5H), 7.40 (s, 5H), 7.34 – 7.30 (m, 2H), 
7.16 (s, 2H).; 
13
C NMR (125 MHz, CDCl3 ) δ 175.94, 173.54, 156.37, 143.98, 140.39, 
138.31, 136.38, 135.97, 134.21, 133.05, 132.95, 132.78, 131.92, 131.66, 130.78, 130.23, 
130.16, 129.81, 129.41, 129.30, 128.74, 128.70, 127.02, 126.52, 125.67, 124.44, 124.31, 
122.97, 122.27, 122.15, 121.48, 121.33, 118.71, 69.16.; HRESIMS (complex as standard) 
calcd for C40H21O2F12 [M+H]
+
 761.1344, found 761.1364. 
 
1,3-bis(3-nitrophenyl)-2,3-diphenylcyclopenta[b]chromen-9(3H)-one and 2,3-bis(3- 
nitrophenyl)- 1,3-diphenylcyclopenta[b]chromen-9(3H)-one (2-3x) 
 
                                                 a                                           b 
Ratio of regioisomers 52:48; Spectrum data of a and b as complex: 
1
H NMR (500 MHz, 
CDCl3) δ 8.33 – 8.22 (m, 4H), 8.22 – 8.10 (m, 3H), 7.93 – 7.89 (m, 1H), 7.80 – 7.72 (m, 
2H), 7.72 (s, 2H), 7.66 – 7.60 (m, 3H), 7.53 (dt, J = 20.9, 8.0 Hz, 3H), 7.47 – 7.30 (m, 
20H), 7.20 – 7.15 (m, 2H), 7.12 (t, J = 7.4 Hz, 1H), 7.04 (q, J = 7.8 Hz, 2H), 6.77 – 6.71 
(m, 2H).; 
13
C NMR (125 MHz, CDCl3) δ = 176.43, 176.22, 173.79, 173.60, 156.32, 
156.28, 148.99, 148.82, 148.11, 148.01, 144.40, 142.81, 139.91, 139.87, 139.28, 137.84, 
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136.98, 136.90, 136.41, 136.29, 136.16, 135.85, 135.21, 135.09, 134.01, 133.95, 133.38, 
130.98, 130.48, 130.40, 130.09, 129.88, 129.65, 129.43, 129.31, 129.25, 129.02, 128.94, 
128.87, 128.80, 128.68, 128.44, 126.88, 126.81, 126.32, 126.29, 125.92, 125.63, 125.47, 
125.43, 124.42, 124.32, 123.86, 123.66, 123.12, 122.69, 121.27, 120.91, 118.80, 118.73, 





1,3-di(naphthalen-2-yl)-2,3-diphenylcyclopenta[b]chromen-9(3H)-one or 2,3-di 
(naphthalene -2-yl)-1,3-diphenylcyclopenta[b]chromen-9(3H)-one  (2-3y) 
 
                                                     a                                     b 
Ratio of regioisomers 59:41; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.31 
(d, J = 7.7 Hz, 1H), 7.95 (d, J = 15.5 Hz, 2H), 7.80 (m, 6H), 7.49 (m, 14H), 7.02 (dd, J = 
16.0, 9.1 Hz, 1H), 6.96 – 6.85 (m, 4H). ; 13C NMR (125 MHz, CDCl3) δ 177.17, 173.54, 
155.92, 143.22, 138.94, 137.55, 135.09, 134.66, 133.39, 133.00, 132.92, 132.88, 132.86, 
131.95, 130.75, 129.65, 129.12, 128.65, 128.48, 128.32, 128.24, 128.20, 128.01, 127.66, 
127.58, 127.17, 126.77, 126.74, 126.44, 126.39, 126.29, 125.90, 125.69, 125.44, 125.35, 
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121.30, 118.34, 69.79; HRESIMS (complex as standard) calcd for C44H29O2 [M+H]
+
 
589.2162, found 589.2176. 
 
1
H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 7.7 Hz, 1H), 7.97 (s, 1H), 7.84 – 7.72 (m, 3H), 
7.63 – 7.54 (m, 4H), 7.48 (m, 4H), 7.42 – 7.25 (m, 14H), 6.93 (d, J = 8.5 Hz, 1H). 13C 
NMR (125 MHz, CDCl3 ) δ 177.20, 173.51, 155.90, 142.52, 139.52, 137.56, 135.10, 
134.35, 133.36, 132.91, 132.70, 132.28, 132.22, 130.48, 129.68, 129.15, 128.87, 128.67, 
128.25, 128.16, 128.08, 128.01, 127.63, 127.55, 127.35, 126.90, 126.76, 126.44, 126.36, 
126.29, 125.94, 125.65, 125.43, 125.35, 121.16, 118.32, 69.69.; HRESIMS (complex as 
standard) calcd for C44H29O2 [M+H]
+
 589.2162, found 589.2176. 
 
1,3-diphenyl-2,3-di(thiophen-2-yl)cyclopenta[b]chromen-9(3H)-one or 2,3-diphenyl -1,3- 
di (thio- phen-2-yl)cyclopenta[b]chromen-9(3H)-one (2-3z) 
 
                                                    a                                          b 
Ratio of regioisomers 66:34; Spectrum data of a or b: 
1
H NMR (500 MHz, CDCl3) δ 8.34 
(dd, J = 8.0, 1.6 Hz, 1H), 7.65 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.38 – 
7.34 (m, 5H), 7.28 – 7.25 (m, 2H), 7.22 (t, J =5.8 Hz, 1H), 7.11 (dd, J = 3.9, 2.8 Hz, 3H), 
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7.02 – 6.99 (m, 2H), 6.89 – 6.87 (m, 2H). ; 13C NMR (125 MHz, CDCl3) δ 176.51, 
174.00, 156.07, 143.90, 139.35, 137.80, 135.32, 134.91, 133.53, 132.20, 131.56, 131.04, 
129.24, 128.78, 128.66, 128.33, 128.26, 127.04, 127.01, 126.93, 126.78, 126.00, 125.94, 
125.87, 120.44, 118.71, 66.47; HRESIMS (complex as standard) calcd for C32H21O2S2 
[M+H]
+
 501.0977, found 501.0996. 
 
Spectrum data of a and b as complex: 
1
H NMR (500 MHz, CDCl3 ) δ = 8.35 (d, J = 7.9 
Hz, 2H), 8.25 (d, J = 7.9 Hz, 1H), 7.64 (dt, J = 11.0, 8.6 Hz, 2H), 7.57 – 7.53 (m, 2H), 
7.50 – 7.44 (m, 6H), 7.40 (m, 9H), 7.32 – 7.24 (m, 3H), 7.22 (t, J = 7.3 Hz, 1H), 7.13 (t, J 
= 7.5 Hz, 4H), 7.06 (dd, J = 8.6, 4.5 Hz, 1H), 7.04 – 7.00 (m, 2H), 6.90 (d, J = 7.8 Hz, 
2H), 6.74 (t, J = 4.2 Hz, 1H), 6.60 (d, J = 3.4 Hz, 1H).; 
13
C NMR (125 MHz, CDCl3 ) δ = 
176.49, 176.36, 173.97, 173.91, 156.28, 156.05, 143.89, 139.34, 138.29, 137.78, 137.56, 
137.17, 136.33, 135.30, 134.90, 133.52, 133.45, 132.19, 131.54, 131.04, 130.41, 129.33, 
129.22, 129.10, 129.07, 128.89, 128.77, 128.70, 128.64, 128.59, 128.32, 128.25, 127.03, 
127.00, 126.91, 126.76, 126.67, 126.52, 126.36, 125.99, 125.93, 125.86, 125.74, 120.90, 
120.42, 118.78, 118.69, 66.46, 65.74.; HRESIMS (complex as standard) calcd for 
C32H21O2S2 [M+H]
+







2.4.4 X-Ray Crystallographic Analysis 
        The configuration of the product 2-3a was assigned by X-ray crystallographic 
analysis of a single crystal of 2-3a (Figure 2.1). The configurations of other products 
were assigned by analogy. 
 
Figure 2.1 X-ray structure of 2-3a 
Table 2.5 Crystal data and structure refinement for 2-3a. 
 
Identification code  a427 
Empirical formula  C36 H24 O2 
Formula weight  488.55 
Temperature  223(2) K 
Wavelength  0.71073 Å 
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Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.4946(8) Å a= 90°. 
 b = 9.7428(7) Å b= 92.355(2)°. 
 c = 21.0397(15) Å g = 90°. 
Volume 2559.0(3) Å3 
Z 4 
Density (calculated) 1.268 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 1024 
Crystal size 0.50 x 0.16 x 0.12 mm3 
The ta range for data collection 1.86 to 27.50°. 
Index ranges -14<=h<=16, -12<=k<=12, -27<=l<=25 
Reflections collected 17688 
Independent reflections 5876 [R(int) = 0.0419] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9908 and 0.9624 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5876 / 0 / 343 
Goodness-of-fit on F2 1.092 
Final R indices [I>2sigma(I)] R1 = 0.0600, wR2 = 0.1256 
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R indices (all data) R1 = 0.0817, wR2 = 0.1357 




















Chapter 3 Palladium-catalyzed Oxidative Cycloaddition via C–
H/N–H Activation: Access to Benzazepines 
 
An efficient synthesis of benzazepine heterocycles method was developed. It utilizes 
simple and readily available isatins and alkynes, and employs a direct Pd (II)-
catalyzed oxidative cycloaddition. These heterocycles are well tolerated in the 
reaction, which allowing access to a number of unique molecular structures. The 
significance of benzazepine scaffold as design element should render this method 




        The wealth of nitrogen-containing heterocycles in biologically active molecules has 
attracted chemists to develop increasingly efficient methods toward their synthesis.
84 
Recently, chemists have turn to their attention to solve the finite nature of chemical 
feedstocks coupled with the negative impacts of manufacturing waste.
85
 In this regard, 
directed C–H activation towards the formation of C–C and C–heteroatom bonds has 
received the most attractive and substantial attention because of its sustainable and 
environmentally benign features.
86
 In particular, Pd-catalyzed oxidative cycloaddition of 
alkynes by C–H/N–H bond cleavages have proven reliable to form the corresponding 
nitrogen-containing heterocycles through an atom- and step-economical synthetic 
manner.
87 
In recent elegant reports, Jiao et al. described a direct approach for constructing 
indoles from anilines and alkynes by Pd-catalyzed oxidative C–H/N–H activation, 
involving a five-membered ring cyclization (Scheme 3.1a).
88 
In addition, other transition 
metals (e.g. Ru and Rh) have also been applied to assemble indole and other five-
membered ring structure based nitrogen-containing heterocycles via a similar strategy.
89
  
        More recently, a one-pot Pd-catalyzed C–H/N–H activation of alkynes has been 
reported to facilitate an isoquinolinone synthesis, which including a nitrogen-containing 
six-membered ring formation.
90 
Although these protocols have proved to be effective, as 
demonstrated by their utilization in constructing five- or six-membered ring involved N-
heterocycles, Pd-catalyzed oxidative cyclization for the direct synthesis of a nitrogen-





Scheme 3.1 Pd-catalyzed oxidative cycloaddition for five- to seven-membered ring 
formation, involving a C–H/N–H activation. a) Indole synthesis. b) Isoquinolone synthesis. 
c) Benzazepine synthesis. 
 




        Benzazepines, known as a seven-membered ring based nitrogen-containing 
heterocycles, are ubiquitous bioactive scaffolds which are closely linked to 
pharmaceutical activity, and play a significant role as a structural design element in 
medicinal chemistry.
91 
As exemplified in Figure 3.1, Mozavaptan is used as an orally 
effective, nonpeptide arginine vasopressin V-2 receptor antagonist.
92
 Lotensin is a 
prescription medication that has been licensed for treating high blood pressure 
(hypertension), congestive heart failure, and chronic renal failure by inhibiting 
angiotensin-converting enzyme (ACE) in human subjects.
93 
Anafranil is identified as an 
antiobsessional drug that belongs to the class of pharmacologic agents known as tricyclic 
antidepressants.
94
 Besides anafranil, its analogues, tienopramine and amezepine are also 
classified as antidepressants.
95 
        Reported methods for benzazepine synthesis are mainly requiring multiple synthetic 
steps.
96
 A direct intermolecular and efficient methods starting from simple and readily 
available starting materials would not only enable a new set of accessible scaffolds, but 
also allow additional and late-stage modification of existing compounds having 
biological properties. To address this limitation, we dedicated to utilize a direct C–H/N–
H activation method to construct benzazepine scaffold. We envisioned that such proposed 
strategy could be applied to the efficient production of valuable benzazepine heterocycles 







3.2 Results and Discussion 
3.2.1 Reaction Optimization 
        Our investigation began with the Pd-catalyzed oxidative cycloaddition of isatin 3-1a 
and diphenylacetylene 3-2a to give the corresponding benzazepine 3-3aa (Table 3.1). In 
experiments to optimize reaction parameters, the best results were obtained with a 
catalytic amount of Pd(OAc)2 as catalyst and a stoichiometric amount of AgOAc as 
oxidant in a mixed solvent of MeCN/1,4-Dioxane (v/v = 1:1) (Table 3.2, entry 18). Under 
these conditions, conversion was complete within 24 h at 120 
o
C (entry 18, 83% isolated 
yield). Variation of oxidants (Table 3.1, entries 2–15), or solvents (Table 3.2, entries 1–
18) led to a decrease in chemical yield. The effect of temperature is also summarized in 
Table 3.2 (entries 16–20), a similar yield was achieved at a slightly low temperature (100 
o
C, 81%, entry 18). However, further lowering the temperature led to a slow reaction 
conversion (entries 19–20, 56% and 18%, respectively). Moreover, the ratio of 3-1a/3-2a 
is sensitive to a high degree of conversion. For example, changing the ratio of 3-1a/3-2a 
from 1:5 to 1:3 generated a significant loss of reaction yield Table 3.1 (entries 3 and 4). 
Notably, N2 is likely essential to the reaction. As highlighted in Table 3.1, while the 
reaction carried out in air, only a moderate reaction yield was obtained under standard 















  Yield (%)
[d]
 
1 – – <5 
2 CuI – 16 
3 CuBr – <5 
4 AgCO2CF3 – 28 
5 AgSbF6 – <5 
6 AgI – 20 
7 CuOAc – 35 
8 CuCl2 – <5 
9 CuBr2 – <5 
10 Cu(OAc)2 – 40 
11 BQ
[e]
 – 15 
12 (NH4)2S2O8 – <5 
13 PhI(OAc)2 – 24 
14 Oxone – <5 
15 AgOAc – 77 
16 AgOAc – 38[f] 
17 AgOAc HOAc <5 
18 AgOAc TFA <5 
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19 AgOAc K3PO4 <5 
20 AgOAc K2CO3 <5 
 
        
 a 
Reaction conditions: DMF (2.0 mL), 3-1a (0.2 mmol, 1.0 equiv.), 3-2a (1.0 mmol, 
5.0 equiv.), 10 mol% Pd(OAc)2, 120 °C, 24 h and N2. 
b
 Oxidant (0.4 mmol, 2.0 equiv.). 
c
 
Additive (0.4 mmol, 2.0 equiv.). 
d





 3.0 equiv. of 3-2a used. 
 




Entry Solvent T [°C] Yield [%]
[b]
 
1 MeCN 100 53
[c]
 
2 1,4-Dioxane 100 38 
3 Diglyme
[d]
 120 <5 
4 Acetone 40 <5 
5 Toluene 120 <5 
6 1,4-Dioxane 100 38 
7 DCE
[e]
 100 22 
8 MeOH 80 <5 
9 i-PrOH 100 <5 
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10 DMF 120 77 
11 DMA
[f]
 120 59 
12 DMSO 120 15 
13 NMP
[g]
 120 58 
14 MeCN/DMF (v/v = 1:1) 120 35 
15 MeCN/NMP (v/v = 1:1) 120 28 
16 MeCN/1,4-Dioxane (v/v = 1:1) 120 83 
17 MeCN/1,4-Dioxane (v/v = 1:1) 120 55
[h]
 
18 MeCN/1,4-Dioxane (v/v = 1:1) 100 81 
19 MeCN/1,4-Dioxane (v/v = 1:1) 80 56 
20  MeCN/1,4-Dioxane (v/v = 1:1) 60 18 
 
        
a
 Reaction conditions: solvent (2.0 mL), 1a (0.2 mmol, 1.0 equiv.), 2a (1.0 mmol, 
5.0 equiv.), 10 mol% Pd(OAc)2, AgOAc (2.0 equiv.), 24 h and N2. 
b
 Isolated yield after 
column purification. 
c
 Two rounds. 
d









 Air used to replace N2. 
 
3.2.2 Substrate Scope 
        After identifying the optimized conditions, the scope of istains 3-1 were examined. 
As presented in Table 3.3, the substitution pattern of istains could be varied successfully: 
C5-substituted electron-withdrawing, neutral and electron-donating substituents were 
tolerated and demonstrated remarkably high yields in all cases (3-3ba to 3-3fa, 3-3ja to  
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a
 Reaction conditions: MeCN/1,4-Dioxane (v/v = 1:1) (2 mL), 3-1b to 3-1o (0.2 




3-3ka). Especially substrates with electron-withdrawing and/or electron-donating 
substituents at the 4- or 7-position also showed moderate to high reactivity and afforded 
the corresponding benzazepine products (Table 3.3, 3-3ga to 3-3ha, 3-3la to 3-3oa). To 
further indicate the generality and potential of our approach, a series of alkynes 3-2 were 
explored to react with 3-1a in the reaction. With respect to alkyne substituents, the 
reaction shows broad substrate tolerance among internal alkynes. Electron-rich tolanes 
participate in high yields (Table 3.4, 3-3ab and 3-3ac, 3-3ae and 3-3af) while electron-
deficient systems are somewhat recalcitrant (Table 3.4, 3-3ad and 3-3ah). Heteroaryl, 
ester and aliphatic alkynes are also tolerated (3-3ak, 3-3am, 3-3al). When unasymmetric 
alkynes are employed, two regioisomers are usually observed (3-3ae to 3-3ak). In 
addition, a symmetric diethyl alkyne, 2-butyne was also examined in this system, but 
surprisingly generated an unknown structure (not shown). Gratifyingly, a series of unique 
and unexpected pyrrole fused 3-indolinone structures were obtained with the use of a 
naphthalene-ring based isatin 3-1t under somewhat currently unknown reaction 
mechanism (Table 3.5). Notably, although two molecules of diphenylacetylene 3-2a 
participated in reaction, a combination of one phenyl ring, one carbon atom, and one 
oxygen atom diminished from the desired structure. Surprisingly, when a carbazole 3-1p 
reacted with diphenylacetylene 3-2a, the corresponding carbazole-fused azepine 3-3pa 
was obtained in 87% yield (Scheme 3.1). This finding will greatly enrich the diversity of 





Table 3.4 Scope of alkynes 
[a] 
 
        
a
 Reaction conditions: MeCN/1,4-Dioxane (v/v = 1:1) (2 mL), 3-1a (0.2 mmol, 1.0 
equiv.), 3-2b to 3-2m (1.0 mmol, 5.0 equiv.), 10 mol% Pd(OAc)2, 100 °C, 24 h and N2. 
[b] r.r. was determined by NMR (r.r. = ratio of regioisomers). 
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         a
 Reaction conditions: MeCN/1,4-Dioxane (v/v = 1:1) (2 mL), 3-1t (0.2 mmol, 1.0 
equiv.), 3-2a, 3-2c, 3-2d, 3-2j,  and 3-2o (1.0 mmol, 5.0 equiv.), 10 mol% Pd(OAc)2, 
100 °C, and N2. 
b
 r.r. was determined by NMR (r.r. = ratio of regioisomers). 
c
 Isolated 






Scheme 3.2 Carbazole-fused azepine synthesis 
 
3.2.3 Synthetic transformations of benzazepine 3aa. 
        The multifunctional characteristics of the palladium-catalyzed oxidative 
cycloaddition products can be used in chemoselective transformations to access various 
frameworks with high degrees of adduct 3-3aa was readily converted to polysubstituted 
quinoline 3-4 only by using 2.0 equivalents of meta-chloroperoxybenzoic acid (m-CPBA). 
The structure of polysubstituted quinoline 3-4 was approved by X-ray structure analysis. 
Pleasingly, a common hydrogenation process rapidly triggered a complete conversion 
and afforded an unexpected dimer 3-5 in only 0.5 h.
 
Moreover, the C1–C2 bond cleavage 
proceeded smoothly by a FeCl3 catalyst, affording a mixture of ring opened analogous 3-
7 and 3-8 (ratio = 55:45)
 
bearing an acyl chloride and acyl azide functional group on 
nitrogen, respectively. Notably, a dehydrogenation process, in the presence of Cu(OTf)2 
and AlCl3 as promoters, eventually allowed benzazepine 3-3aa converte to a complex 3-6, 





3.2.4 Control experiment and competition experiment 
        To gain some mechanistic insights into the process of this reaction, control 
experiments were conducted (scheme 3). To address the importance and irreplaceability 
of C7–H and N–H bonds, substrates 3-1q (C7–Cl vs C7–H), 3-1r (N–Me vs N–H) and 3-
1s (oxindole vs isatin 3-1a) were tested and no any desired cycloaddition adducts were 
detected (Scheme 3). This result reveals that C7–H and N–H both are critical reaction 
sites and blocking any of these two sites will cause a failure of the reaction. To further 
understand the effect of the substitution pattern, two competition experiments were 
conducted (Table 3.6). The more electron-rich isatin 3-1f apparently reacted faster than 
more electron-deficient isatin 3-1j (Table 3.6, 3-3fa:3-3ja = 19:11). On the other hand, 
the more electron-rich alkyne 3-2c was more favoured in this oxidative cycloaddition. 
However, the more electron-deficient alkyne 3-2d was failed to generate the targeting 










   Scheme 3.3 Synthetic transformations of benzazepine 3-3aa 
 
        Reaction conditions: a) 3-3aa (0.1 mmol), m-CPBA (0.2 mmol), DCM (2 mL), r.t., 
0.5 h, 85%; b) 3-3aa (0.1 mmol), 10% Pd/C, H2  balloon, THF (2 mL), r.t., 0.5 h, 95%; c) 
3-3aa (0.1 mmol), FeCl3 (0.5 mmol), TMSN3 (2 mmol), DCE (3 mL), 60 
o
C, 6 h, 57%; d) 







Scheme 3.4 Control experiments. 
 
        Reaction conditions: MeCN/1,4-Dioxane (v/v = 1:1) (2 mL), 3-1q to 3-1s (0.2 mmol, 
1.0 equiv.), 3-2a (1.0 mmol, 5.0 equiv.), 10 mol% Pd(OAc)2, 100 
o
C, 24 h and N2. 
 








3.2.5 Mechanistic Investigations  
        On the basis of known transition-metal-catalyzed C–H activation/oxidative 
cycloaddition reactions, a possible mechanism is proposed to the present catalytic 
reaction (Scheme 3.4).  
  Scheme 3.5 Plausible catalytic cycles 
 
 
        The formation of benzazepine 3-3aa can probably start with a palladation of isatin 
3-1a to yield the arylpalladium acetate 3-9 (Scheme 3.4, route A). The followed syn-
addition of arylpalladium acetate 3-9 to diphenylacetylene 3-2a would generate the 
vinylpalladium intermediate 3-10. Then the insertion of another molecule of 3-2a will be 
proceeded to afford the butadienylpalladium intermediate 3-11. Finally, intramolecular 
palladation of 3-11 would lead to palladabenzocycloheptatriene 3-13, which subsequently 
would undergo reductive elimination to yield benzazepine 3-3aa. An alternative pathway 
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could start from the reaction of Pd(OAc)2 with two molecules of diphenylacetylene 3-2a 
to give a proposed palladacyclopentadiene intermediate 3-12 (Scheme 3.4, route B),
97 
which transferring to intermediate palladabenzocycloheptatriene 3-13 by the 
incorporation of isatin 3-1a. Hereafter, a reductive elimination of the 
palladabenzocycloheptatriene 3-13 would lead to the desired benzazepine 3-3aa. 
Simultaneously, the Pd (0) species produced in the reduction/elimination step are 
eventually re-oxidized by the addition of Ag(OAc)2 as oxidant to regenerate Pd(II). 
 
3.3 Conclusions 
        In summary, we have developed an efficient synthesis of benzazepine heterocycles. 
The method utilizes simple and readily available isatins and alkynes, and employs a 
direct Pd (II)-catalyzed oxidative cycloaddition. We found that heterocycles are well 
tolerated in the reaction, which allowing access to a number of unique molecular 
structures. The significance of benzazepine scaffold as design element should render this 
method attractive for synthetic and medicinal chemistry. We believe that this work will 
arouse more research interest in efficient synthesis of other biologically active 
heterocycles. Such studies are actively under way in this laboratory, and more results will 




3.4 Experimental Section 
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3.4.1 Material and General Methods 





C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or a 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26), carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) was 
used as a reference. Multiplicity was indicated as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). Coupling 
constants were reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in ESI mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography 
(TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds were 
visualized with a UV light at 254 nm. Further visualization was achieved by staining with 
iodine. Flash chromatography separations were performed on Merck 60 (0.040-0.063 mm) 
mesh silica gel.  
        Compounds 3-1a, 3-1f, 3-1g, 3-1h, 3-1i, 3-2a, 3-2j, 3-2k, 3-2l and 3-2m were 
commercially available. Compounds 3-1b to 3-1e
98
, 3-1j to 3-1o
98
; 3-2b to 3-2k
99 
were 
prepared according to literature, respectively. 
 
 




        To a solution of diphenylacetylene 3-2a (178.0 mg, 1.0 mmol) and isatin 3-1a (29.4 
mg, 0.2 mmol) in 2.0 ml MeCN/1,4-dioxane (v/v = 1:1), palladium diacetate (4.5 mg, 
0.02 mmol) and silver acetate (66.4 mg, 0.4 mmol) were added. The reaction was 
refluxed at 100 
o
C for 24 h and cooled to room temperature. The reaction mixture was 
extracted with DCM for 3 times, and combined organic layers were then dried over 
anhydrous MgSO4, filtered, and the solvent removed under reduced pressure. The crude 
product was purified by column chromatography on silica gel, eluted by 
hexane/EtOAc=25:1 then 10:1 to afford 81.3 mg (81% yield) of the desired product 3-
3aa as red powder. 
 
        To a solution of diphenylacetylene 3-2a (178 mg, 1 mmol) and 1H-benzo[g]indole-
2,3-dione 3-1t (39.4 mg, 0.2 mmol) in 2.0 ml MeCN/1,4-dioxane (v/v = 1:1) was added 
palladium (II) acetate (4.5 mg, 0.02 mmol) as and silver acetate (66.4 mg, 0.4 mmol). The 
reaction was refluxed at 100 
o
C for 30 h and then cooled to room temperature. The 
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reaction mixture was extracted with DCM three times. The combined organic phases 
were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
The crude product was purified by silica gel flash chromatography and eluted by 
hexane/EtOAc=25:1 then 10:1 to afford 56.3 mg (63 % yield) of the desired product 3-
3ta as dark red powder. 
 
3.4.3 Competition Experiments. 
 
 
        To a solution of diphenylacetylene 3-2a (178.0 mg, 1.0 mmol), 5-methoxyisatin 3-1f 
(35.4 mg, 0.2 mmol) and 5-chloroisatin 3-1j (36.2 mg, 0.2 mmol) in 2.0 ml MeCN/1, 4-
dioxane (v/v = 1:1) was added palladium diacetate (4.5 mg, 0.02 mmol) as catalyst and 
silver acetate (66.4 mg, 0.4 mmol) as an oxidant. The reaction was refluxed at at 100 
o
C 
for 12 h. The reaction mixture was cooled to room temperature and extracted with DCM 
three times. The combined organic phases were dried over anhydrous MgSO4, filtered, 
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and concentrated under reduced pressure. The crude product was purified by silica gel 
flash chromatography and eluted by hexane/EtOAc = 50:1 then 5:1 to afford 3-3fa (20.2 
mg) and 3-3ja (11.4 mg) respectively.  
        To a solution of bis (4 - methoxyphenyl) acetylene 3-2c (238 mg, 1 mmol), bis (4 - 
chlorophenyl) acetylene 3-2d (246.0 mg, 1.0 mmol) and isatin (29.4 mg, 0.2 mmol) in 2.0 
ml MeCN/1, 4-dioxane (v/v = 1:1) was added palladium (II) acetate (4.5 mg, 0.02 mmol) 
as catalyst and silver acetate (66.4 mg, 0.4 mmol) as an oxidant. The reaction was 
refluxed at 100 
o
C for 24 h. The reaction mixture was cooled to room temperature and 
extracted with DCM three times. The combined organic phases were dried over MgSO4, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
silica gel flash chromatography and eluted by hexane/EtOAc = 25:1 then 3:1 to afford 3-
3ac (43.0 mg) and 3-3ax (32.0 mg) respectively. 
 




        To a stirred solution of 3-3aa (50.1 mg, 0.1 mmol) in DCM (2.0 mL) was added m-
CPBA (0.2 mmol). The resulting mixture was stirred at r.t. for 0.5 h. After the conversion 
was complete indicated by TLC, the solvent was removed by evaporation and the residue 
was purified by silica gel flash chromatography and eluted by hexane/EtOAc=20:1 to 






        To a stirred solution of 3-3aa (50.1 mg, 0.1 mmol) in THF (2.0 mL) was added Pd/C 
(10 % w/w). The resulting mixture was stirred at r.t. for 0.5 h under H2 balloon. After 
complete conversion as indicated by TLC, the solvent was removed by evaporation and 
the residue was directly purified by silica gel flash chromatography and eluted by 











        To a mixture of copper (II)-trifluoromethanesulfonate (1.64 g, 4.5 mmol) and 
aluminum chloride (667 mg, 5 mmol) in carbon disulfide (10 mL), 3-3aa (50.0 mg, 0.1 
mmol) was added. After stirring at room temperature for 24 h under N2, the mixture was 
poured into H2O and extracted with DCM three times. The combined organic phases 
were dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
The crude product was purified by silica gel flash chromatography and eluted by 
hexane/EtOAc = 20:1 then 4:1 to afford 30.2 mg of product 3-6 (61 % yield) as dark 
green powder. 
 
Product 3-7 and 3-8 
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        To a stirred solution of 3-3aa (50.1 mg, 0.1 mmol) in 1, 2-dichloroethane (3.0 mL) 
were added TMSN3 (2.0 mmol) and FeCl3 (0.5 mmol). The resulting mixture was stirred 
at 60 
o
C for 6 h. After complete conversion as indicated by TLC, the solvent was 
removed by evaporation and the residue was diluted with water and extracted with ethyl 
acetate (3 x 10.0 mL). The combined organic layers were dried over anhydrous MgSO4 
and concentrated in vacuo. The resulting product was purified by column 
chromatography on silica gel using hexane/ ethyl acetate (20:1) as eluent to afford the 3-7 
and 3-8 as a complex (30.4 mg, 57 %). 
 
 







H NMR (300 MHz, CDCl3): δ 7.56 (dd, J = 7.3, 1.2 Hz, 1H), 7.23 – 6.92 (m, 18H), 6.79 
– 6.75 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 181.83, 161.85, 160.11, 145.38, 141.57, 
140.51, 140.24, 139.62, 138.22, 137.25, 135.87, 131.39, 130.79, 130.76, 130.67, 130.42, 
128.39, 128.27, 128.19, 127.58, 127.48, 127.07, 126.86, 126.27, 124.68, 121.71; HRMS 
(ESI) calcd for C36H24NO2 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.37 (s, 1H), 7.13 – 6.87 (m, 17H), 6.72 (m, 4H), 2.24 (s, 
3H); 
13
C NMR (125 MHz, CDCl3): δ 182.03, 162.12, 158.11, 145.26, 142.09, 140.59, 
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140.49, 140.37, 139.55, 138.33, 136.91, 136.23, 135.88, 131.42, 130.77, 130.70, 130.53, 
130.41, 128.34, 128.24, 128.14, 127.55, 127.44, 127.41, 127.01, 126.79, 124.93, 121.79, 
21.30; HRMS (ESI) calcd for C37H26NO2 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.42 (t, J = 9.9 Hz, 1H), 7.13 – 6.90 (m, 17H), 6.79 – 6.72 
(m, 4H), 2.76 (hept, J = 6.9 Hz, 1H), 1.14 (d, J = 6.9 Hz, 6H); 
13
C NMR (125 MHz, 
CDCl3): δ 182.14, 162.05, 158.30, 147.15, 145.00, 140.57, 140.42, 140.39, 139.71, 
138.36, 136.90, 135.90, 131.47, 130.79, 130.75, 130.63, 130.43, 128.25, 128.21, 128.11, 
127.53, 127.43, 127.40, 127.00, 126.79, 122.29, 121.69, 33.84, 23.91; HRMS (ESI) calcd 
for C39H30NO2 [M+H]
+








H NMR (500 MHz, CDCl3): δ 7.54 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 2.0 Hz, 1H), 7.13 – 
6.97 (m, 10H), 6.93 – 6.88 (m, 6H), 6.76 – 6.73 (m, 4H), 1.15 (s, 9H); 13C NMR (125 
MHz, CDCl3): δ 182.24, 161.96, 158.02, 149.53, 144.83, 140.65, 140.44, 140.33, 139.89, 
139.57, 138.44, 136.87, 135.92, 131.50, 130.77, 130.47, 130.39, 128.24, 128.19, 128.10, 
127.53, 127.45, 127.39, 126.99, 126.80, 121.46, 121.32, 35.05, 31.28; HRMS (ESI) calcd 
for C40H32NO2 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.34 (d, J = 1.6 Hz, 1H), 7.13 – 6.95 (m, 11H), 6.93 – 
6.88 (m, 7H), 6.76 – 6.72 (m, 4H), 2.44 (t, J = 7.6 Hz, 2H), 1.54 – 1.44 (m, 2H), 1.31 – 
1.16 (m, 8H), 0.92 – 0.85 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 182.09, 
162.07, 158.26, 145.11, 141.75, 141.22, 140.61, 140.54, 140.41, 139.70, 138.38, 136.95, 
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135.92, 131.47, 130.79, 130.75, 130.57, 130.45, 128.29, 128.21, 128.12, 127.54, 127.44, 
127.39, 127.01, 126.80, 124.31, 121.75, 35.44, 32.16, 31.23, 29.48, 29.24, 23.08, 14.54; 
HRMS (ESI) calcd for C43H38NO2 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.14 – 7.00 (m, 11H), 6.96 – 6.88 (m, 6H), 6.76 – 6.72 (m, 
5H), 3.73 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 182.06, 162.21, 158.22, 154.23, 
145.80, 140.76, 140.34, 140.27, 139.12, 138.28, 136.66, 135.78, 132.17, 131.43, 130.69, 
130.60, 130.42, 128.89, 128.42, 128.25, 128.18, 127.56, 127.47, 127.02, 126.85, 122.10, 
107.20, 56.34; HRMS (ESI) calcd for C37H26NO3 [M+H]
+









H NMR (500 MHz, CDCl3): δ 7.06 – 6.96 (m, 14H), 6.82 – 6.80 (m, 5H), 6.73 – 6.70 (m, 
2H), 2.61 (s, 3H), 1.79 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 181.86, 164.20, 163.56, 
151.74, 145.31, 141.89, 141.57, 140.05, 139.67, 139.32, 137.77, 137.56, 135.57, 131.47, 
131.30, 131.26, 130.95, 130.38, 128.24, 128.18, 127.85, 127.63, 127.44, 127.35, 127.03, 








H NMR (500 MHz, CDCl3): δ 7.05 – 6.88 (m, 16H), 6.76 – 6.74 (m, 2H), 6.70 – 6.68 (m, 
2H), 4.35 (s, 3H), 3.77 (s, 3H), 3.21 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 176.84, 
163.06, 162.44, 159.32, 155.81, 143.82, 142.14, 141.56, 141.18, 139.42, 138.14, 137.78, 
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137.66, 135.62, 131.38, 131.29, 130.29, 130.23, 130.09, 128.26, 128.20, 127.67, 127.55, 
127.37, 127.27, 126.90, 126.81, 118.13, 109.23, 63.38, 61.74, 60.97; HRMS (ESI) calcd 
for C39H30NO5 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.24 (dd, J = 5.8, 2.6 Hz, 1H), 7.21 – 6.89 (m, 17H), 6.76 
– 6.74  (m, 4H); 13C NMR (125 MHz, CDCl3): δ 181.27, 161.84, 161.64, 159.87, 156.06, 
146.78, 140.72, 139.98, 139.88, 138.68, 137.90, 137.22, 135.56, 132.93, 132.88, 131.33, 
130.59, 130.45, 130.40, 128.63, 128.34, 127.86, 127.77, 127.65, 127.56, 127.19, 127.04, 











H NMR (500 MHz, CDCl3): δ 7.52 (d, J = 2.1 Hz, 1H), 7.19 – 6.92 (m, 17H), 6.76 – 
6.73 (m, 4H.; 
13
C NMR (125 MHz, CDCl3): δ 180.88, 161.24, 158.33, 146.75, 140.53, 
140.45, 139.95, 139.80, 138.69, 137.86, 137.28, 135.52, 132.52, 132.35, 131.31, 130.62, 
130.47, 130.39, 128.64, 128.36, 127.81, 127.66, 127.54, 127.21, 127.04, 124.14, 122.24; 
HRMS (ESI) calcd for C36H23Cl NO2 [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.55 (dd, J = 7.4, 1.2 Hz, 1H), 7.18 – 6.99 (m, 11H), 6.96 
– 6.91 (m, 6H), 6.77 – 6.74 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 181.89, 161.81, 
160.22, 145.31, 141.49, 140.55, 140.41, 140.23, 139.57, 138.21, 137.28, 135.97, 131.41, 
130.80, 130.78, 130.68, 130.49, 128.40, 128.28, 128.22, 127.59, 127.49, 127.47, 127.10, 
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H NMR (500 MHz, CDCl3): δ 7.12 (t, J = 7.3 Hz, 2H), 7.10 – 6.89 (m, 16H), 6.74 – 6.71 
(m, 4H); 
13
C NMR (125 MHz, CDCl3): δ 178.79, 160.97, 160.66, 145.42, 141.57, 140.30, 
140.15, 139.96, 139.08, 137.95, 137.70, 135.66, 133.43, 131.30, 130.71, 130.61, 130.41, 
129.07, 128.53, 128.35, 128.32, 127.64, 127.59, 127.52, 127.19, 126.98, 118.77; HRMS 
(ESI) calcd for C36H23ClNO2 [M+H]
+







H NMR (500 MHz, CDCl3): δ 7.21 (d, J = 8.5 Hz, 1H), 7.15 – 7.01 (m, 8H), 7.00 – 6.88 
(m, 9H), 6.77 – 6.68 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 179.30, 161.21, 160.95, 
145.54, 141.44, 140.30, 140.20, 139.99, 139.20, 137.94, 137.81, 135.67, 131.31, 130.81, 
130.74, 130.60, 130.43, 129.62, 128.53, 128.36, 127.66, 127.53, 127.21, 127.00, 121.31, 
120.43; HRMS (ESI) calcd for C36H23BrNO2 [M+H]
+
 580.0907, found 580.0899. 
 
8-Chloro-4,5,6,7-tetraphenylazepino[3,2,1-hi]indole-1,2-dione (3-3na)  
 
1
H NMR (500 MHz, CDCl3): δ 7.56 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.06 – 
6.98 (m, 14H), 6.85 – 6.81 (m, 4H), 6.74 – 6.72 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 
180.76, 164.96, 162.52, 147.62, 146.34, 142.16, 140.19, 139.15, 138.29, 138.05, 137.16, 
135.06, 131.39, 131.12, 130.98, 130.26, 129.16, 128.62, 128.36, 127.79, 127.72, 127.62, 
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127.58, 127.33, 127.28, 124.79, 120.36; HRMS (ESI) calcd for C36H23ClNO2 [M+H]
+
 





H NMR (500 MHz, CDCl3): δ 7.46 (m, 2H), 7.08 – 6.97 (m, 14H), 6.84 – 6.79 (m, 4H), 
6.72 (d, J = 7.0 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ 181.04, 164.92, 162.47, 147.72, 
140.06, 139.41, 139.23, 138.25, 137.12, 137.02, 135.00, 132.51, 132.11, 131.71, 131.41, 
131.00, 128.68, 128.38, 127.85, 127.68, 127.62, 127.38, 127.33, 124.49, 120.86; HRMS 
(ESI) calcd for C36H23BrNO2 [M+H]
+






H NMR (500 MHz, CDCl3): δ  7.91 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 7.0 Hz, 2H), 7.14 – 
6.79 (m, 22H), 6.73 (d, J = 8.0 Hz, 1H), 6.57 – 6.55  (m , 2H); 13C NMR (125 MHz, 
CDCl3): δ 154.27, 143.83, 143.50, 143.06, 142.48, 141.86, 141.79, 139.99, 138.26, 
132.35, 132.18, 131.23, 131.17, 130.86, 130.10, 129.00, 128.04, 127.50, 127.34, 127.29, 
126.69, 126.55, 126.43, 126.35, 126.03, 125.72, 123.29, 121.47, 120.10, 119.08, 117.04; 
HRMS (ESI) calcd for C40H28N [M+H]
+





H NMR (500 MHz, CDCl3): δ 7.53 – 7.51 (m, 1H), 7.19 (dd, J = 7.9, 1.0 Hz, 1H), 7.08 – 
7.05 (m, 1H), 6.96 – 6.94 (m, 4H), 6.92 – 6.85 (m, 4H), 6.76 (d, J = 7.8 Hz, 4H), 6.67 (m, 
4H), 2.23 (s, 3H), 2.17 (s, 6H), 2.16 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 182.03, 
162.14, 160.23, 145.62, 141.49, 140.25, 139.03, 137.80, 137.66, 137.44, 137.41, 136.86, 
136.38, 136.15, 135.38, 133.07, 131.38, 131.30, 131.17,130.89, 130.67, 130.63, 130.51, 
130.27, 129.04, 128.99, 128.33, 128.26, 128.12, 127.50, 126.05, 125.99, 124.23, 121.61, 
21.61, 21.54, 21.51; HRMS (ESI) calcd for C40H32NO2 [M+H]
+








H NMR (500 MHz, CDCl3): δ 7.51 (d, J = 7.0 Hz, 1H), 7.19 (dd, J = 7.9, 1.1 Hz, 1H), 
7.07 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 7.0 Hz, 2H), 6.70 – 6.65 (m, 
7H), 6.59 (d, J = 7.9 Hz, 2H), 6.50 (dd, J = 8.8, 2.5 Hz, 4H), 3.70 (s, 3H), 3.66 (s, 3H), 
3.64 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ 181.97, 162.06, 160.01, 158.95, 158.63, 
158.39, 158.19, 145.41, 141.49, 140.11, 138.94, 137.06, 133.15, 133.00, 132.39, 131.93, 
131.76, 131.64, 131.39, 130.83, 128.32, 125.98, 124.23, 121.56, 113.74, 113.67, 113.33, 










H NMR (500 MHz, CDCl3): δ 7.55 (d, J = 7.0 Hz, 1H), 7.13 – 7.04 (m, 6H), 6.97 – 6.93 
(m, 6H), 6.90 – 6.87 (m, 2H), 6.65 – 6.62 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 
181.10, 161.35, 159.69, 143.87, 141.51, 140.34, 139.75, 138.40, 138.06, 136.07, 135.74, 
134.57, 133.97, 133.71, 133.69, 133.46, 132.50, 131.86, 131.81, 131.59, 129.95, 129.03, 
128.92, 128.40, 128.28, 126.70, 125.38, 121.88; HRMS (ESI) calcd for C36H19NCl4NaO2 
[M+Na]
+
 660.0062, found 660.0088. 
 






Ratio of regioisomers = 11:9; Spectrum data of a and b; 
1
H NMR (500 MHz, CDCl3): δ 
7.53 (d, J = 7.3 Hz, 1H), 7.21 – 7.19 (m, 1H), 7.07 (t, J = 8.0 Hz, 1H), 6.99 – 6.85 (m, 
8H), 6.77 – 6.72 (m, 4H), 6.67 – 6.62 (m, 4H), 2.55 – 2.41 (m, 8H), 1.51 – 1.45  (m, 2H), 
1.36 – 1.09 (m, 20H), 0.92 – 0.87 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 182.15, 
162.05, 160.25, 145.77, 143.74, 143.10, 142.75, 142.73, 142.54, 142.51, 141.81, 141.54, 
141.29, 141.27, 141.07, 141.04, 140.21, 140.08, 140.04, 139.12, 139.09, 139.04, 138.05, 
138.03, 137.80, 137.77, 137.49, 137.44, 137.40, 135.74,  133.36, 133.33, 133.29, 131.35, 
131.31, 131.26, 130.85, 130.77, 130.70, 130.64, 130.57, 130.33, 128.54, 128.27, 128.16, 
127.67, 127.61, 127.54, 127.52, 127.40, 127.38, 126.84, 126.73, 126.02, 124.26, 124.24, 
121.61, 35.97, 35.90, 35.78, 32.10, 32.08, 32.06, 31.47, 31.24, 30.15, 29.19, 29.11, 28.89, 
28.87, 28.84, 28.82, 28.79, 23.05, 23.00, 22.98, 15.79, 15.62, 15.31, 14.57, 14.53, 14.49; 
HRMS (ESI) calcd for C52H56NO2 [M+H]
+







Ratio of regioisomers = 11:9; Spectrum data of a and b;
 1
H NMR (500 MHz, CDCl3): δ 
7.54 (dd, J = 7.5, 2.5 Hz, 1H), 7.17 – 7.06 (m, 5H), 7.01 – 6.90 (m, 11H), 6.83 – 6.71 (m, 
4H), 6.66 – 7.06  (m, 1H), 2.38 – 2.34 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 181.69, 
161.83, 161.79, 160.05, 159.99, 145.50, 144.71, 141.54, 141.51, 140.39, 140.12, 139.95, 
139.91, 139.03, 138.72, 138.68, 138.08, 138.06, 137.81, 137.32, 137.30, 137.13, 136.99, 
136.93, 136.57, 132.32, 132.27, 131.70, 131.28, 131.16, 131.03, 130.99, 130.80, 130.71, 
130.65, 130.58, 130.31, 128.48, 128.35, 128.23, 127.77, 127.68, 127.56, 127.20, 127.15, 
127.01, 126.93, 126.24, 126.03, 125.86, 125.42, 125.33, 124.67, 124.63, 121.66, 15.73, 
15.60; HRMS (ESI) calcd for C38H28NO2S2 [M+H]
+ 





Ratio of regioisomers = 3:2; Spectrum data of a or b;
 1
H NMR (500 MHz, CDCl3): δ 7.55 
(dd, J = 7.5, 1.5 Hz, 1H), 7.27 – 7.25  (m, 3H), 7.21 – 7.18 (m, 3H), 7.11 (t, J = 7.5 Hz, 
1H), 7.03 (d, J = 8.5 Hz, 2H), 6.97 – 6.91 (m, 8H), 6.78 – 6.74 (m, 4H), 0.19 (s, 9H), 0.15 
(s, 9H); 
13
C NMR (125 MHz, CDCl3): δ 181.97, 162.01, 160.31, 145.37, 141.63, 140.80, 
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140.47, 140.44, 140.26, 139.56, 138.24, 137.39, 136.10, 133.26, 133.19, 131.40, 130.87, 
130.68, 130.00, 129.55, 127.58, 127.46, 127.00, 126.79, 126.25, 124.59, 121.71, -0.74, -
0.79; HRMS (ESI) calcd for C42H40NO2Si2 [M+H]
+
 646.2592, found 646.2605. 
 
1
H NMR (500 MHz, CDCl3): δ 7.55 (dd, J = 7.5, 1.0 Hz, 1H), 7.18 – 7.00 (m, 16H), 6.70 
– 6.67 (m, 4H), 0.15 (s, 9H), 0.13 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 181.92, 161.90, 
160.17, 145.53, 141.55, 140.63, 140.56, 140.12, 139.29, 138.91, 138.69, 138.60, 137.41, 
135.91, 132.38, 132.29, 130.96, 130.82, 130.58, 130.44, 129.86, 128.40, 128.30, 128.13, 
127.42, 126.23, 124.60, 121.72, -0.76, -0.79; HRMS (ESI) calcd for C42H40NO2Si2 
[M+H]
+






Ratio of regioisomers = 7:3; Spectrum data of a or b;
 1
H NMR (500 MHz, CDCl3): δ = 
7.66 – 7.63 (m, 2H), 7.50 – 7.47 (m, 3H), 7.18 (t, J = 7.5 Hz, 1H), 7.09 – 7.03 (m, 9H), 
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7.00 – 6.97 (m, 2H), 6.70 – 6.65 (dd, J = 7.5, 1.5 Hz, 2H); 13C NMR (125 MHz, CDCl3): 
δ = 180.74, 160.87, 159.89, 145.81, 143.77, 142.17, 140.93, 140.21, 138.47, 138.34, 
134.62, 132.63, 132.08, 131.90, 131.82, 131.10,130.86,  130.84, 130.21, 130.04, 129.07, 
129.00, 128.84, 128.61, 128.30, 127.19, 126.01, 124.40, 124.33, 122.28, 122.23, 
122.16,121.75, 121.72, 121.00; HRMS (ESI) calcd for C40H19F12NNaO2 [M+Na]
+ 
 
796.1116, found 796.1140. 
 
1
H NMR (500 MHz, CDCl3): δ = 7.60 (dd, J = 7.5, 2.0 Hz, 1H), 7.46 (s, 2H), 7.23 – 7.06 
(m, 14H), 7.00 (d, J = 7.0 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ =  180.70, 160.96, 
159.32, 144.17, 143.73, 142.02, 140.33, 138.94, 134.42, 132.04, 131.79, 131.74, 131.52, 
131.47, 130.79, 130.17, 130.13, 129.40, 129.28, 129.12, 128.85, 128.56, 127.03, 126.17, 
124.25, 122.13, 122.08, 122.01, 121.22, 121.05; HRMS (ESI) calcd for C40H19F12NNaO2 
[M+Na]
+ 
















H NMR (500 MHz, CDCl3): δ 
7.53 – 7.51  (m, 2H), 7.18 – 7.13  (m, 1H), 7.10 – 7.03  (m, 12H), 6.98 – 6.86 (m, 15H), 
6.72 – 6.69 (m, 4H), 6.66 – 6.63 (m, 4H), 1.26 – 1.18 (m, 36H); 13C NMR (125 MHz, 
CDCl3): δ 181.76, 161.89, 161.78, 160.25, 160.03, 151.36, 151.27, 150.74, 150.34, 
145.70, 143.56, 141.70, 141.58, 141.27, 141.24, 140.63, 139.07, 138.80, 138.47, 136.98, 
136.95, 136.88, 136.75, 135.67, 135.42, 133.39, 133.07, 132.91, 132.83, 132.76, 132.67, 
132.41, 132.32, 132.22, 132.15, 132.00, 130.65, 130.55, 130.22, 130.04, 130.00, 128.66, 
127.99, 127.84, 127.69, 126.31, 125.41, 125.31, 125.30, 124.82, 124.74, 124.65, 121.79, 
121.77, 34.92, 34.82, 31.65, 31.55; HRMS (ESI) calcd for C44H38Cl2NO2 [M+H]
+ 
 












H NMR (500 MHz, CDCl3): δ 
7.77 – 7.57 (m, 7H), 7.51 – 7.36 (m, 6H), 7.34 – 7.06 (m, 8H), 6.04 – 6.87 (m, 6H); 13C 
NMR (125 MHz, CDCl3): δ 181.76, 161.90, 161.86, 161.83, 160.19, 145.80, 145.71, 
145.29, 145.20, 141.72, 141.60, 141.04, 140.40, 140.16, 140.09, 139.55, 138.14, 138.03, 
137.87, 137.80, 137.76, 137.07, 135.80, 133.23, 133.06, 132.96, 132.94, 132.87, 132.50, 
132.29, 132.21, 131.32, 130.88, 130.70, 130.65, 130.61, 130.43, 130.34, 129.95, 129.47, 
129.04, 129.00, 128.62, 128.44, 128.32, 128.26, 128.18, 128.13, 128.10, 128.03, 127.99, 
127.87, 127.84, 127.80, 127.69, 127.65, 127.57, 127.53, 127.46, 127.16, 126.97, 126.94, 
126.83, 126.70, 126.60, 126.55, 126.44, 126.31, 126.24, 126.18, 126.14, 124.78, 124.74, 
124.72, 121.78; HRMS (ESI) calcd for C44H27NNaO2 [M+Na]
+ 









Ratio of regioisomers = 3:2; Spectrum data of a or b;
 1
H NMR (500 MHz, CDCl3): δ 7.62 
(d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 7.0 Hz, 1H), 7.32 – 7.29 (m, 
5H), 7.22 – 7.18 (m, 14H), 7.16 – 7.10 (m, 8H), 6.95 – 6.93 (m, 1H), 6.86 – 6.78 (m, 6H), 
6.70 (dd, J = 5.2, 3.7 Hz, 2H), 6.60 (dd, J = 5.2, 3.7 Hz, 1H), 6.44 (d, J = 3.0 Hz, 1H); 
13
C NMR (125 MHz, CDCl3): δ 181.56, 181.46, 162.29, 162.07, 159.40, 159.27, 147.39, 
142.06, 141.64, 141.59, 141.50, 141.40, 141.26, 140.62, 140.50, 139.90, 139.43, 138.32, 
137.88, 137.36, 135.83, 134.96, 133.63, 133.13, 133.04, 132.90, 132.87, 131.71, 131.02, 
130.94, 130.71, 130.63, 130.44, 130.26, 130.03, 129.90, 128.96, 128.83, 128.46, 128.00, 
127.78, 127.62, 127.58, 127.33, 127.13, 126.94, 126.89, 126.80, 126.74, 126.72, 126.65, 
126.42, 126.22, 126.18, 125.12, 124.76, 124.73, 122.15, 122.09; HRMS (ESI) calcd for 
C32H19NNaO2S2 [M+Na]
+ 








Ratio of regioisomers = 13:7; Spectrum data of a or b;
 1
H NMR (500 MHz, CDCl3): δ 
7.46 – 7.28 (m, 9H), 7.08 (d, J = 7.0 Hz, 2H), 7.01 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.0 Hz, 
1H), 1.97 (s, 3H), 1.41 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 182.58, 162.28, 162.03, 
158.33, 141.55, 141.13, 140.40, 139.28, 138.25, 136.37, 135.26, 131.14, 130.44, 130.12, 
129.20, 129.02, 128.06, 128.02, 125.95, 123.89, 121.65, 23.67, 19.31; HRMS (ESI) calcd 
for C26H20NO2 [M+H]
+ 
 378.1489, found 378.1485. 
        
1
H NMR (500 MHz, CDCl3): δ 7.46 – 7.41 (m, 3H), 7.38 (t, J = 7.0 Hz, 3H), 7.34 – 7.25 
(m, 1H), 7.21 (d, J = 7.0 Hz, 2H), 7.11 (d, J = 7.0 Hz, 2H), 7.02 – 6.99 (m, 1H), 6.90 (dd, 
J  = 7.9, 2.0 Hz, 1H), 1.85 (s, 3H), 1.79 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 182.24, 
161.41, 159.58, 141.51, 140.94, 140.54, 137.29, 136.51, 131.38, 131.04, 130.38, 129.88, 
129.58, 129.26, 129.09,128.78, 128.65, 128.47, 128.23, 128.09, 125.82, 123.81, 121.25, 
21.90, 19.75; HRMS (ESI) calcd for C26H20NO2 [M+H]
+ 








H NMR (500 MHz, CDCl3): δ 7.58 (dd, J = 8.0, 1.5 Hz, 1H), 7.41 (dd, J = 7.0, 3.5 Hz, 
4H), 7.37 – 7.34 (m, 2H), 7.31 – 7.29 (m, 2H), 7.22 – 7.19 (m, 2H), 7.12 – 7.09 (m, 1H), 
7.02 (dd, J = 7.5, 1.5 Hz, 1H), 3.46 (s, 3H), 3.45 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
180.35, 166.69, 166.20, 160.26, 158.82, 147.32, 145.88, 142.52, 139.16, 133.99, 132.51, 
129.95, 129.75, 129.58, 129.48, 129.26, 128.88, 128.72, 126.90, 126.60, 124.48, 121.97, 
52.77, 52.58; HRMS (ESI) calcd for C28H20NO6 [M+H]
+ 
 466.1285, found 466.1277. 
 





H NMR (500 MHz, CDCl3): δ 7.76 (t, J = 8.0 Hz, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.56 – 
7.54  (m, 2H), 7.46 (t, J = 8.5 Hz, 1H), 7.38 – 7.30 (m, 8H), 7.20 – 7.17 (m, 3H), 7.02 (dd, 
J = 7.0, 2.0 Hz, 2H), 6.81 – 6.77 (t, J = 8.0 Hz,, 1H), 6.67 (d, J = 8.5 Hz, 1H); 13C NMR 
(125 MHz, CDCl3): δ 179.85, 144.00, 138.77, 136.91, 134.11, 132.69, 132.23, 131.73, 
131.56, 131.28, 130.24, 129.92, 129.72, 129.49, 129.29, 128.76, 128.49, 128.31, 128.10, 
127.22, 127.08, 126.20, 125.58, 121.40, 120.06; HRMS (ESI) calcd for C33H22NO 
[M+H]
+ 





H NMR (500 MHz, CDCl3): δ 7.76 – 7.72 (m, 2H), 7.62 (d, J = 8.5 Hz, 1H), 7.54 (dd, J 
= 7.0, 2.0 Hz, 2H), 7.26 (d, J = 1.5 Hz, 1H), 7.25 (d, J = 1.5 Hz, 2H), 6.93 (dd, J = 7.0, 
2.0 Hz, 2H), 6.89 (t, J = 2.0 Hz, 2H), 6.84 (dd, J = 7.0, 2.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 
1H), 6.76 – 6.74 (m, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 179.59, 160.77, 160.07, 158.79, 143.87, 138.71, 137.21, 133.01, 132.63, 
132.42, 131.70, 129.38, 129.28, 129.02, 127.96, 126.76, 126.72, 126.13, 125.75, 125.07, 
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124.34, 121.47, 120.11, 114.97, 114.06, 113.77, 55.88, 55.67, 55.59; HRMS (ESI) calcd 
for C36H27NNaO4 [M+Na]
+ 
 560.1832, found 560.1837. 
 
8, 9, 10-Tris(4-chlorophenyl)-7H-benzo[g]pyrrolo[1,2-a]indol-7-one (3-3td) 
 
1
H NMR (500 MHz, CDCl3): δ 7.78 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.67 (d, 
J = 8.0 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.39 – 7.36 (m, 3H), 7.30 – 7.26 (m, 4H), 7.22 – 
7.20 (m, 2H), 6.93 – 6.89 (m, 3H), 6.72 (d, J = 8.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): 
δ 179.78, 143.82, 138.92, 136.33, 135.39, 134.87, 133.70, 132.98, 132.44, 132.11, 131.47, 
130.73, 130.59, 130.01, 129.64, 129.57, 129.19, 128.82, 128.66, 128.61, 128.47, 127.57, 
126.47, 125.20, 121.25, 120.15; HRMS (ESI) calcd for C33H19Cl3NNaO [M+Na]
+ 
 







8, 10-Di(naphthalen-2-yl)-9-phenyl-7H-benzo[g]pyrrolo[1,2-a]indol-7-one (3-3tj) 
 
Ratio of regioisomers = 19:1; Spectrum data of a and b;
1
H NMR (500 MHz, CDCl3): δ 
8.15 (s, 1H), 7.83 – 7.72 (m, 4H), 7.67 – 7.55 (m, 3H), 7.49 – 7.12 (m, 14H), 7.05 (dd, J 
= 8.0, 2.0 Hz, 1H), 6.83 – 6.77 (m, 1H), 6.69 (dd, J = 8.5, 4.0 Hz, 1H); 13C NMR (125 
MHz, CDCl3): δ 179.87, 144.04, 144.02, 138.81, 137.02, 134.17, 133.68, 133.63, 133.54, 
132.73, 132.69, 132.63, 132.37, 132.26, 131.77, 131.53, 131.35, 130.29, 130.23, 130.13, 
130.04, 129.97, 129.77, 129.65, 129.59, 129.54, 129.37, 129.33, 129.15, 129.07, 128.85, 
128.82, 128.58, 128.39, 128.13, 128.06, 128.01, 127.98, 127.88, 127.64, 127.31, 127.14, 
126.79, 126.33, 126.29, 126.24, 125.62, 121.46, 120.10; HRMS (ESI) calcd for 
C41H25NNaO [M+Na]
+ 







H NMR (500 MHz, CDCl3): δ 7.78 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.68 – 
7.60 (m, 3H), 7.59 – 7.56 (m, 4H), 7.52 – 7.49 (m, 4H), 7.39 – 7.36 (m, 1H), 7.09 (t, J = 
8.0 Hz, 2H), 6.82 – 6.79 (m, 1H), 6.50 (d, J = 8.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): 
δ 179.86, 143.82, 139.06, 137.10, 135.76, 134.87, 134.49, 132.52,  132.21, 131.39, 
130.68, 130.62, 130.41, 129.88, 129.70, 128.72, 128.48, 128.04, 126.78, 126.75, 126.59, 
125.99, 125.96, 125.64, 125.61, 124.83, 123.44, 121.15, 120.22; HRMS (ESI) calcd for 
C36H18F9NO [M+H]
+ 








H NMR (500 MHz, CDCl3): δ 7.56 – 7.54 (m, 1H), 7.15 – 7.09 (m, 3H), 6.97 – 6.87 (m, 
5H), 6.69 – 6.60 (m, 6H), 6.52 (d, J = 8.5 Hz, 2H), 3.69 (s, 3H), 3.68 (s, 3H); 13C NMR 
(125 MHz, CDCl3): δ 181.66, 161.88, 160.15, 159.16, 158.66, 144.99, 141.22, 141.14, 
138.82, 138.72, 138.61, 135.92, 133.70, 133.03, 132.57, 132.42, 132.06, 131.92, 131.75, 
131.58, 130.32, 130.13, 128.90, 128.79, 128.10, 127.98, 126.32, 124.92, 121.80, 113.84, 
113.33, 113.79, 113.28, 113.15, 55.46; HRMS (ESI) calcd for C38H25Cl2NNaO [M+Na]
+ 
 
652.1053, found 652.1071. 
 
2,3,4-Triphenylquinoline-8-carboxylic acid (3-4) 
 
1
H NMR (500 MHz, CDCl3) δ 8.73 (d, J = 7.5 Hz, 1H), 7.76 (dd, J = 7.5, 1.5 Hz, 1H), 
7.65 (t, J = 8.0 Hz, 1H), 7.42 – 7.40 (m, 2H), 7.35 – 7.27 (m, 6H), 7.17 – 7.16 (m, 5H), 
6.94 (dd, J = 7.5, 1.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ 168.06, 158.33, 151.17, 
144.97, 139.13, 137.24, 136.24, 135.60, 134.40, 132.53, 131.66, 130.46, 130.36, 129.46, 
128.65, 128.59, 128.52, 128.26, 127.62, 127.51, 127.48, 124.96; HRMS (ESI) calcd for 
C28H20NO2 [M+H]
+








H NMR (500 MHz, CDCl3) δ 7.12 – 6.73 (m, 46H), 4.50 (s, 1H), 3.71 (s, 1H); 
13
C NMR 
(125 MHz, CDCl3) δ 170.57, 143.67, 143.64, 140.66, 140.59, 140.13, 138.51, 136.27, 
134.23, 134.13, 131.61, 130.97, 130.73, 130.59, 130.52, 128.31, 128.22, 128.11, 127.82, 
127.77, 127.39, 127.30, 127.02, 126.83, 126.54, 12; HRMS (ESI) calcd for 
C72H48N2NaO4 [M+Na]
+
 1027.3506, found 1027.3460. 
 






H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 8.0, 1H), 8.66 (d, J = 8.0, 1H), 8.27 (d, J = 8.0, 
1H), 8.07 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0, 1H), 7.75 (t, J = 8.5, 1H), 7.67 (t, J = 7.5, 
1H), 7.62 – 7.54 (m, 2H), 7.35 – 7.29 (m, 2H), 7.24 – 7.14 (m, 4H), 7.01 (t, J = 7.5 Hz, 
1H); 
13
C NMR is not available due to poor solubility of this compound; MS (ESI) found 
496.1; HRMS (ESI) calcd for C36H18NO2 [M+H]
+
 496.1332, found 496.1350. 
 
9-Cyano-2,3,4,5-tetraphenyl-1H-benzo[b]azepine-1-carbonyl chloride and 9-cyano-
2,3,4,5-tetraphenyl-1H-benzo[b]azepine-1-carbonyl azide (3-7 and 3-8)  
 
Ratio of regioisomers = 55:45,
  1
H NMR (500 MHz, CDCl3) δ 7.71 – 7.56 (m, 2H), 7.45 – 
7.29 (m, 3H), 7.22 – 6.98 (m, 13H), 6.92 – 6.79 (m, 5H); 13C NMR (125 MHz, CDCl3) δ  
157.13, 156.69, 150.98, 150.06, 144.99, 141.97, 141.83, 141.27, 140.25, 140.22, 139.89, 
139.18, 138.99, 138.93, 138.59, 138.21, 137.55, 137.43, 137.02, 135.96, 135.83, 135.53, 
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135.41, 134.23, 134.00, 133.79, 133.43, 131.77, 131.38, 131.33, 131.28, 131.21, 131.15, 
131.01, 130.89, 130.86, 130.83, 130.80, 129.29, 128.99, 128.88,128.74, 128.66, 128.50, 
128.45, 128.33, 128.30, 128.20, 128.16, 128.14, 128.10, 127.94, 127.84, 127.51, 127.43, 
127.40, 127.38, 126.94, 116.25, 116.04, 115.89, 112.46, 112.23, 111.64; HRMS (ESI) 
calcd for C36H23ClN2NaO [M+Na]
+ 
 557.1392, found 557.1402 and C36H23N2NaO 
[M+Na]
+ 















3.5 X-Ray Crystallographic Analysis 
3.5.1 X-Ray Crystallographic Analysis of Benzazepine Product and Pyrrole Fused 3-
indolinones 
        The configuration of the product 3-3da was assigned by X-ray crystallographic 
analysis of a single crystal of 3-3da (Figure 3.2). The configurations of other products 
were assigned by analogy. 
 
Figure 3.2 X-ray structure of 3-3da 
Table 3.7 Crystal data and structure refinement for 3-3da 
Empirical formula  C40 H31NO2 
Formula weight  557.66 
Temperature  100(2) K 
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Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 17.119(2) Å a= 90°. 
 b = 13.5180(18) Å b= 107.639(3)°. 
 c = 27.388(4) Å g = 90°. 
Volume 6040.1(14) Å3 
Z 8 
Density (calculated) 1.226 Mg/m3 
Absorption coefficient 0.075 mm-1 
F(000) 2352 
Crystal size 0.42 x 0.16 x 0.06 mm3 
Theta range for data collection 1.26 to 27.50° 
Index ranges -22<=h<=22, -17<=k<=17, -29<=l<=35 
Reflections collected 41963 
Independent reflections 13858 [R(int) = 0.1174] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9955 and 0.9693 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 13858 / 114 / 812 
Goodness-of-fit on F2 0.987 
118 
 
Final R indices [I>2sigma(I)] R1 = 0.0759, wR2 = 0.1489 
R indices (all data) R1 = 0.1683, wR2 = 0.1855 
Largest diff. peak and hole 0.548 and -0.523 e.Å-3 
 
        The configuration of the product 3-3ta was assigned by X-ray crystallographic 
analysis of a single crystal of 3-3ta (Figure 3.3). The configurations of other products 
were assigned by analogy. 
 
Figure 3.3 X-ray structure of 3-3ta 
Table 3.8 Crystal data and structure refinement for 3-3ta 
Empirical formula  C33H21N O 
Formula weight  447.51 
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Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.2494(5) Å a= 114.7120(10)°. 
 b = 12.0514(6) Å b= 96.4520(10)°. 
 c = 13.5778(7) Å g = 106.3700(10)°. 
Volume 1409.87(12) Å3 
Z 2 
Density (calculated) 1.335 Mg/m3 
Absorption coefficient 0.353 mm-1 
F(000) 584 
Crystal size 0.60 x 0.46 x 0.28 mm3 
Theta range for data collection 1.71 to 27.49° 
Index ranges -13<=h<=13, -15<=k<=15, -17<=l<=17 
Reflections collected 18377 
Independent reflections 6458 [R(int) = 0.0298] 
Completeness to theta = 27.50° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9075 and 0.8160 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6458 / 0 / 352 
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Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0695, wR2 = 0.1726 
R indices (all data) R1 = 0.0845, wR2 = 0.1836 
Largest diff. peak and hole 0.600 and -0.491 e.Å-3 
 
3.5.2 X-Ray Crystallographic Analysis of Synthetic transformation of Benzazepine 
3-3aa 
 
Figure 3.4 X-ray structure of 3-4 
Table 3.9 Crystal data and structure refinement for 3-4 
Empirical formula  C28H19NO2 
Formula weight  401.44 
Temperature  100(2) K 
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Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 12.022(11) Å a= 90°. 
 b = 7.246(7) Å b= 104.207(18)°. 
 c = 23.72(2) Å g = 90°. 
Volume 2004(3) Å3 
Z 4 
Density (calculated) 1.331 Mg/m3 
Absorption coefficient 0.084 mm-1 
F(000) 840 
Crystal size 0.40 x 0.10 x 0.10 mm3 
Theta range for data collection 2.16 to 25.00° 
Index ranges -12<=h<=14, -8<=k<=8, -28<=l<=28 
Reflections collected 10818 
Independent reflections 3533 [R(int) = 0.0895] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9917 and 0.9673 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3533 / 0 / 284 
Goodness-of-fit on F2 1.009 
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Final R indices [I>2sigma(I)] R1 = 0.0807, wR2 = 0.2075 
R indices (all data) R1 = 0.1305, wR2 = 0.2388 
Largest diff. peak and hole 0.389 and -0.413 e.Å-3 
 
 
Figure 3.5 X-ray structure of 3-5 
Table 3.10 Crystal data and structure refinement for 3-5 
Empirical formula  C78.25 H60.50 N2 O7.25 
Formula weight  1144.79 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
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Unit cell dimensions a = 13.6777(11) Å a= 90°. 
 b = 29.760(2) Å b= 111.566(2)°. 
 c = 16.5143(13) Å g = 90°. 
Volume 6251.6(9) Å3 
Z 4 
Density (calculated) 1.216 Mg/m3 
Absorption coefficient 0.078 mm-1 
F(000) 2408 
Crystal size 0.28 x 0.18 x 0.10 mm3 
Theta range for data collection 1.49 to 25.00° 
Index ranges -14<=h<=16, -35<=k<=32, -19<=l<=19 
Reflections collected 36618 
Independent reflections 11018 [R(int) = 0.1100] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9923 and 0.9786 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11018 / 402 / 889 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0901, wR2 = 0.1947 
R indices (all data) R1 = 0.1465, wR2 = 0.2214 




Figure 3.6 X-ray structures of 3-7 and 3-8 
Table 3.11 Crystal data and structure refinement for 3-7 and 3-8 
Empirical formula  C38H28.50Cl0.50N3.38O1.50 
Formula weight  574.12 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  I2/a 
Unit cell dimensions a = 18.527(3) Å a= 90°. 
 b = 10.1040(14) Å b= 98.228(3)°. 
 c = 32.704(4) Å g = 90°. 




Density (calculated) 1.259 Mg/m3 
Absorption coefficient 0.120 mm-1 
F(000) 2405 
Crystal size 0.60 x 0.18 x 0.17 mm3 
Theta range for data collection 2.22 to 27.50° 
Index ranges -24<=h<=16, -13<=k<=13, -42<=l<=42 
Reflections collected 21083 
Independent reflections 6950 [R(int) = 0.0458] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9799 and 0.9315 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6950 / 5 / 417 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0639, wR2 = 0.1763 
R indices (all data) R1 = 0.0872, wR2 = 0.1895 
Largest diff. peak and hole 0.735 and -0.247 e.Å-3 
The crystal is monoclinic, space group I2/a. The asymmetric unit contains mixtures of the 
compounds C36H23N4O and C36H23NOCl with the occupancy ratio=45:55, and a quarter 
hexane and two quarterly occupied methanol. H atoms of the solvents were not located 
but were included in the formula. Final R values are R1=0.0639 and wR2=0.1763 for 2-
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theta up to 55º. 
 
3.5.3 X-Ray Crystallographic Analysis of two regioisomers of unasymmetric alkynes 
product  
        The two regioisomers configuration of the product 3-3ah was assigned by X-ray 
crystallographic analysis of a single crystal of 3-3ah-a and 3-3ah-b (Figure 3.7, 3.8). 
The configurations of other products were assigned by analogy. 
 
Figure 3.7 X-ray structures of 3-3ah-a 
Table 3.12 Crystal data and structure refinement for 3-3ah-a 
Empirical formula  C40H19F12NO2 
Formula weight  773.56 
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Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.4075(5) Å α= 91.8990(10)°. 
 b = 11.0590(6) Å β= 90.9700(10)°. 
 c = 17.9296(10) Å γ = 92.3290(10)°. 
Volume 1664.50(16) Å3 
Z 2 
Density (calculated) 1.543 Mg/m3 
Absorption coefficient 0.141 mm-1 
F(000) 780 
Crystal size 0.31 x 0.19 x 0.05 mm3 
Theta range for data collection 1.84 to 25.00° 
Index ranges -9<=h<=9, -13<=k<=13, -21<=l<=21 
Reflections collected 17908 
Independent reflections 5847 [R(int) = 0.0422] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7456 and 0.6844 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5847 / 92 / 493 
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Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0669, wR2 = 0.1515 
R indices (all data) R1 = 0.0805, wR2 = 0.1592 
Largest diff. peak and hole 0.906 and -0.612 e.Å-3 
 
 
Figure 3.8 X-ray structures of 3-3ah-b 
Table 3.13 Crystal data and structure refinement for 3-3ah-b 
Empirical formula  C40H19F12NO2 
Formula weight  773.56 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.6455(19) Å a= 99.181(3)°. 
 b = 18.488(4) Å b= 99.391(3)°. 
129 
 
 c = 22.049(5) Å g = 101.856(3)°. 
Volume 3334.2(13) Å3 
Z 4 
Density (calculated) 1.541 Mg/m3 
Absorption coefficient 0.141 mm-1 
F(000) 1560 
Crystal size 0.60 x 0.40 x 0.20 mm3 
Theta range for data collection 0.96 to 27.50° 
Index ranges -11<=h<=11, -24<=k<=23, 0<=l<=28 
Reflections collected 14797 
Independent reflections 14797 [R(int) = 0.0000] 
Completeness to theta = 27.50° 96.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.745685 and 0.579236 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14797 / 425 / 1029 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0997, wR2 = 0.2334 
R indices (all data) R1 = 0.1703, wR2 = 0.2850 
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Chapter 4 Enamine and Iminium Organocatalysis  
4.1 Organocatalysis  
        Organocatalysis refers to the use of small organic molecules to catalyze different organic 
reactions, is a relatively new and popular field within the domain of important biological and 
pharmaceutical molecules synthesis, especially about the related chiral molecule (or 
enantioselective) synthesis. Organocatalysis can be divided into five major areas based on the 
generic modes of activation (Scheme 4.1), one is enamine catalysis,
1
 which promotes reaction 
via enamine intermediates generated from secondary amine catalysis or primary amine 
catalysis with related ketones or aldehydes, the other one is the iminium catalysis 
2
 which is 
desired based on the capacity of the reversible formation of iminium ions from α,β – 
unsaturated aldehydes with chiral or non-chiral amines, another one is hydrogen-bond 
catalysis that the activation of a substrate and organization of the transition state could occur 
through well-defined hydrogen-bonding interaction.
3 
Recently, the electrophilicity of the 
singly occupied molecular orbital (SOMO) catalysis based on the concept that one-electron 
oxidant of an electron-rich enamine selectively can generate a reactive radical cation with 
three π-electrons is introduced by MacMillan4 and counterion catalysis which are known 




        Organocatalysis became a focus of research in the late 1990s and 2000s. Began with the 










 and many 
others researchers, organoctalytic methods, especially the asymmetric organocatalytic 
methods, were developed fast in the last decade. Although huge advantages have been 




Scheme 4.1 Generic modes of activation used in organocatalysis 
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progress of iminium and enamine catalysis will be emphasized in the following section. 
 
4.2 Iminium and Enamine Catalysis 
        The iminium and enamine catalytic reactions can be regarded as amine-based 
reactions.
11
The fundamental concept of iminium catalysis, proposed by MacMillan in 2000, 
9a
 involves the reversible condensation of a secondary amine 4-1 with α, β-unsaturated 
aldehyde 4-2 to give the corresponding iminium ion 4-3. The formation of this iminium ion 
simulates the p-electronics and equilibrium dynamics traditionally associated with Lewis acid 
activation lowering the energy of the LUMO of the p-system and promoting subsequent 
hydrolysis reaction. Later, similar iminium catalysis was successfully applied in the other D-
A reactions,
12, 13 
1, 3 – dipolar cycloaddtions,14 and conjugate additions.15Moreover, 
epoxidation, cyclopropanations, and conjugate reductions which catalyzed by iminium 
catalysis were also well developed recently.
16-19 
        The enamine catalysis, on the other hand, refers to primary and secondary amines 4-7 of 
electrophilic substitution reaction in the α-position of carbonyl compounds 4-8 and related 
reactions via enamine intermediates. In such transformations an enamine intermediate 4-10 is 
formed by reacting a carbonyl compound with an amine under dehydration conditions.
20
 
        Reactions of the enamine can proceed via an addition or substitution route depending on 
the nature of the reaction partner. Iminium ions 4-11/4-12 are usually generated, which are 





enamine catalysis were widely applied in others organic reactions involving many different 
electrophiles, such as azodicarboxylates (N=N) in α-aminations,8c, 21 imines (C=N) in 
Mannich reactions,
8a
 nitrosobenzene (O=N) in α-aminooxylation,22 Michael acceptors (C=C)  
 




others C-C bonds or C-halide bonds formation. Enamines react 
readily with a wide variety of electrophiles, and the range of reactions that can be catalyzed 
by enamine catalysis is summarized in Scheme 4.3.          
        Recent years have witnessed an explosive growth in the field of enamine catalysis. In 
these two types of catalysis, the basis of iminium catalysis is from lowering the energy of the 
LUMO energy of the system, which makes them more electrophilic, acidic, and more prone 
to certain pericylic reactions. And the reversible generation of enamines from a catalytic 
amount of an amine and a carbonyl compound is the basis of enamine catalsis. The key 
process to form the enamine intermediate is the HOMO increasing effect. Meanwhile, the 
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iminium catalysis and enamine catalysis are closely related. Iminium catalysis promotes 
reaction via enamine, while enamine catalysis activates reaction via iminium ion formation.  
        Secondary amine and primary amine mediated enamine or iminium catalysis has 
achieved great success in many symmetric and asymmetric transformations, several reviews 
on this topic have appeared and highlighted these progresses.
24-33
Here, only the cycloaddtions 
reactions catalyzed by iminium or enamine will be outlined and 1, 3-dipolare cycloadditions 
reactions will be specially emphasized, as well as its application to the synthesis of important 
compounds including natural products, pharmaceuticals. 
 




4.2.1 Secondary and Primary Amine-Mediated Enamine and Iminium 
Catalysis in [4+2] and [4+3] Cycloaddition Reactions 
4.2.1.1 [4+2] Cycloaddtion Reactions 
        The Diels-Alder [4+2] cycloaddition has evolved to become an integral transformation 
that is routinely exploited in total synthesis since its orginal discovery in 1928.
34
 Great 
attentions have been focused on developing the symmetric and asymmetric variants of this 
type of reaction.
35-39
 Based on the importance and wide application of this cycloaddition, 
iminium and enamine catalysis are also apply into this transformation. 
        The pioneering work was explored by MacMillan and co-workers, the use of the 
imidazolidininium salt to generate iminium ion intermediates was identified as a new 




           
Scheme 4.4 [4+2] cycloaddition using imidazolidinone catalyst 
        The major deficiency in the use of 4-15 was the low levels of diasteroselectivity 
observed in these transformations. Improvements have been achieved using biaryl catalyst 4-
20 and diarysilyl ether 4-21. Applying 4-20 as the catalyst in the cycloaddition between 
cyclopentadiene and cinnamaldehyde impressively improved the diastereoselectivity from 
1:5.5 (endo: exo) to 1:20 (endo: exo) (Scheme 4.5). However, long reaction time and -20 
o
C 





Then, the 4-21 was explored to promote the same transformation (Scheme 4.5). 




Scheme 4.5 Improved exo-selectivity using new iminium activator 
        Base on these observations, modifications to the architecture of imidazolidinone catalyst 
provided the furyl derivative 4-22 which proved to be a powerful catalyst for the asymemetric 
D-A cycloaddition of simple α, β – unsaturated ketones.12Although the high 
enantioselectivity and good diastereoselectivity for cyclohexenyl ketones, the 
imidazolidinone catalyst could not be widely used as others ketones activator. This chemical 
challenge was successfully solved by Jorgensen and co-worker via the new imidazolidinone 







Scheme 4.6 Iminium activator of simple enones and acyclic enones 
        Moreover, more cycloadditions have been explored based on similar strategies via the 
intramolecular pathway. Recently, several succeeded cases applied the imidazolidinone 
derivatives 4-30 in the intramolecular cycloadditions to produce complex carbocyclic ring 
structures which had been exploited in synthesis to prepare a number of natural products via 








        The transformation that used secondary armines as the catalyst in the concept of LUMO 
energy lowering iminium ion activation has been reported widely within the literature. The 
similar mode of this activation was also possible to use primary amines as efficient catalysts. 
Although few reports have been published in this area, initial results suggested it would 
become an equally fruitful field with broad application. In particular, the reduced steric bulk 
around the catalytic nitrogen has allowed for expansion of the scope of these reactions to 
more hindered substrates (Scheme 4.8). 
 
Scheme 4.8 Activation mode of substitute acroleins via primary and secondary amines 
        The enatioselective Diels-Alder reaction of α-acyloxyacroleins was firstly reported by 
Ishihara and co-worker via a complex triamine catalyst,
50 
subsequently, they explored a 





Scheme 4.9 Iminium activator of intermolecular cycloaddition via primary amine 
        Later, Deng and co-worker reported an interesting expansion to the scope of dienes that 
could be adopted as partners within the [4+2] cycloaddition. Diels-Alder [4+2] adducts were 
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Scheme 4.10 Primary amine as iminium catalysis in [4+2] cycloaddition 
 
4.2.1.2 [4+3] Cycloaddtion Reactions 
In comparison to the preceding classes of cycloaddtion mentioned above, the [4+3] strategies, 
a powerful process with which to access seven membered rings, have received far less 
attention. Harmata showed that imidazolidinone could be applied to catalyze the reaction of 
substituted furans and silyloxypentadienals with high levels of selectivity (Scheme 4.11).
54 
These high levels of selectivity were not maintained for unsubstituted furans and explored the 
way to further develop this as robust synthetic strategy. 
 
Scheme 4.11 Secondary amine as iminium catalysis in [4+3] cycloaddition 
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4.2.2 Secondary and Primary Amine-Mediated Enamine and Iminium 
Catalysis in [3+2] Cycloaddition Reactions 
        The [3+2] cycloaddition strategy provides and effective way to assemble valuable 
intermediates for the construction of biologically and pharmaceutically important alkaloids, 
amino acids, amino carbohydrates and β-lactams.55-59 These reactions almost involve the 
concerted pericyclic addition of a dipole and a dipolarophile called 1, 3-dipolar cycloaddition 
reaction also known as the Huisgen cycloaddition reaction,
60
 and more detail information 
about this type of cycloaddition will be emphasized in next sections. 
 
4.2.2.1 The Background of 1, 3-Dipolar Cycloaddition Reactions 
        The 1, 3-dipolar cycloaddition reaction involves the formation of a 5-membered 
heterocyclic compound through a reaction between a 1, 3-dipolar compound and a 
dipolarophile.
61 
Dipolarophiles are usually alkenes or alkynes while 1, 3-dipolar compounds 
are compounds which contain one or more heteroatoms and contain at least one resonance 
structure that represents a charged dipole separated by a single atom.
 
Examples of 1, 3-
dipolar compounds include azides and diazo compounds. Scheme 4.12 shows the various 
resonance structures of these 1, 3-dipoar compounds.
62-65 
Structure A represents the structure 
commonly presented while structures B and C represent the resonance structures that exist as 
1, 3-dipolar compounds. 
        The first dipole and 1, 3-dipolar cycloaddition was discovered by Curtius and Buchner 
in the 1880‟s.66-68 Basically, 1, 3-dipoles can be divided into two different types: the allyl 






   
Scheme 4.12 Examples of 1, 3-dipoar compounds and their resonance structures 
 
 
Scheme 4.13 Allyl anion and propargyl/allenyl 1, 3-dipoles 
        The allyl anion type is bent and has four electrons in three parallel p orbitals 
perpendicular to the plane of the dipole (Scheme 4.13). The propargyl/allenyl anion type 
dipole is normally linear. The central atom is occasionally presented as hypervalent and is 
limited to nitrogen (Scheme 4.13). The other dipole atoms can be carbon, oxygen and 
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nitrogen. Other main group IV, V, VI elements such as phosphorus and sulfur can also be 
grouped in dipoles. 
        Dipolarophiles showed less diversity than dipoles. Substituted alkenes and alkynes are 
the most commonly treated as dipolarophiles. Carbonyl, enamine, iminium and cyano groups 
which contain double or triple bonds with heteroatoms can also be considered as 
dipolarophiles. 
        Two original proposals for the mechanism of the 1, 3-dipolar cycloaddition have been 
explored: the concerted cycloaddition mechanism, proposed by Rolf Huisgen,
60 
and the 
stepwise mechanism involving a diradical intermediate, proposed by Firestone.
72
 The former 
proposal is now generally accepted.
71
 The 1, 3-dipole reacts with the dipolarophile in a 
concerted, asynchronous, and symmetry-allowed π4s + π2s fashion through a six-electron  
transition state. The stereochemistry of the reactants could be transferred to the product. For 
example, the 1, 3-DC of benzonitrile oxide with trans-dideuterated ethylene gave exclusively 




Scheme 4.14 Concerted and stepwise pathway of 1, 3-dipolar cycloaddition 
        For those step-wise 1, 3-dipolar cycloaddition, the process involves in generating a 





        The concerted 1, 3- dipolar cycloaddition can be interpreted by frontier molecular orbital 
theory (FMO).
74
 Based on FMO, frontier molecular orbitals of the 1, 3-dipole must overlap 
with the molecular orbitals of the same symmetry of the dipolarophile (Scheme 4.15).This 




Scheme 4.15 FMO interpretation of 1, 3-dipole cycloaddition 
        One is the FMO interaction between the highest occupied molecular orbital (HOMO) of 
the dipole and the lowest unoccupied molecular orbital (LUMO) of the dipolarophile.
74 
A 
second type is dominated by the reaction between the HOMO of the dipolarophile and the 
LUMO of the dipole (Scheme 4.15). The last type is HOMO of the dipole can pair with 




        Based on this FMO, two strategies are used to accelerate the cycloaddion reaction. In the 
first strategy, Lewis acids are introduced to lower the LUMO of the dipolarophile (Scheme 
4.16).
76
 Under such conditions the dipole reacts through its HOMO to generate the 
cycloaddition product. Alternatively, additives that increase the electron density of the 





 This approach is less common than the Lewis acid-based 
methods, but is most notably operative in the copper-catalyzed synthesis of triazoles from 
alkynes and azides.
78
 These two strategies increase the transformation efficiency which 
provides an efficient and convergent approach to generate multi-functionalized five-
membered hetereocycles or carbocycles containing several contiguous stereocenters in a 
single operation. So, recent development of applications about these strategies and 
transformations will be discussed in details in next sections. 
 
Scheme 4.16 General strategies to accelerate 1, 3-dipolar cycloaddition 
4.2.2.2 Iminium Catalyzed [3+2] Cycloaddition Reactions 
        The usage of iminium and enamine catalysts in forming biological and pharmaceutical 
important compounds via 1, 3-dipolar cycloadditon is fruitful. The pioneering work was 
explored by MacMillan and co-workers.
14 
The iminium ion activation was effective in the 
reaction of [3+2] cycloaddition between nitrones 4-58 and α, β-unsaturated aldehydes 4-59 
(Scheme 4.17). Although the transformations needed long reaction times varying between 96 
h to 160 h, the product of the yields and enantioselectivities was excellent. These excellent ee 
can be explained by the transition state model 4-62 in which the benzyl arm of the catalyst 




Scheme 4.17 Iminium catalyst activated 1, 3-dipolar cycloaddition 
        Similarly, Karlson and co-workers showed an interesting series of structurally diverse 
chiral secondary amines 4-63 in the cycloaddition of nitrones 4-64 with 1-cycloalkene-1-





Scheme 4.18 Iminium catalyst activated [3+2] cycloaddition of nitrones with α, β-
unsaturated aldehydes 
        Then, more proline derivatives were explored in different [3+2] cycloaddition reactions. 
The initial transformation reported by MacMillan was explored again. 
14
 Interestingly, L-
prolinol derived catalyst 4-68 indicated excellent levels of catalyst activity via high 
diastereoselectivity, high enantioselectivity and short reaction times (Scheme 4.19).
81
 
Moreover, others 1, 3-dipolars were also employed in this [3+2] cycloaddition reactions 




 Scheme 4.19 [3+2] cycloaddition using prolinol derivatives 
Chen‟s research group discovered that L-prolinol derivatives 4-62 can promote the reaction 
between azomethine imines 4-63 and α, β- unsaturated aldehydes (Scheme 4.20).82 
 
Scheme 4.20 Prolinol derivatives promoted [3+2] cycloaddition 
         Subsequently, Vicario and co-workers proved that azomethine ylides 4-67 produced in 
situ can also be effective in prolinol derivatives 4-66 catalyzed [3+2] cycloaddition reactions 
(Scheme 4.21).
83
 Addition of water was found to significantly accelerate the reaction and the 
free hydroxyl group within the catalyst structure was essential for the high selectivities 
observed in these two transformations. 
 
Scheme 4.21 [3+2] cycloaddition of azomethine ylides with unsaturated aldehydes 
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        Also, the scope of iminium ion catalyzed [3+2] cycloaddition with azomethine imines 4-
70 was extended again by Chen and co-workers.
84
 Cyclic α, β-unsaturated ketones 4-71 were 
encompassed using primary amine 4-69 as the catalyst. Although long reaction time was 
required, impressive level of asymmetric induction and excellent yields were achieved in 
these transformations. 
 
Scheme 4.22 Primary amine as iminium activator in [3+2] cycloaddition 
4.2.2.3 Enamine Catalyzed [3+2] Cycloaddition Reactions 
        As mentioned above, the primay and secondary amine catalysis in [3+2] cycloadditon 
reactions via the iminium activation model have been successfully established from the work 
of different research groups. However, these transformations are only suited for α, β-
unsaturated aldehydes or α, β-unsaturated ketones. Therefore, this limitation largely restricts 
the diverse application of these strategies in the preparation of biological and pharmaceutical 
heterocyles. In brief, the advent of novel methods that are devoid of these deficiencies would 
be of great value and particularly necessary to the synthetic community. Carbonyl, enamine, 
iminium and cyano groups, as mentioned, which contain double or triple bonds with 
heteroatoms can also be treated as dipolarophiles.  Encouraging by this fundamental strategy, 
the primary and secondary amine catalysis in [3+2] cycloadditon reactions via the enamine 




Scheme 4.23 Enamine activator in [3+2] cycloaddition reactions 
        The pioneering work was explored by Wang and co-workers in 2011 (Scheme 4.23).
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The first organocatalytic method for the [3+2] cycloaddition reaction of azides 4-74 with 
enamine was developed to produce 1,4,5-trisubstituted-1,2,3-triazoles 4-76 with high 
efficiency, regiospecificity, and functional-group tolerance. Active enamine 4-77 
tautomerized from an iminium ion was treated as the intermediate during this transformation. 
This case was the first one to build the intermediate enamine species as the dipolarophiles 




4.3 Project Objective 
        Recent years have witnessed an explosive growth in the field of iminium and enamine 
catalysis. Primary and secondary amines as catalysis in the cycloaddition transformation of 
biological and pharmaceutical compounds via the iminmium activation model have been 
greatly explored. A number of novel transformations, as described above, have been 
discovered to provide the access to various biological and pharmaceutical important 
heterocylces.  
        Despite these advances in the development of iminium and enamine catalysis in 
different cycloaddition transformations, there are still many challenges that remain to be 
addressed: a) the scope of substrates via iminium activation model would be greatly 
expanded by applying others types of 1, 3-dipoles in building important transformations. b) 
The application of enamine activation model in symmetric and asymmetric 1, 3-dipolar 
cycloaddition reactions to form biological and pharmaceutical important substrates also 
remains a key future objective. This strategy would pave the way for the widespread 
application of this cycloaddition chemistry if enamine catalysis concept can be applied in the 
related transformations. Therefore, in light of this, how to apply the enamine activation model 
in symmetric and asymmetric 1, 3-dipolar cycloaddition reactions will be the aim for further 
investigations. 
        The main purpose of this project is to explore significant enamine activation 
methodologies to overcome the mentioned challenges. The specific aspect of this project is 
using different types of available starting materials via enamine catalyzed transformations to 
form many potential biological and pharmaceutical important molecules. 
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        These significant results of this project should provide a concise way to synthesize 
different types of heterocycles. It may also pave the way to explore more detail information 
of how the enamine catalysis takes the role in the catalytic cycle during promoting the 
reactions. 
        Two different types of reactions to related heterocycles are explored. There are 1,2,3-

















Chapter 5 Room-Temperature Enamine-promoted 
Inverse-Electron-Demand [3+2] Cycloaddition: From 





A general, organocatalytic inverse-electron-demand [3+2] cycloaddition reaction 
between various carbonyls and diazoacetates has been developed. The reaction is 
catalyzed by second amines, “green promoter”, to generate substituted pyrazoles with 




        Pyrazole is widely found as the core structure in a large variety of compounds that 
possess important agrochemical and pharmaceutical activities,
86 
 and the recent successful 
discovery of pyrazole-based anti-inflammatory COX-II inhibitor and insecticide Fipronil 
have amplified the importance of pyrazoles to even a greater extent.
86, 87
 Among the varied 
synthetic protocols to pyrazoles, the 1,3-dipolar cycloaddition
68, 88 
of a diazo compound and 
an alkyne (Scheme 5.1a), and the cyclocondensation of a hydrazine with a 1,3-dicarbonyl 





toxic transitional metals, somewhat limited substrate scope and 
uncontrolled regioselectivity greatly reduce the attractiveness of these known approaches.
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Scheme 5.1 Two general approaches to polysubstituted pyrazoles 
 
        Although the 1,3-dipolar cycloaddition of electron-rich diazo compounds to alkynes is 
known,
92
 the development of efficient process using electron-deficient diazo compounds is 
much less reported,
93
 attributing to the increased HOMO(dipolarophile)-LUMO(dipole) 
energy gap between diazo compounds and alkynes.
74
 One common method has been applied 
to generate pyrazole ring by incorporating either Lewis acids or transition metals to lower the 
LUMO of the alkyne dipolarphiles.
94 
Another attractive, but less common complementary 
strategy is the HOMO-raising activation of the alkynes by forming metal acetylides. For 
example, in 2007, Ready research group reported a mild copper-promoted cycloaddition of 
diazocarbonyl compounds and acetylides.
[95a]
 Later, Liang disclosed a Zn(II) catalyzed 
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intermolecular cycloaddition of various α-diazocarbonyl molecules to terminal alkynes.[95b] 
To the best of our knowledge, no such organocatalytic cycloaddition method has been 
reported by raising the HOMO of the dipolarphiles to achieve the target pyrazole ring. 
 
 
Scheme 5.2 This work: enamines as active synthetic intermediates, allowing the inverse 
electron-demand [3+2] cycloaddition to generate pyrazoles at room temperature. HOMO = 
highest occupied molecular orbital, LUMO = lowest unoccupied molecular orbital. 
 
        In the course of our study on the intermolecular cycloaddition of carbonyls and 
diazoacetates, we made an interesting finding (Scheme 5.2): the in situ formed enamine (versus 
metal acetylide) can promote the cycloaddition to achieve the targeting pyrazole ring. We 
envision that this reaction may contain an unusual organocatalytic HOMO-raising type inverse-
electron-demand (IED) 1, 3-dipolar [3+2] cycloaddition process. In addition, this efficient 
pyrazole synthetic protocol can start from readily available and simple starting materials, 





5.2 Results and Discussion 
5.2.1 Reaction Optimization 
        Initial experiments were conducted by using cyclohexanone 5-2a and ethyl diazoacetate 
5-1a in the presence of 10 mol% loading of amine catalysts, such as primary amines (5-VIII 
and 5-IX), secondary amines (5-I, 5-II, 5-III, 5-IV and 5-V) and tertiary amines (5-VI and 5-
VII). Among the catalysts tested (Table 5.1), pyrrolidine 5-I is identified as the most effective 
catalyst for this transformation. Further optimization of the standard reaction parameters 
revealed that the solvent is the crucial factor for improving the catalysis. When the reaction 
was carried out in DMSO, reactivity was positively influenced, leading to the desired product 
5-3aa in 87% yield.
 
Other solvents, such as toluene, MeCN, DCE, CHCl3, THF, MeOH, IPA, 
DMA, DMF, and 1, 4-dioxane, significantly diminished the chemical yields (Table 5.1, <5-
64%). Lowering the catalyst loading to 5 mol% resulted in a longer reaction time (90% yield 
after 72 h). Changing the 5-1a/5-2a ratio from 1:1 to 1:3 indicated a slightly beneficial effect 
on the efficacy of the reaction (Table 5.1, 71% and 87%, respectively). Finally, the best 
compromise was achieved when performing the cycloaddition reaction at room temperature, 
using 10 mol% of second amine 5-I and 1:2 ratio of 1a/2a in DMSO. 
 
5.2.2 Substrate Scope 
        With the optimized reaction conditions in hand, we then investigated a variety of ketones 
with ethyl diazoacetate 5-1a in the reaction catalyzed by second amine 5-I (10 mol%) at room 
temperature. The results are summarized in Table 5.2. Interestingly, among the various 
examined ketones, cyclic ketones appeared as the substrates of choice, from six to eight 
member ring, gave good to excellent yields under standard conditions (Table 5.2, 5-3aa to 5-
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3aj, 75-96%, 12-10 h). The best yield, however, was obtained with cycloheptanone, which 
afforded the corresponding pyrazole in 96% isolated yield (Table 5.2, 5-3ai). It is worth noting 
that dissymmetrical cyclic ketone afforded a high level of regeioselectivity. For example, 3, 3- 
dimethylcyclohexanone led to a single regioisomer 5-3af (Table 5.2), in which the heterocycle 
is furthest from the gem-dimethyl group for steric reasons. On the other hand, 4, 4-
dimethylcyclohexanone furnished pyrazole 5-3ae (Table 5.2), which is an isomer of 5-3af. The 
regioselectivity can be explained by the cycloaddition occurring with most stabilized enamine. 
 




        
a
 Reaction conditions: 5-1a (0.2 mmol), 5-2a (0.4 mmol), DMSO (0.4 mL), room 
temperature.; 
b
 20 mol% cat. 5-I, 5 h.; 
c
 10 mol% cat. 5-I, 12 h.; 
d
 5 mol% cat. 5-I, 72 h.; 
e
 5-
2a (0.2 mmol). 
f




        Symmetric and dissymmetrical acyclic ketones both gave good yields under the same 
conditions (Table 5.2, 5-3ak, 5-3al). Pleasingly, phenones, such as acetophenone and 
propiophenone were both reactive and afforded good yields, although a higher reaction 
temperature required (Table 5.2, 5-3am and 5-3an, 77% and 71%, 80 
o
C, 24 h).  
 
  Table 5.2 Substrate scope of ketones 
[a] 
 
        
a
 Reaction conditions: 5-1a to 5-1c (0.2 mmol), 5-2a to 5-2n (0.4 mmol), DMSO (0.4 mL), 








        Two other diazoacetates (Table 5.2, 5-1b and 5-1c) were also explored and both afforded 
good yields in the presence of the standard conditions (Table 5.2, 5-3ba and 5-3ca). Moreover, 
a regioselective cycloaddition of diazoacetate with enaminoesters and enaminones, formed in 
situ from activated ketones (β-ketoesters, β-diketones) and a catalytic amount of secondary 
amine 5-I, was investigated. Noteworthily, ketones carrying simply functional groups (e.g. β-
ester and -ketone) could also be successfully employed (Table 5.3, 5-3ao to 5-3ar), achieving 
results similar to those obtained for the general ketone counterparts (Table 5.3, 81-91%, 8-12 
h). To further indicate the generality and potential of our approach, other types of carbonyls 
(e.g. aldehydes) were explored in the reaction with diazoacetates 5-1a to 5-c. However, 
catalyst 5-I indicated a slow conversion based on previous standard conditions. 
 
   Table 5.3 Substrate scope of 1,3-dicarbonyls 
[a] 
 
        
a
 Reaction conditions: 5-1a (0.2 mmol), 5-2o to 5-2r (0.4 mmol), DMSO (0.4 mL), 5-I (10 
mol%), room temperature.  
 
        Finally, acyclic secondary diethyl amine 5-IV was identified to be the best promoter in 
the reaction of diazoacetates with aldehydes after further optimizing the reaction parameters. 
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As outlined in Table 5.4, the corresponding adducts 5-3 were obtained in moderate to excellent 
yields (51-96%). A certain level of variation is possible at the side chain of the carbonyl group. 
For example, straight-chain aldehydes having different lengths were tolerated, which gave the 
cycloadducts in good to high yields (Table 5.4, 76-94%, 18-40 h). Pleasingly, aldehydes 
suffered with more bulky alkyl chains were also afforded good yields (Table5.4, 5-3ai’ and 5-
3am’, 80% and 74%, respectively). Moreover, the catalytic reaction was also applicable to 
functionalized aldehydes. Aldehydes bearing aromatic ring, heteroatom, and alkenyl motifs 
were fully compatible with the method (Table 5.4, 5-3aj’ to 5-3ap’, 51-81%).  
 






        
a
 Reaction conditions: 5-1a to 5-1c (0.2 mmol), 5-2a' to 5-2q' (0.6 mmol), DMSO (0.4  






        To further illustrate the unique catalytic specificity of catalysts in the reaction, we 
conducted competition experiments. As highlighted in Scheme 5.3, propionaldehyde (5-2a’) 
reacts with ethyl diazoacetate (5-1a) much faster than 3-pentanone (5-2l) in the presence of 
acyclic secondary diethyl amine 5-IV as catalyst (Scheme 5.3, only 5-3aa’ formed, 49% yield). 
On the contrary, the propionaldehyde (5-2a’) reacts with ethyl diazoacetate (5-1a) much 
slower than 3-pentanone (5-2l) in the presence of cyclic secondary amine 5-I as catalyst 
(Scheme 5.4, only 5-3al formed, 55% yield). Moreover, the reaction was not only limited to 
ethyl diazoacetate as the methyl and benzyl diazoacetates performed similarly in the 
cycloaddition (Table 5.4, 5-3bc’ and 5-3cc’, 96% and 86%, respectively). 
 




        
a
 Reaction conditions: 1a (0.2 mmol), 2a' (0.2 mmol), 2l (0.2 mmol), DMSO (0.4 mL), cat.     
(20 mol%), room temperature, 12 h. 
169 
 
5.2.3 Application of the method 
        With the ability to engage a wide range of carbonyls in this reaction, we sought to apply 
this method to the synthesis of GPR 109a agonist 5-8 
96
 in only two steps (Scheme 5.4). To 
begin, ethyl diazoacetate 5-1a was treated with 2-pentanone 5-2v followed by addition of cat. 
5-I (10 mol%) to furnish the intermediate pyrazole 5-3av in 75% yield (Scheme 5.4). 
Subsequent hydrolysis allows intermediate pyrazole 5-3av convert to the target, GPR 109a 
agonist 5-8 in a moderate yield (Scheme 5.4, 53%). 




5.2.4 Mechanistic Investigations  
        Our postulated reaction pathways are summarized in Scheme 5.5. While the reaction 
mechanism is unclear at this stage, it is still believed that the sequence is triggered by the 
generation of enamine 5-4 via the condensation of pentanal 5-2c’ and diethylamine 5-IV. 
Enamine 5-4 acts as the electron-rich olefinic partner, and reacts with a deuterium benzyl 
diazoacetate 5-1d via an inverse-electron-demand 1,3-dipolar [3+2] cycloaddition process to 
access the intermediate 5-5. Notably, this cycloaddition process demonstrates a high 
regioselectivity, which leading to directly introduce a diverse set of substituents to pyrazole 
scaffold. Intermediate 5-5 can convert to intermediate 5-6 after tautomerization triggered by a 
1,3-hydride shift. A subsequent and selective C-H1 bond-breaking induces the formation of 
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the active intermediate 5-7. To prove our hypothesis on selective C-H bond-breaking, we 
conducted a deuterium-labeling experiment (Scheme 5.6).
 
The enamine promoted 
cycloaddition reaction carried out with β-deuterated benzyl diazoacetate 5-1d yielded 5-3d’c 
without any deuterium incorporation on the pyrazole ring, which supporting our proposed 
selective C-H1 bond-breaking (Scheme 5.6). We envision that the C-H1 bond is activated by 
the adjacent electron-withdrawing ester group, which resulting a priority bond cleavage than 
C-H2. Lastly, an elimination step followed by a tautomerization leads to the generation of the 
final product 5-3dc’. 
 












In summary, a general, organocatalytic inverse-electron-demand [3+2] cycloaddition reaction 
between various carbonyls and diazoacetates has been developed. The reaction is catalyzed 
by second amines, “green promoter”, to generate substituted pyrazoles with high levels of 
regioselectivity. It is noteworthy that this [3+2] cycloaddition proceeds efficiently under 
room temperature with a simple and inexpensive catalyst. Considering the large variety and 
ready availability of the starting materials (e.g. ketones, β -ketoesters, β-diketones, and 
aldehydes) and the operational simplicity, a convenient, practical and highly modular 
pyrazole synthesis has been developed. We believe that this work will arouse more research 
interest in organocatalytic synthesis of other biologically active heterocycles. Such studies are 
actively under way in this laboratory, and more results will be reported in due course. 
 
5.4 Experimental Section 
5.4.1 Material and General Methods 




C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or a AMX500 (500 
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MHz) spectrometer. Chemical shifts were reported in parts per million (ppm), and the 
residual solvent peak was used as an internal reference: proton (chloroform δ 7.26), carbon 
(chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) was used as a reference. Multiplicity 
was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd 
(doublet of doublet), bs (broad singlet). Coupling constants were reported in Hertz (Hz). Low 
resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI mode. 
All high resolution mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer. 
For thin layer chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were 
used, and compounds were visualized with a UV light at 254 nm. Further visualization was 
achieved by staining with iodine. Flash chromatography separations were performed on 
Merck 60 (0.040-0.063 mm) mesh silica gel.  
         Compounds 5-1a to 5-1c, 5-2q to 5-2u, 5-2o to 5-2q were prepared according to 
literature,
 97-99
 respectively. Compounds 5-2a to 5-2p, 5-2v, 5-2a' to 5-2n' were commercially 
available. 
 
5.4.2 Representative Procedures for the Synthesis of Pyrazoles 
a) IED-[3+2] Cycloaddition of Ketones:  
  
        To a solution of cyclohexanone 5-2a (0.4 mmol, 2.0 equiv) in DMSO was added 10 mol % 
pyrrolidine and then ethyl 2-diazoacetate 5-1a (0.2 mmol, 1.0 equiv.). The reaction was 
stirred at r.t. for 12 h. The solution was then evaporated to dryness under reduced pressure to 
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give a crude residue which was purified by silica gel column chromatography eluted by 
hexane/EtOAc = 10:1 then 4:1 to afford 32 mg (87 % yield) of 5-3aa as pale yellow oil. 
 
b) IED-[3+2] Cycloaddition of Aldehydes: 
 
        To a solution of pentanal 5-2c' (1.0 mmol, 5.0 equiv.) in DMSO was added 20 mol % 
diethylamine as catalyst and then ethyl 2-diazoacetate 5-1a (0.2 mmol, 1.0 equiv.). The 
reaction was stirred at r.t. for 24 h. The solution was then evaporated to dryness under 
reduced pressure to give a crude residue which was purified by silica gel column 
chromatography eluted by hexane/EtOAc = 10:1 then 4:1 to afford 5-3ac' (32 mg, 86 % yield) 
as pale yellow oil. 
 
c) GPR 109a Synthesis:  
 
        To a solution of pentan-2-one 5-2v (0.4 mmol, 2.0 equiv.) in DMSO was added 10 mol% 
pyrrolidine as catalyst and ethyl 2-diazoacetate 5-1a (0.2 mmol, 1.0 equiv.). The reaction was 
stirred at r.t. for 12 h. The solution was then evaporated to dryness under reduced pressure to 
give a crude residue which was purified by silica gel column chromatography eluted by 
hexane/EtOAc = 10:1 then 4:1 to afford 27 mg (75% yield) of 5-3av as pale yellow oil. Then 
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followed with the procedure as reported in literature,
100 
 the GPR 109a agonist was finally 
obtained in 53% yield . 
 
 d) Procedure for Competition Reaction:  
 
        To a solution of propionaldehyde 5-1b' (0.2 mmol, 1.0 equiv.) and pentan-3-one 5-1l 
(0.2 mmol, 1.0 equiv) in DMSO was added 20 mol% pyrrolidine as catalyst and then ethyl 2-
diazoacetate 5-2a (0.2 mmol, 1.0 equiv.). The reaction was stirred at r.t. for 12 h. The 
solution was then evaporated to dryness under reduced pressure to give a crude residue which 
was purified by silica gel column chromatography eluted by hexane/EtOAc = 15:1 then 4:1 to 
afford 20 mg (55% yield) of 5-3al as pale yellow oil.  
 
        To a solution of propionaldehyde 5-1b' (0.2 mmol, 1.0 equiv.), and pentan-3-one 5-1l 
(0.2 mmol, 1.0 equiv.) in DMSO was added 20 mol % diethylamine as catalyst and then ethyl 
2-diazoacetate 5-2a (0.2 mmol, 1.0 equiv). The reaction was stirred at r.t. for 12 h. The 
solution was then evaporated to dryness under reduced pressure to give a crude residue which 
was purified by silica gel column chromatography eluted by hexane/EtOAc = 10:1 then 4:1 to 
afford 16 mg (49% yield) of 5-3aa' as pale yellow oil.  
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e) Synthesis of Benzyl α-Deuteriodiazoacetate95a, 96b, 101 
        Benzyl alcohol (0.54 g, 5 mmol) was dissolved in ethyl acetoacetate (6.5 g, 50 mmol 
and then refluxed under N2 for 5 h. Unreacted ethyl acetoacetate was removed under reduced 
pressure, and benzyl acetoacetate was purified by flash chromatography (5% ethyl acetate in 
hexanes) for next step.  
        To a solution of benzyl acetoacetate (960 mg, 5 mmol) in acetonitrile (10 ml) was added 
Et3N (653 mg, 6.5 mmol). The reaction mixture was cooled in an ice bath and a solution of 
tosyl azide (1.08 g, 5.5 mmol) in acetonitrile (10 ml) was added slowly. The reaction mixture 
was allowed to warm up to r.t. After stirring for 10 h, solvent was removed under reduced 
pressure. The residue was dissolved in ether and washed with 5% aqueous KOH solution. To 
a solution of the crude benzyl 2-diazo-acetoacetate (1.03 g, 5.0 mmol) in acetonitrile (15 mL) 
was added 5% KOH (20 mL), and then the reaction was stirred at r.t. for 1 h. The reaction 
mixture was extracted with ether, and the organic layer was separated, dried over Mg2SO4, 
and concentrated under reduced pressure which was purified by flash chromatography 
(hexane: ethyl acetate from 100:1 to 10:1) to provide benzyl diazoacetate as a yellow liquid.  
        Benzyl diazoacetate (5.0 mmol) was combined with anhydrous ether (30 mL) in a 100 
mL Morton flask. About 30 mL of 10% NaOD in D2O was added, and the complex solution 
was vigorously stirred for 1 day at room temperature. The two layers were separated and the 
organic layer was collected by syringe, and then dried by MgSO4. The solution was filtered 
and carefully concentrated by rotary evaporation at room temperature. This procedure was 
repeated two to three times, each time using fresh 10% NaOD in D2O until 
1
H NMR analysis 
indicated that deuterium incorporation at C(α) was >98% by comparing the residual NMR 




f) Deuterium Labeling Experiments. 
        Initially, fresh prepared benzyl α-D-diazoacetate 5-1d (0.2 mmol, 1.0 equiv., >98% D) 
was added into the solution of pentanal 5-2c' (1.0 mmol, 3.0 equiv.) and 20 mol % 
diethylamine in anhydrous DMSO, then vigorously stirred at r.t. for 12 h. The reaction was 
then stopped and evaporated to dryness under reduced pressure to give a crude residue which 
was purified by silica gel column chromatography eluted by hexane/EtOAc = 10:1 then 4:1 to 
afford 5-3dc'. 
1
H NMR analysis indicated that 3dc' (assumed deuterium product) was exactly 
same as 5-3cc' (non-deuterated product) which indicated by the NMR of residual hydrogen 
signal at δ 6.62. In addition, several others reaction factors (D6-DMSO and/or D2O) which 
may affect the labeling experiments were also examined, but 
1
H NMR data of 3dc'-2 to 3dc'-







5.4.3 Analytical Data of the Pyrazoles 
Ethyl 4, 5, 6, 7-tetrahydro-1H-indazole-3-carboxylate (5-3aa) 
 
1
H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.5 Hz, 2H), 2.74 (t, J = 6.2 Hz, 2H), 2.68 (t, J = 
6.2 Hz, 2H), 1.80-1.74 (m, 4H), 1.35 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
162.58, 145.27, 136.25, 119.78, 60.93, 23.31, 22.98, 22.47, 21.89, 14.73; HRMS (ESI): calcd. 
for C10H14N2O2 [M-H]
-
 193.0977, found 193.0983. 
 
Ethyl 6-ethyl-4, 5, 6, 7-tetrahydro-1H-indazole-3-carboxylate (5-3ab) 
 
1
H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.5 Hz, 2H), 2.94 – 2.85 (m, 2H), 2.66 – 2.60 (m, 
1H), 2.26 – 2.18 (m, 1H), 1.96 – 1.93 (m, 1H), 1.68 – 1,66 (m , 1H), 1.50 – 1.27 (m, 6H), 
0.96 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.21, 146.55, 135.20, 120.15, 
61.08, 36.39, 29.45, 29.01, 28.66, 21.30, 14.79, 12.00; HRMS (ESI): calcd. for C12H18N2O2 
[M-H]
-
 221.1290, found 221.1287. 
 
Diethyl 4, 5, 6, 7-tetrahydro-1H-indazole-3, 6-dicarboxylate (5-3ac) 
 
1
H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.5 Hz, 2H), 4.17 (q, J = 7.0 Hz, 2H), 3.03 – 2.87 
(m, 3H), 2.82 – 2.68 (m, 2H), 2.21 – 2.15 (m, 1H), 1.87 – 1.80 (m, 1H), 1.36 (t, J = 7.5 Hz, 
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3H), 1.26 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 175.18, 161.78, 130.45, 128.77, 
119.28, 61.26, 61.18, 40.21, 26.38, 25.28, 20.89, 14.76, 14.65; HRMS (ESI): calcd. for 
C13H18N2O4 [M-H]
- 
265.1188, found 265.1182. 
 
Ethyl 1', 4', 5', 7'-tetrahydrospiro [[1, 3] dioxolane-2, 6'-indazole]-3'-carboxylate (5-3ad) 
 
1
H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.0 Hz, 2H), 4.02 – 4.00 (m, 4H), 2.94 (t, J = 7.0 
Hz, 4H), 1.93 (t, J = 7.0 Hz, 2H), 1.35 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
161.38, 148.51, 140.56, 118.90, 109.10, 65.15, 61.27, 34.03, 32.18, 19.52, 14.77; HRMS 
(ESI): calcd. For C12H16N2O4 [M-H]
-
 251.1032, found 251.1029. 
 
Ethyl 6, 6-dimethyl-4, 5, 6, 7-tetrahydro-1H-indazole-3-carboxylate (5-3ae) 
 
1
H NMR (500 MHz, CDCl3): δ 4.36 (q, J = 7.5 Hz, 2H), 2.74 (t, J = 6.5 Hz, 2H), 2.45 (s, 2H), 
1.53 (t, J = 6.5 Hz, 2H), 1.37 (t, J = 7.5 Hz, 3H), 0.99 (s, 6H); 
13
C NMR (125 MHz, CDCl3): 
δ 162.11, 146.90, 134.98, 118.90, 61.12, 36.38, 36.34, 30.79, 28.31, 19.16, 14.81; HRMS 
(ESI): calcd. for C12H18N2O2 [M-H]
-
 221.1290, found 221.1293. 
 





H NMR (500 MHz, CDCl3): δ 4.36 (q, J = 7.5 Hz, 2H), 2.69 (t, J = 7.0 Hz, 2H), 2.53 (s, 2H), 
1.58 (t, J = 7.0 Hz, 2H), 1.37 (t, J = 7.5 Hz, 3H), 0.99 (s, 6H); 
13
C NMR (125 MHz, CDCl3): 
δ 162.07, 145.53, 135.41, 120.13, 61.14, 35.96, 35.61, 30.37, 28.38, 19.81, 14.81; HRMS 
(ESI): calcd. for C12H18N2O2 [M-H]
-
 221.1290, found 221.129. 
 
Ethyl 1, 4, 5, 7-tetrahydropyrano [3, 4-c] pyrazole-3-carboxylate (5-3ag) 
 
1
H NMR (500 MHz, CDCl3): δ 4.79 (s, 2H), 4.38 (q, J = 7.0 Hz, 2H), 3.90 (t, J = 5.6 Hz, 2H), 
2.88 (t, J = 5.6 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 160.82, 
147.59, 132.15, 117.40, 65.45, 64.78, 61.56, 23.02, 14.77; HRMS(ESI): calcd. for C9H12N2O3 
[M-H]
-
 195.0770, found 195.0777. 
Ethyl 1, 4, 5, 7- tetrahydrothiopyrano [3, 4-c] pyrazole-3-carboxylate (5-3ah) 
 
1
H NMR (500 MHz, CDCl3): δ 4.36 (q, J = 7.0 Hz, 2H), 3.78 (s, 2H), 3.07 (t, J = 6.0 Hz, 2H), 
2.85 (t, J = 6.0 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 161.33, 
143.58, 134.16, 119.46, 61.46, 26.79, 24.38, 14.76; HRMS(ESI): calcd. for C9H12N2O2S  [M-
H]
-
 211.0541, found 211.0545. 
 





H NMR (500 MHz, CDCl3): δ 4.36 (q, J = 7.0 Hz, 2H), 2.92 (t, J = 6.0 Hz, 2H), 2.81 (t, J = 
6.0 Hz,  2H), 1.92 – 1.80 (m, 2H), 1.69 – 1.60 (m, 4H), 1.37 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ 161.53, 151.60, 134.06, 124.53, 60.61, 32.11, 28.38, 27.19, 24.16, 
14.21; HRMS (ESI): calcd. for C11H16N2O2 [M-H]
-
 207.1134, found 207.1142. 
 
Ethyl 4, 5, 6, 7, 8, 9-hexahydro-1H-cycloocta[c]pyrazole-3-carboxylate (5-3aj) 
 
1
H NMR (500 MHz, CDCl3): δ 4.37 (q, J = 7.0 Hz, 2H), 2.87 (t, J = 6.5 Hz, 2H), 2.78 (t, J = 
6.5 Hz, 2H), 1.71 – 1.66 (m, 4H), 1.48 – 1.46 (m, 2H), 1.40 – 1.25 (m, 5H); 13C NMR (125 
MHz, CDCl3): δ 161.11, 150.72, 133.61, 122.63, 60.72, 30.18, 29.18, 25.66, 25.53, 25.42, 
21.36, 14.30; HRMS (ESI): calcd. for C12H18N2O2 [M-H]
-
 221.1290, found 221.1296. 
 
Ethyl 4, 5-dimethyl-1H-pyrazole-3-carboxylate (5-3ak) 
 
1
H NMR (500 MHz, CDCl3): δ 4.34 (q, J = 7.0 Hz, 2H), 2.25 (s, 3H), 2.21 (s, 3H), 1.36 (t, J 
= 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.29, 144.28, 136.41, 118.07, 61.06, 14.71, 
10.88, 9.09; HRMS(ESI): calcd. for C8H12N2O2 [M-H]
-
 167.0821, found 167.0825. 
 





H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.0 Hz, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.25 (s, 
3H), 1.35 (t, J = 7.5 Hz, 2H), 1.10 (t, J = 7.0Hz, 1H); 
13
C NMR (125 MHz, CDCl3): δ 162.03, 
144.24, 135.68, 124.77, 61.09, 17.26, 15.46, 14.68, 10.95; HRMS(ESI): calcd. for C9H14N2O2 
[M-H]
-
 181.0977, found 181.0982. 
 
Ethyl 4-phenyl-1H-pyrazole-3-carboxylate (5-3am) 
 
1
H NMR (500 MHz, CDCl3): δ 7.98 (s, 1H), 7.54 (d, J = 7.0Hz, 2H), 7.40 (t, J = 7.0 Hz, 2H), 
7.34 (t, J = 7.5 Hz, 1H), 4.34 (t, J = 7.0 Hz, 2H), 1.29 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 
MHz, CDCl3): δ 161.16, 131.71, 129.50, 127.97, 127.50, 125.61, 61.14, 14.08; HRMS(ESI): 
calcd. for C12H12N2O2 [M-H]
-
 215.0821, found 215.0827. 
 
Ethyl 5-methyl-4-phenyl-1H-pyrazole-3-carboxylate (5-3an) 
 
1
H NMR (500 MHz, CDCl3): δ 7.39 (t, J = 7.0 Hz, 2H), 7.33 (q, J = 7.0 Hz, 3H), 4.25 (q, J = 
7.5 Hz, 2H), 2.29 (s, 3H), 1.20 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 161.77, 
132.60, 130.69, 129.42, 129.11, 128.28, 127.67, 123.70, 61.31, 14.43, 11.51; HRMS(ESI): 
calcd. for C13H14N2O2 [M-H]
-
 229.0977, found 229.0985. 
 





H NMR (500 MHz, CDCl3): δ = 3.85 (s, 3H), 2.73 (t, J = 5.8 Hz 2H), 2.68 (t, J = 5.8 Hz, 
2H), 1.80 – 1.75 (m, 4H); 13C NMR (125 MHz, CDCl3): δ = 163.15, 144.52, 136.73, 119.80, 





Benzyl 4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (5-3ca) 
 
1
H NMR (500 MHz, CDCl3): δ = 7.40 (d, J = 7.0 Hz, 2H), 7.38 – 7.30 (m, 3H), 5.34 (s, 2H), 
2.73 (t, J = 5.7 Hz, 2H), 2.64 (t, J = 5.7 Hz, 2H), 1.76 – 1.72 (m, 4H); 13C NMR (125 MHz, 
CDCl3): δ = 162.10, 145.97, 136.31, 135.40, 129.01, 128.67, 128.64, 120.25, 66.73, 23.28, 
22.99, 22.60, 21.94; HRMS(ESI): calcd. for C15H15N2O2 [M-H]
-
 255.1139, found 255.1132. 




H NMR (500 MHz, CDCl3): δ 7.41 – 7.36 (m, 3H), 7.35 – 7.32 (m, 2H), 4.25 (q, J = 7.5 Hz, 
4H), 1.19 (t, J = 7.5 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): δ 160.16, 130.43, 130.10, 127.88, 
127.81, 127.24, 61.27, 13.77; HRMS(ESI): calcd. for C15H16N2O4 [M-H]
-





Ethyl 5-benzoyl-4-phenyl-1H-pyrazole-3-carboxylate (5-3ap) 
 
1
H NMR (500 MHz, CDCl3): δ 7.88 (d, J = 7.0 Hz, 2H), 7.48 (t, J = 7.5 Hz, 1H), 7.37 – 7.23 
(m, 7H), 4.31 (q, J = 7.5 Hz, 2H), 1.22 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
188.48, 160.64, 146.38, 137.08, 135.34, 133.44, 130.86, 130.83, 130.59, 128.82, 128.48, 
128.20, 127.94, 61.97, 14.28; HRMS(ESI): calcd. for C19H16N2O3 [M-H]
-
 319.1083, found 
319.1092. 
 
Ethyl 4-phenyl-5-(thiophene-3-carbonyl)-1H-pyrazole-3-carboxylate (5-3aq) 
 
1
H NMR (500 MHz, CDCl3): δ 8.10 (s, 1H), 7.68 (d, J = 4.5 Hz, 1H), 7.44 – 7.35 (m, 6H), 
7.12 (t, J = 4.5 Hz, 1H), 4.29 (q, J = 7.5 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 
MHz, CDCl3): δ 179.65, 160.03, 143.36, 136.16, 135.33, 130.84, 130.71, 128.62, 128.42, 










H NMR (500 MHz, CDCl3): δ 12.17 (s, 1H) 7.41-7.35 (m, 3H), 7.34 – 7.33 (m, 2H), 7.30 – 
7.23 (m, 3H), 7.22 – 7.19 (m, 2H), 4.25 (q, J = 7.0 Hz, 2H), 4.19 (s, 2H), 1.18 (t, J = 7.0 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): δ 192.44, 160.57, 134.20, 130.56, 130.16, 128.85, 128.53, 
128.14, 127.55, 127.30, 61.91, 46.90, 14.21; HRMS(ESI): calcd. for C20H18N2O3 [M-H]
-
 
333.1239, found 333.1249. 
 
Ethyl 5-methyl-1H-pyrazole-3-carboxylate (5-3aa') 
 
1
H NMR (500 MHz, CDCl3): δ 6.58 (s, 1H), 4.37 (q, J = 7.0 Hz, 2H), 2.37 (s, 3H), 1.36 (t, J 
= 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.51, 143.26, 142.25, 107.63, 61.29, 14.69, 
11.80; HRMS(ESI): calcd. for C7H9N2O2 [M-H]
-
 153.0670, found 153.0672. 
 
Ethyl 5-ethyl-1H-pyrazole-3-carboxylate (5-3ab') 
 
1
H NMR (500 MHz, CDCl3): δ 8.59 (s, 1H), 6.57 (s, 1H), 4.34 (q, J = 7.0 Hz, 2H), 2.72 (q, J 
= 7.5 Hz, 2H), 1.32 (t, J = 7.0 Hz, 3H), 1.24 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): 
δ 162.61, 149.35, 142.18, 106.05, 61.22, 19.71, 14.66, 13.68; HRMS(ESI): calcd. for 
C8H11N2O2 [M-H]
-
 167.0826, found 167.0826. 
 





H NMR (500 MHz, CDCl3): δ 6.57 (s, 1H), 4.35 (q, J = 7.0 Hz, 2H), 2.65 (t, J  = 7.5 Hz, 
2H), 1.67 – 1.60 (m, 2H), 1.33 (t, J = 7.0 Hz, 3H), 0.92 (t, J = 7.5 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 162.50, 148.18, 142.00, 106.74, 61.27, 28.47, 22.85, 14.70, 14.08; 
HRMS(ESI): calcd. for C9H13N2O2 [M-H]
-
 181.0983, found 181.0977. 
 
Ethyl 5-butyl-1H-pyrazole-3-carboxylate (5-3ad') 
 
1
H NMR (500 MHz, CDCl3): δ 9.42 (s, 1H), 6.55 (d, J = 2.5 Hz, 1H), 4.32 (q, J = 7.0 Hz, 
2H), 2.66 (q, J = 7.5 Hz, 2H), 1.61 – 1.55 (m, 2H), 1.33 – 1.28 (m, 5H), 0.85 (t, J = 7.5 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): δ 162.66, 147.88, 142.27, 106.48, 61.16, 31.57, 25.95, 
22.56, 14.63, 14.10; HRMS(ESI): calcd. for C10H15N2O2 [M-H]
-
 195.1139, found 195.1142. 
 
Ethyl 5-pentyl-1H-pyrazole-3-carboxylate (5-3ae') 
 
1
H NMR (500 MHz, CDCl3): δ 8.93 (s, 1H), 6.56 (s, 1H), 4.33 (q, J = 7.0 Hz, 2H), 2.68 – 
2.65  (m, 2H), 1.62 – 1.60 (m, 2H), 1.34 – 1.27 (m, 7H), 0.85 (t, J = 7.0 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ 162.59, 148.11, 142.17, 106.56, 61.22, 31.69, 29.21, 26.33, 22.75, 
14.67, 14.34.; HRMS(ESI): calcd. for C11H17N2O2 [M-H]
-
 209.1296, found 209.1295. 
 





H NMR (500 MHz, CDCl3): δ 6.60 (s, 1H), 4.38 (q, J = 7.5 Hz, 2H), 2.70 (t, J = 7.5 Hz, 2H), 
1.67 – 1.62 (m, 2H), 1.39 – 1.27 (m, 11H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 162.43, 148.65, 142.05, 106.73, 61.30, 32.16, 29.59, 29.55, 29.43, 26.59, 23.06, 
14.73, 14.49; HRMS(ESI): calcd. for C13H21N2O2 [M-H]
-
 237.1609, found 237.1604. 
 
Ethyl 5-octyl-1H-pyrazole-3-carboxylate (5-3ag') 
 
1
H NMR (500 MHz, CDCl3): δ 6.58 (s, 1H), 4.37 – 4.33 (m, 2H), 2.67 (t, J = 7.5 Hz, 2H), 
1.64 – 1.61 (m, 2H), 1.37 – 1.24 (m, 13H), 0.85 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 162.42, 148.62, 141.84, 106.73, 61.33, 32.28, 29.73, 29.63, 29.58, 26.56, 23.09, 
14.74, 14.53; HRMS(ESI): calcd. for C14H23N2O2 [M-H]
-
 251.1765, found 251.1754. 
 





H NMR (500 MHz, CDCl3): δ 6.58 (s, 1H), 4.36 (q, J = 7.0 Hz, 2H), 2.67 (t, J = 7.5 Hz, 2H), 
1.65 – 1.60 (m, 2H), 1.37 – 1.24 (m, 15H), 0.86 (t, J = 6.5 Hz , 3H); 13C NMR (125 MHz, 
CDCl3): δ 162.22, 148.85, 141.52, 106.87, 61.39, 32.32, 29.93, 29.78, 29.74, 29.59, 26.74, 
23.12, 14.76, 14.56; HRMS(ESI): calcd. for C15H25N2O2 [M-H]
-
 265.1922, found 265.1927. 
 
Ethyl 5-isopropyl-1H-pyrazole-3-carboxylate (5-3ai') 
 
1
H NMR (500 MHz, CDCl3): δ 6.55 (d, J = 1.8 Hz, 1H), 4.33 – 4.29 (m, 2H), 3.04 – 2.98 (m, 
1H), 1.29 (t, J = 7.5 Hz, 3H), 1.23 (d, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): δ 
162.51, 154.07, 141.73, 104.82, 61.18, 26.57, 22.72, 14.63; HRMS(ESI): calcd. for 
C9H13N2O2 [M-H]
-
 181.0983, found 181.0977. 
 
Ethyl 5-benzyl-1H-pyrazole-3-carboxylate (5-3aj') 
 
1
H NMR (500 MHz, CDCl3): δ.33 (t, J = 8.0 Hz, 2H), 7.25 (m, 3H), 6.59 (s, 1H), 4.36 (q, J = 
7.0 Hz, 2H), 4.08 (s, 2H), 1.36 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 161.82, 
148.44, 140.74, 138.66, 129.16, 127.15, 107.87, 61.49, 33.44, 14.70; HRMS(ESI): calcd. for 
C13H13N2O2 [M-H]
-
 229.0983, found 229.0980. 
 





H NMR (500 MHz, CDCl3): δ = 7.12 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 6.55 (s, 
1H), 4.33 (q, J = 7.0 Hz, 2H), 3.98 (s, 2H), 3.78 (s, 3H), 1.33 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(125 MHz, CDCl3): δ = 161.83, 158.86, 148.85, 140.78, 130.61, 130.16, 114.58, 107.72, 
61.49, 55.73, 32.54, 14.71; HRMS(ESI): calcd. for C14H15N2O3 [M-H]
-
 259.1088, found 
259.1089. 
 
Ethyl 5-(methylthiomethyl)-1H-pyrazole-3-carboxylate (5-3al') 
 
1
H NMR (500 MHz, CDCl3): δ 6.77 (s, 1H), 4.38 (q, J = 7.5 Hz, 2H), 3.74 (s, 2H), 2.05 (s, 
3H), 1.38 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 161.13, 147.85, 139.41, 108.31, 
61.75, 29.94, 15.67, 14.74; HRMS(ESI): calcd. for C8H11N2O2S [M-H]
-
 199.0547, found 
199.0544. 
 
Ethyl 5-(1-phenylethyl)-1H-pyrazole-3-carboxylate (5-3am') 
 
1
H NMR (500 MHz, CDCl3): δ 7.30 (t, J = 7.5 Hz, 2H), 7.23 – 7.19 (m, 3H), 6.64 (s, 1H), 
4.33 (q, J = 7.0 Hz, 2H), 4.21 (q, J = 7.5 Hz, 1H), 1.65 (d, J = 7.5 Hz, 3H), 1.34 (t, J = 7.0 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): δ 161.98, 153.02, 144.40, 140.86, 129.12, 127.76, 127.22, 
189 
 





Ethyl 5-(6-methylhept-5-en-2-yl)-1H-pyrazole-3-carboxylate (5-3an') 
 
1
H NMR (500 MHz, CDCl3): δ 6.58 (s, 1H), 5.04 (t, J = 7.0 Hz, 1H), 4.34 (q, J = 7.5 Hz, 2H), 
2.91 (dd, J = 14.1, 7.0 Hz, 1H), 1.93 – 1.91 (m, 2H), 1.66 – 1.54 (m, 5H), 1.51 (s, 3H), 1.34 (t, 
J = 7.5 Hz, 3H), 1.25 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.29, 153.68, 
141.42, 132.40, 124.23, 105.41, 61.30, 37.46, 31.68, 26.09, 26.06, 20.95, 18.07, 14.71; 
HRMS(ESI): calcd. for C14H21N2O2 [M-H]
-
 249.1609, found 249.162. 
 
Ethyl 5-(2-benzoyl-3-ethoxy-3-oxopropyl)-1H-pyrazole-3-carboxylate (5-3ao') 
 
1
H NMR (500 MHz, CDCl3): δ 7.99 (d, J = 8.0 Hz, 2H), 7.57 – 7.55 (m, 1H), 7.45 (t, J = 8.0 
Hz, 2H), 6.64 (s, 1H), 4.77 (t, J = 7.0 Hz, 1H), 4.32 (t, J = 7.0 Hz, 2H), 4.11 (q, J = 7.0 Hz, 
2H), 3.39 (d, J = 7.0 Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H), 1.11 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(125 MHz, CDCl3): δ 194.87, 169.57, 161.52, 146.22, 136.27, 134.25, 129.29, 129.22, 
108.35, 62.33, 61.55, 54.32, 26.26, 14.69, 14.32; HRMS(ESI): calcd. for C18H19N2O5 [M-H]
-
 




Ethyl 5-(2-(ethoxycarbonyl)-3-oxobutyl)-1H-pyrazole-3-carboxylate (5-3ap') 
 
1
H NMR (500 MHz, CDCl3): δ 6.62 (s, 1H), 4.36 (q, J = 7.0 Hz, 2H), 4.23 – 4.16 (m, 1H), 
3.90 (t, J = 7.0 Hz, 1H), 3.23 – 3.20 (m, 2H), 2.28 (s, 3H), 1.36 (t, J = 7.5 Hz, 3H), 1.25 (t, J 
= 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 202.74, 169.33, 161.28, 146.65, 139.80, 
108.28, 62.37, 61.65, 59.34, 30.14, 25.47, 14.73, 14.48; HRMS(ESI): calcd. for C13H17N2O5 
[M-H]
-
 281.2243, found 281.2237. 
 
Ethyl 5-((1H-indol-3-yl)methyl)-1H-pyrazole-3-carboxylate (5-3aq') 
 
1
H NMR (500 MHz, CDCl3): δ 8.13 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 8.0 Hz, 
1H), 7.20 (t, J = 7.5 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 7.02 (s, 1H), 6.66 (s, 1H), 4.34 (q, J = 
7.0 Hz, 2H), 4.17 (s, 2H), 1.35 (t, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 161.95, 
136.90, 132.18, 130.01, 127.42, 123.01, 122.87, 120.21, 119.24, 112.61, 111.76, 107.57, 
61.51, 23.37, 14.75; HRMS(ESI): calcd. for C13H17N2O5 [M-H]
-
 281.2243, found 281.2237. 
 





H NMR (500 MHz, CDCl3): δ 6.60 (s, 1H), 3.88 (s, 3H), 2.67 (t, J = 7.5 Hz, 2H), 1.67 (q, J 
= 7.5 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 163.05, 147.81, 
142.12, 106.73, 52.23, 28.27, 22.80, 14.04; HRMS(ESI): calcd. for C8H11N2O2 [M-H]
-
 
167.0826, found 167.0832. 
 
benzyl 5-propyl-1H-pyrazole-3-carboxylate (5-3cc') 
 
1
H NMR (500 MHz, CDCl3): δ 7.40 (d, J = 7.0 Hz, 2H), 7.37 – 7.32 (m, 3H), 6.60 (s, 1H), 
5.35 (s, 2H), 2.60 (t, J = 7.5 Hz, 2H), 1.64 – 1.58 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); 13C NMR 
(125 MHz, CDCl3): δ 162.41, 147.72, 142.00, 136.21, 128.95, 128.69, 128.65, 106.81, 66.83, 
28.18, 22.72, 14.02; HRMS(ESI): calcd. for C14H15N2O2 [M-H]
-
 243.1139, found 243.1135. 
 
Ethyl 5-ethyl-4-methyl-1H-pyrazole-3-carboxylate (5-3av) 
 
1
H NMR (500 MHz, CDCl3): δ 4.35 (q, J = 7.0 Hz, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.25 (s, 
3H), 1.39 (t, J = 7.0 Hz, 3H), 1.25 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.00, 
144.24, 135.68, 124.77, 61.09, 17.26, 15.46, 14.69, 10.95; HRMS(ESI): calcd. for C9H14N2O2 
[M-H]
-
 181.0977, found 181.0982. 
 





H NMR (500 MHz, d
6
-DMSO): δ 12.84 (s, 1H), 2.54 (q, J = 7.5 Hz, 2H), 2.13 (s, 3H), 1.14 
(t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, d
6
-DMSO): δ 162.98, 147.57, 136.18, 115.37, 17.93, 
13.40, 8.38; HRMS(ESI): calcd. for C7H9N2O2 [M-H]
-
 153.0670, found 153.0669. 
 
 
5.4.4 X-Ray Crystallographic Analysis 
        The configuration of the product 5-3aa was assigned by X-ray crystallographic analysis 
of a single crystal of 5-3aa (Figure 5.1). The configurations of other products were assigned 
by analogy. 
 
Figure 5.1 X-ray structure of 5-3aa 
Table 5.5 Crystal data and structure refinement for 5-3aa 
Empirical formula  C10H14N2O2 
Formula weight  194.23 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
193 
 
Space group  P2(1)/n 
Unit cell dimensions a = 12.4631(10) Å a= 90°. 
 b = 15.2751(13) Å b= 108.852(2)°. 
 c = 16.8492(14) Å g = 90°. 
Volume 3035.6(4) Å3 
Z 12 
Density (calculated) 1.275 Mg/m3 
Absorption coefficient 0.090 mm-1 
F(000) 1248 
Crystal size 0.60 x 0.50 x 0.36 mm3 
Theta range for data collection 1.79 to 27.50° 
Index ranges -13<=h<=16, -19<=k<=19, -21<=l<=14 
Reflections collected 20637 
Independent reflections 6946 [R(int) = 0.0398] 
Completeness to theta = 27.50° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9683 and 0.9479 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6946 / 42 / 413 
Goodness-of-fit on F2 1.064 
Final R indices [I>2sigma(I)] R1 = 0.0566, wR2 = 0.1406 
R indices (all data) R1 = 0.0741, wR2 = 0.1505 





Chapter 6 Amine-catalyzed [3+2] Huisgen Cycloaddition 




An enamine catalyzed strategy is utilized to fully promote the Huisgen [3+2] 
cycloaddition with a broad spectrum of carbonyls and azides to access the efficient 






        Organocatalytic activation of readily available substrates has led to the rapid 
development of many reactions in the last decade.
102
 Enamine catalysis, as one of the most 
powerful tools, has been extensively investigated and reported to undergo a diverse set of 





Although many transformations have been reported, the enamine-azide [3+2] Huisgen 
cycloaddition still remains a challenging topic. Recently we discovered the first example of 
organocatalytic regiospecific enamide-azide [3+2] cycloadditions of alpha-functionalized 
ketones to azides (Scheme 6.1a).
85
 However, we recognized that the substituents at the 4-
position on the 1,2,3-triazole skeleton were largely identified and just defined as electron-
withdrawing groups. This limitation will potentially restrict the wide applications of this 
synthetic methodology. Herein, we wish to report our further endeavors in the examples of 
amine-catalyzed [3+2] cycloadditions on a broad spectrum of carbonyls and azides to access 




Scheme 6.1 Strategies to form 1,2,3-triazoles 
 





Additionally, 1,2,3-triazole moieties are attractive connections in 
biological systems because they are stable to metabolic degradation and capable of hydrogen 
bonding to biomolecular targets and which can also improve the solubility.
105 
Although the 
1,2,3-triazole does not occur in nature, it has biological activity.
106
 Thereby, the significance 
of triazole compounds in medicinal chemistry is indubitable. In light of their occurrence in a 
broad spectrum of important pharmaceutically active compounds, such as those examples 
outlined in Scheme 6.3,
[104u-w]
 highly substituted 1,2,3-triazoles have triggered a sustainably 
increasing attention in the synthetic chemistry community. Although significant preparation 
methods of such motifs are reported in some elegant works, the example of synthetic 




Scheme 6.2. Methods for the synthesis of highly substituted 1,2,3-triazoles
 
 





[3+2] cycloadditions of linear alkynes or highly strained alkynes with 
azides, have been described, these reactions are often slow because of high activation energy 
(ca. 24-16 kcal.mol)
109
 and also produce a mixture of regioisomers (Scheme 6.2). The Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) has been developed as a powerful tool to 
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access 1,2,3-triazole molecules, but is usually restricted to terminal alkynes and only 
facilitates 1,4-disubstituted 1,2,3-triazole formation (Scheme 6.2).
110
 In addition, in spite of 
its vast successes in industry, this strategy is not ideal for biological applications. Recent 
studies indicate that Cu(I) can cause oxidative DNA degradation.
111
 Although the careful 
selection of Cu(I)-stabilizing ligands can avoid DNA degradation and even facilitate this 
cycloaddition process in living organism.
112
 However, Cu itself caused cytotoxicity may 
remain an issue when pharmaceutical therapeutics are desired. Therefore, in search of ideal 
strategy to replace known methods, we believe that a metal-free, enamine catalyzed, and 
broad substrate tolerant method would be the first preferred solution. 
 
Scheme 6.3 Representative examples of bioactive 1,2,3-triazoles 
 
6.2 Results and Discussion 
6.2.1 Reaction Optimization for Highly Substituted 1,2,3-triazoles 
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        Optimization studies of organocatalytic enamine-azide [3+2] cycloaddition were 
initiated by an investigation of phenyl azide 6-1a and cyclohexanone 6-2a in the presence of 
a catalytic amount of secondary α–amino acid, L–proline (6-I; Table 6.1). The initial 
experimental result shows that only 40% yield was obtained in 24 h. To improve the catalytic 
activity, we then examined six-member ring based secondary amine catalysts 6-III and 6-IV. 
It is noted that the ring size is not crucial for reaction yield and rate (Table 6.1, 33% and 44% 
yield, respectively). Moreover, a diverse set of acyclic secondary amines were tested, but 
exhibited a poorer catalytic performance (24%, <5%, and <5%; respectively). Besides 
secondary amine, primary amine 6-IX and tertiary amine 6-VIII were also evaluated in this 
model reaction system. As shown in Table 6.1, tertiary amine 6-VIII had no catalytic activity 
in the process (<5% yield).  
 
Table 6.1 Evaluation of organocatalysts 
[a] 
 
           a




        Primary amine 6-IX just afforded a 26% yield in 24 h too. Finally a substituent-free, less 
bulky secondary amine, pyrrolidine 6-II indicated a higher activity (84%, 24 h). After 
identifying the suitable catalyst 6-II, we attempted to optimize the reaction by varying 
different other parameters systemically. Initially, various solvents including NMP, DMF, 
DMA, MeOH, 1, 4-Dioxane, DCE, Toluene, and CH3CN were screened, and we eventually 
discovered that the high yield in polar solvent could be a result of strengthened polar 
interaction among substrates, and catalyst. Screening showed that no obvious improvement in 
reaction rate and yield could be achieved by other solvents. We have also investigated the 
temperature and catalyst loading. As expected, a lower temperature (50 
o
C) or lower catalyst 
loading (5 mol%) incurred a significant decrease in yield. Consequently, pyrrolidine 6-II and 
DMSO were found to be effective in offering appreciable results in organocatalystic  
enamine-azide [3+2] cycloaddition process. 
 




Entry Cat. Solvent T (
o
C) t (h) Yield (%)
[e]
 
1 I DMSO 80 24 40 
2 II DMSO 80 24 84 
3
[b]
 II DMSO 80 48 70 
4
[c]
 II DMSO 60 48 54 
5
[d]
 II DMSO 60 120 74 
6 II MeOH 80 24 62 
7
[f]
 II NMP 80 72 50 
8 II DMF 80 72 50 
9
[g]
 II DMA 80 72 48 
10 II Toluene 80 72 34 
11 II THF 80 72 16 
12 II 1,4-Dioxane 80 72 38 





 II DCE 80 72 54 
15 II CHCl3 80 72 60 
16 III DMSO 80 24 33 
17 IV DMSO 80 24 44 
18 V DMSO 80 24 24 
19 VI DMSO 80 24 <5 
20 VII DMSO 80 24 <5 
21 VIII DMSO 80 24 <5 
22 IX DMSO 80 24 26 
 
        
a 
Unless otherwise noted, the reaction conditions were as follows: 0.5 M in solvent, and 
the ratio of 6-1a/6-2a is 1:2, 20 mol% catalyst. 
b
 10 mol% catalyst. 
c









Isolated yield of product 6-3a. 
f 
N-Methyl-2-
pyrrolidone (NMP) as solvent. 
g
 Dimethylacetamide (DMA) as solvent. 
h
 1,2-Dichloroethane 
(DCE) as solvent. 
 
6.2.2 Substrate Scope 
        Once the optimized conditions were identified (Table 6.1), substrates were examined. 
The scope of amine–catalyzed [3+2] Huisgen cycloaddition of azides is indicated by the 
examples listed in Table 6.3. It was found that the pyrrolidine 6-II–catalyzed cycloaddition 
was applicable to a variety of azides 6-1a to 6-1l to afford 1,2,3-triazoles in moderate to high 
yields (Table 6.3, 45–88%). The reactions were performed smoothly and rarely affected by 
the electronic nature of the substituents on the aromic rings. Electron-withdrawing (Table 6.3, 
entries 5, 6, and 8), electron-donating (Table 6.3, entries 2–4, and 10), or electron-neutral 
(Table 6.3, entry 1) groups on the phenyl ring of azides did not affect the reaction. In some 
cases, the steric effect appeared to have negative effects on the reaction yield. For example, 
an ester group at o–position on the phenyl ring gave a lower yield (Table 6.3, entry 9, 45%). 
Notably, naphthalene ring was also suitable for this system (Table 6.3, entry 12, 60%). If a 
lower catalyst loading (10 mol%) was employed, the reaction still afforded a good yield in a 
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reasonable time (Table 6.3, 78%, 30 h). However, the reaction dramatically slowed down (<5% 
yield, 24 h) when an alkyl (ethyl group) azide was applied to replace the phenyl azide. Slow 
conversion of starting material was detected by 
1
H NMR analysis. We envision that the 
delocalization of the aromatic system (phenyl ring) may stabilize the 1, 3-dipolar azide and 
its intermediate to lead a high reaction rate and yield.  
 




































        
a 
Reaction conditions: 6-1a to 6-1i (0.25 mmol, 1.0 equiv.), 6-2a (0.5 mmol, 2.0 equiv.), 




Yield of isolated product. [c]
 
10 mol% of 
catalyst. 
 
        Having investigated the reactivity of azides, we then evaluated carbonyls (Table 6.4). To 
our delight, this method can tolerate a broad range of unmodified, commercially available 
carbonyl compounds. Cyclic six-member ring based ketones gave good to high yields (Table 
6.4, entries 1–6). This six-member ring can bear alkyl, ester, dialkyl, or ketal groups on the p-
or m-positions of ketones (Table 6.4, entries 1–5). Furthermore, this six-member ring can also 
tolerate a heteroatom (Table 6.4, entry 6). Interestingly, seven or eight-member ring sized 
cyclic ketones efficiently provided high yields under standard conditions which demonstrated 
the ring size of ketones had limited effect on this cycloaddition (Table 6.4, entries 7–8, 94% 
and 85%, respectively). To prove the high efficiency exhibited in seven or eight member ring 
based ketones, we therefore reduced the catalyst loading from 20 mol% to 10 mol%. The 
reaction still afforded a 89% yield in 30 h (Table 6.4, entry 7). It is noteworthy that acyclic 
ketones also gave appreciable reaction yields (Table 6.4, entries 9–10). For example in Table 
3, dissymmetric acyclic ketone 2-butanone 6-2j showed a 75% yield in 24 h, and did not 
observe any other regioisomers in this reaction process. Symmetric acyclic ketone 3-
pentanone 6-2k supported a 65% yield in 20 h. Additionally, a phenyl ring fused 
cyclohexanone 6-2l attended reaction also happened at room temperature (Table 6.4, entry 11) 
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and afforded a slightly lower yield due to the undesirable instability and decomposition of 
product 6-3al under this reaction condition (Table 6.4, entry 11, 57%, 10 h). Except for the 
above types of ketones 6-2a to 6-2l, we also examined some β-functionalized ketones (Table 
6.4, entries 12–16). Gratifyingly, β-ketonnitrile 6-2m, 1,3-diketone 6-2n, and β-ester ketone 
6-2o exhibited high efficiency and high reaction yields (Table 6.4, entries 12–14, 90–95%). 
Appreciatively, an alkyl azide 6-1n can be involved in this process to react with active β-
ketonnitrile and afforded an appreciable synthetic yield (Table 6.4, entry 16, 80%, 24 h). In 
contrast to our previous reported results for catalyzed by the acylic secondary amine catalyst 
(diethyl amine 6-V),
85 
we found that the cyclic second amine (pyrrolidine 6-II) can also 
eficiently catalyze these tranformations in the presense of current optimized reaction 
conditions. The regioselectivity of product 6-3aa and 6-3ac was determined by using single 
crystal X-ray diffraction analysis. 
        To further extent the scope of azides, we then examined a tosyl azide 6-1n. As showed 
in Scheme 6.4, the reaction is completely different. In this case, the pyrrolidine 6-II worked 
as a starting material to easily access the installation of a biological interest compound, N-
tosyl amidine 6-3na in 85% yield. We deduce that when the triazoline ring carries an 
electron-withdrawing group at the N1-position, it is very labile. 
        Thus, the first formated triazoline intermediate decomposes immediately to produce 
amidine 6-3na through rearrangement and loss of the N2. Surprisingly, L-proline showed no 
activity in this reaction. However, β-tetralone 6-2l reacted with tosyl azide 6-1n in the 
presence of L-proline and efficiently produced the desired triazole compound 6-3nl (Eq. (b), 
85%, 5 h, r.t.). In this case, no amidine product was formed. It may be due to the steric 
hindered carboxylic group. It will inhibit the potential rearrangement and prohibit the 
formation of the crowded amidine. Subsequent attempts to introduce two linear and less 
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bulkyl aldehydes (propionaldehyde 6-2r and 2-phenylacetaldehyde 6-2s) to the reaction were 
unsuccessfully. The failure to achieve the desired triazoles might be attributed to the 
competitive self-aldol reaction. 
 
Table 6.4 Substrate scope of carbonyls 
[a] 
 
Entry 6-2b to 6-2i Product
[b]


























































        
a 
Reaction conditions: 6-1a or 6-1m (0.25 mmol, 1.0 equiv.), 6-2a (0.5 mmol, 2.0 equiv.), 




Yield of isolated product. 
c













        Thus, the first formated triazoline intermediate decomposes immediately to produce 
amidine 6-3na through rearrangement and loss of the N2. Surprisingly, L-proline showed no 
activity in this reaction. However, β-tetralone 6-2l reacted with tosyl azide 6-1n in the 
presence of L-proline and efficiently produced the desired triazole compound 6-3nl (Scheme 
6.4, 85%, 5 h, r.t.). In this case, no amidine product was formed. It may be due to the steric 
hindered carboxylic group. It will inhibit the potential rearrangement and prohibit the 
formation of the crowded amidine. Subsequent attempts to introduce two linear and less 
bulkyl aldehydes (propionaldehyde 6-2r and 2-phenylacetaldehyde 6-2s) to the reaction were 
unsuccessfully. The failure to achieve the desired triazoles might be attributed to the 
competitive self-aldol reaction. 
 
6.2.3 Application and Plausible Reaction Mechanism 
        To demonstrate the synthetic utility of this methodology, we applied it to the synthesis 
of CB1 cannabinoid receptor antagonist (Scheme 6.5). The catalyst 6-II–catalyzed Huisgen 
[3+2] cycloaddition between azide 6-1n and β-keto ester 6-2q under optimized reaction 
conditions enabled the installation of the intermediate 6-3nq in 98% yield in 0.5 h. The 6-3nq 
is a key intermediate and can be converted into target CB1 cannabinoid receptor antagonist 











        As shown in Scheme 6.6, we proposed a plausible catalytic cycle to explain the reaction 
pathway. While the reaction mechanism is still unclear at this stage, it is believed that the 
sequence is triggered by the generation of enamine 6-4 via the condensation of carbonyl 6-2a 
and catalyst pyrrolidine 6-II. Enamine 6-4 acts as the electron-rich olefinic partner, and reacts 
with phenyl azide 6-1a via a Huisgen 1,3-dipolar cycloaddition process to access the 
intermediate, triazoline 6-5.  
 




        More importantly, this process demonstrates a complete and unique regiospecificity 
which led us readily to introduce a diverse set of functional substituents to desired 1, 4, and 5 
positions. In fact, except for enamine-triggered cycloaddition process, enolate-triggered 
cycloaddition process catalyzed by organic base can also potentially afford desired 
intermediate 6-5. Apparently, the results of the catalyst screening revealed that the process 
catalyzed by an organic base, such as tertiary amine 6-VIII (Table 1, <5% yield), will not be 
the main contribution for 1,2,3-triazole synthesis. Thereafter, a plausible 1,3-hydride shift 
might assist the formation of a zwitterion 6-7. Finally, an elimination step caused the 
generation of final product, regioselective 1,2,3,-triazole 6-3aa. Meanwhile, the catalyst 6-II 
was released and applied to next catalytic cycle. According to our experimental evidence, we 
predict that the rate-determining step is probably the 1,3-dipolar cycloaddition process. The 
observation of enamine formation process via LCMS suggests that the catalytic cycle 
accumulates at this stage. In addition, no further evidence indicates the presence of the 
triazoline intermediate 6-5. Finally, we are aware that the existence of active catalytic 
enamine specie will provide a more reliable picture for reaction mechanism. 
 
6.3 Conclusions 
        Driven by the lack of efficient synthesis of highly substituted 1,2,3-triazoles, herein, we 
have developed an enamine catalyzed strategy by using small organic molecule as 
organocatalyst to fully promote the Huisgen [3+2] cycloaddition on a broad spectrum of 
carbonyls and azides to access the efficient assembly of a vast pool of highly substituted 
1,2,3-triazoles. Especially the employment of the commonly used and commercially available 
carbonyls have resulted in an introduction of a diverse set of functional groups, such as alkyls, 
aryls, nitriles, esters, ketones, etc, to the 1, 4, or 5 position on 1,2,3-triazole scaffold. This 
might be manipulated for accessing more useful sophisticated heterocyclic compounds. More 
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significantly, the reaction process exhibits a complete regioselectivity with none of 
regioisomer formation. The versatility of amine catalyzed Huisgen cycloaddition seems 
endless, yet we are still in the early development stages of this concept-driven research. In 
addition, we believe that the presented methodology opens access to more interesting 
compounds which are available for potential biological evaluation. Further extension of this 
synthetic strategy to other types of reactions is under way in our laboratory and will be 
presented in due course. 
 
6.4 Experimental Section 
6.4.1 Material and General Methods 




C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or a AMX500 (500 
MHz) spectrometer. Chemical shifts were reported in parts per million (ppm), and the 
residual solvent peak was used as an internal reference: proton (chloroform δ 7.26), carbon 
(chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) was used as a reference. Multiplicity 
was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd 
(doublet of doublet), bs (broad singlet). Coupling constants were reported in Hertz (Hz). Low 
resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI mode 
and API 3000™ in APCI (Heated Nebulizer) mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography (TLC), 
Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds were visualized 
with a UV light at 254 nm. Further visualization was achieved by staining with iodine. Flash 
chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel.  
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        Compounds 6-1a to 6-1l were prepared according to literature, 114 respectively. 
Compounds 6-2b to 6-2m were commercially available. 
 
6.4.2 Representative Procedure for Enamine-azide [3+2] Cycloaddition 
 
        To a solution of phenyl azide 6-1a (0. 25 mmol, 1 equiv.), cyclohexanone 6-2a (0.5 
mmol, 2.0 equiv.) in 0.5 ml of DMSO, pyrrolidine (4.1 L, 0.05 mmol, 0.2 equiv.) as catalyst 
was added. The reaction mixture was stirred at 80 
o
C for 24 h. The crude product was 
purified by column chromatography on silica gel, eluted by hexane/EtOAc = 10:1 then 4:1 to 
afford 42 mg (84% yield) of the desired product 6-3aa as a pale-yellow oil. 
 
 
        To a solution of 3,4-dihydronaphthalen-2(1H)-one 6-2a (0.5 mmol, 2.0 equiv.) in 0.5 ml 
DMSO, pyrrolidine (4.1 L, 0.05 mmol, 0.2 equiv.) or L-proline (5.7 mg, 0.05 mmol, 0.2 
equiv.) as catalyst was added. The reaction was continued for another 0.5 h, and then 
azidobenzene 6-1a (0. 25 mmol, 1.0 equiv.) (pyrrolidine as catalyst) or 4-
methylbenzenesulfonyl azide 6-1n (0.25 mmol, 1.0 equiv.) (L-proline as catalyst) was added 
to the reaction system. The reaction mixture was stirred at room temperature for 1-10 h. The 
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crude product was purified by column chromatography on silica gel, eluted by hexane/EtOAc = 
10:1 then 4:1 to afford aim product. 
 
6.4.3 Analytical Data for Enamine-azide [3+2] Cycloaddition 
1-Phenyl-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3aa)  
 
The title compound was prepared according to the general procedure described above in 
84%yield; 
1
H NMR (500 MHz, CDCl3): δ 7.57 – 7.50 (m, 4H), 7.47 – 7.43 (m, 1H), 2.85 (t, J 
= 4.9 Hz, 2H), 2.75 (t, J = 5.0 Hz, 2H), 1.93 – 1.84 (m, 4H).; 13C NMR (125 MHz, CDCl3): δ 
144.43, 137.37, 132.47, 129.89, 129.02, 123.56, 23.20, 22.92, 22.39, 22.27; HRMS (ESI)  
calcd for C12H14N3 [M+H]
+
 200.1182, found 200.1186. 
 
1-(4-Methoxyphenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ba)  
 
The title compound was prepared according to the general procedure described above in 88% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.47 – 7.37 (m, 2H), 7.04 – 6.91 (m, 2H), 3.84 (s, 3H), 
2.80 (s, 2H), 2.65 (s, 2H), 1.84 (m, 4H).; 
13
C NMR (125 MHz, CDCl3): δ 160.10, 144.12, 
132.52, 130.39, 125.11, 114.96, 56.01, 23.14, 22.93, 22.38, 21.98; HRMS (ESI) calcd for C13 
H16 N3O [M+H]
+




1-(4-Isopropylphenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ca)  
 
The title compound was prepared according to the general procedure described above in 85% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.46 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.38 – 7.35 (m, 2H), 
2.99 (m, 1H), 2.84 (d, J = 4.9 Hz, 2H), 2.74 (d, J = 5.2 Hz, 2H), 1.88 (m, 4H), 1.30 (d, J = 7.2 
Hz, 6H).; 
13
C NMR (125 MHz, CDCl3): δ 149.97, 144.24, 135.08, 132.44, 127.84, 123.53, 





1-(4-Heptylphenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3da)  
 
The title compound was prepared according to the general procedure described above in 72% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.45 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 2.84 
(t, J = 5.2 Hz, 2H), 2.73 (t, J = 5.2 Hz, 2H), 2.70 – 2.65 (m, 2H), 1.91 – 1.83 (m, 4H), 1.72 – 
1.61 (m, 2H), 1.40 – 1.25 (m, 8H), 0.90 (t, J = 6.9 Hz, 3H).; 13C NMR (125 MHz, CDCl3): δ 
144.30, 144.18, 135.11, 132.48, 129.83, 123.51, 36.03, 32.27, 31.80, 29.67, 29.62, 23.27, 
23.13, 23.02, 22.47, 22.27, 14.56; HRMS (ESI) calcd for C19 H28N3 [M+H]
+
 298.2278, found 
298.2290. 
 




The title compound was prepared according to the general procedure described above in 72% 
yield; NMR (500 MHz, CDCl3): δ 7.56 – 7.41 (m, 4H), 2.83-2.78 (m, 2H), 2.76-2.65 (m, 1H), 
1.91 – 1.82 (m, 4H).; 13C NMR (125 MHz, CDCl3): δ 144.70, 135.86, 134.88, 132.44, 130.12, 





1-(4-(Trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3fa)  
 
The title compound was prepared according to the general procedure described above in 68% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.82 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 8.5 Hz, 2H), 2.86 
(d, J = 5.9 Hz, 2H), 2.82 (d, J = 6.0 Hz, 2H), 1.96 – 1.88 (m, 4H); 13C NMR (125 MHz, 
CDCl3): δ 145.10, 140.14, 132.54, 131.08, 127.28, 127.25, 127.22, 127.19, 125.17, 123.35, 









The title compound was prepared according to the general procedure described above in 75% 
yield;
 1
H NMR (500 MHz, CDCl3): δ 7.40 (t, J = 8.1 Hz, 1H), 7.15 – 7.05 (m, 2H), 6.97 (dd, 
J = 8.3, 1.9 Hz, 1H), 4.62 (hept, J = 6.1 Hz, 1H), 2.85 (t, J = 5.1 Hz, 2H), 2.76 (t, J = 5.0 Hz, 
2H), 1.95 – 1.84 (m, 4H), 1.37 (d, J = 5.6 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 159.24, 
144.48, 138.45, 132.52, 130.64, 116.68, 115.36, 111.19, 70.93, 23.29, 23.00, 22.46;  HRMS 
(ESI) calcd for C15H20N3O [M+H]
+
 258.1601, found 258.1609. 
1-(3-Chlorophenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ha)  
 
The title compound was prepared according to the general procedure described above in 62% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 1.7 Hz, 1H), 7.52 – 7.43 (m, 3H), 2.86 (s, 
2H), 2.78 (s, 2H), 1.91 (m, 4H).; 
13
C NMR (125 MHz, CDCl3): δ 144.80, 138.34, 135.70, 
132.52, 131.00, 129.15, 123.69, 121.49, 23.17, 22.84, 22.37; HRMS calcd for C12H12ClN3 
[M+H]
+
 234.0793, found 234.0802. 
 
Ethyl 2-(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1-yl)benzoate (6-3ia)  
 
The title compound was prepared according to the general procedure described above in 45% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 8.08 (dd, J = 7.8, 1.5 Hz, 1H), 7.69 (td, J = 7.7, 1.6 Hz, 
1H), 7.62 (td, J = 7.6, 1.3 Hz, 1H), 7.40 (dd, J = 7.8, 1.1 Hz, 1H), 4.18 – 4.10 (m, 2H), 2.90 – 
2.83 (m, 2H), 2.53 – 2.46 (m, 2H), 1.90 – 1.84 (m, 4H), 1.11 (t, J = 7.2 Hz, 3H).; 13C NMR 
(125 MHz, CDCl3): δ 165.62, 143.14, 136.01, 134.62, 133.13, 131.95, 130.36, 129.32, 
128.29, 62.03, 23.15, 22.95, 22.30, 20.81, 14.29; HRMS (ESI) calcd for C15H18N3O2 [M+H]
+
 




1-(3,5-Dimethylphenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ja)  
 
The title compound was prepared according to the general procedure described above in 80% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.16 (s, 2H), 7.09 (s, 1H), 2.84 (t, J = 5.1 Hz, 2H), 2.74 
(t, J = 5.0 Hz, 2H), 2.40 (s, 6H), 1.92 – 1.84 (m, 4H).; 13C NMR (125 MHz, CDCl3): δ 144.24, 
139.76, 137.18, 132.41, 130.66, 121.35, 23.21, 22.97, 22.42, 22.28, 21.72; HRMS (ESI) 
calcd for C14H18N3 [M+H]
+
 228.1495, found 228.1500. 
 
1-(4-Cloro-3-methylphenyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ka)  
 
The title compound was prepared according to the general procedure described above in 67% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.51 – 7.46 (m, 2H), 7.31 (dd, J = 8.5, 2.5 Hz, 1H), 
2.84 (d, J = 5.4 Hz, 2H), 2.77 – 2.71 (m, 2H), 2.46 (s, 3H), 1.91 – 1.86 (m, 4H); 13C NMR 
(125 MHz, CDCl3): δ 144.59, 138.21, 135.74, 135.04, 132.45, 130.36, 125.90, 121.90, 23.18, 
22.88, 22.38, 22.28, 20.70; HRMS (ESI) calcd for C13H15ClN3 [M+H]
+
 248.0949, found 
248.0956. 
 




The title compound was prepared according to the general procedure described above in 60% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 8.04 (d, J = 8.3 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.60 
(d, J = 7.5 Hz, 2H), 7.56 – 7.50 (m, 2H), 7.38 (d, J = 8.4 Hz, 1H), 2.94 (t, J = 6.1 Hz, 2H), 
2.48 – 2.40 (m, 2H), 1.97 – 1.90 (m, 2H), 1.90 – 1.82 (m, 2H).; 13C NMR (125 MHz, CDCl3): 
δ 143.58, 135.03, 134.64, 133.31, 130.74, 129.85, 128.69, 128.17, 127.41, 125.51, 124.90, 
123.08, 23.19, 22.95, 22.43, 20.95; HRMS (ESI) calcd for C16H16N3 [M+H]
+
 250.1339, found 
250.1350. 
 
5-Ethyl-1-phenyl-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ab)  
 
The title compound was prepared according to the general procedure described above in 73% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.62 – 7.49 (m, 4H), 7.49 – 7.43 (m, 1H), 3.04 (dd, J = 
15.8, 5.0 Hz, 1H), 2.84 – 2.70 (m, 2H), 2.40 (dd, J = 15.0, 10.0 Hz, 1H), 2.08 – 2.00 (m, 1H), 
1.77 (d, J = 5.6 Hz, 1H), 1.56 – 1.46 (m, 3H), 1.03 (t, J = 7.4 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 144.38, 136.98, 132.07, 129.47, 128.57, 123.01, 36.03, 28.85, 28.36, 27.91, 21.23, 
11.65; HRMS calcd for C14H18N3 [M+H]
+
 228.1495, found 228.1493. 
 
Ethyl 1-phenyl-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (6-3ac)  
 
The title compound was prepared according to the general procedure described above in 63% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.57 – 7.50 (m, 4H), 7.48 – 7.43 (m, 1H), 4.23 – 4.17 
(m, 2H), 3.19 (dd, J = 16.0, 5.7 Hz, 1H), 3.09 – 3.00 (m, 1H), 2.94 – 2.78 (m, 3H), 2.39 – 
2.24 (m, 1H), 1.99 (ddt, J = 19.5, 15.9, 5.8 Hz, 1H), 1.34 – 1.26 (m, 3H); 13C NMR (125 
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MHz, CDCl3): δ 174.56, 137.16, 131.73, 129.96, 129.19, 123.47, 61.28, 39.92, 25.87, 25.08, 
21.02, 14.62; HRMS (ESI) calcd for C15H18N3O2 [M+H]
+
 272.1394, found 272.1406. 
 
5 ,5-Dimethyl-1-phenyl-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ad)  
 
The title compound was prepared according to the general procedure described above in 77% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.60 (m, 2H), 7.54 (m, 2H), 7.49 – 7.44 (m, 1H), 2.77 (t, 
J = 6.4 Hz, 2H), 2.65 (s, 2H), 1.66 (t, J = 6.4 Hz, 2H), 1.09 (s, 6H); 
13
C NMR (125 MHz, 
CDCl3): δ144.66, 137.49, 131.34, 129.93, 129.03, 123.44, 36.20, 36.10, 31.00, 28.22, 19.51; 
HRMS (ESI) calcd for C14H18N3 [M+H]
+
 228.1495, found 228.1500. 
 
6,6-Dimethyl-1-phenyl-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole (6-3ae)  
 
The title compound was prepared according to the general procedure described above in 71% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.56 – 7.48 (m, 4H), 7.44 (m, 1H), 2.84 (t, J = 6.5 Hz, 
2H), 2.51 (s, 2H), 1.66 (t, J = 6.5 Hz, 2H), 1.02 (s, 6H); 
13
C NMR (125 MHz, CDCl3): δ 
142.91, 136.90, 132.03, 129.48, 128.62, 123.22, 35.62, 35.41, 31.21, 27.80, 19.16; HRMS 
(ESI) calcd for C14H18N3 [M+H]
+
 228.1459, found 228.1492. 
 




The title compound was prepared according to the general procedure described above in 75% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.59 – 7.50 (m, 4H), 7.49 – 7.44 (m, 1H), 4.14 – 4.00 
(m, 4H), 3.09 (s, 2H), 2.96 – 2.86 (m, 2H), 2.09 – 1.99 (m, 2H); 13C NMR (125 MHz, CDCl3): 
δ 143.22, 137.17, 131.39, 129.95, 129.21, 123.53, 108.74, 65.25, 33.60, 32.17, 19.59; HRMS 
(ESI) calcd for C14 H15N3O2 [M+H]
+
 258.1237, found 258.1242. 
 
1-Phenyl-1,4,6,7-tetrahydrothiopyrano[3,4-d][1,2,3]triazole (6-3ag)  
 
The title compound was prepared according to the general procedure described above in 82% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.59 – 7.53 (m, 2H), 7.51 (m, 3H), 3.96 (s, 2H), 3.06 – 
2.99 (m, 2H), 2.94 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 140.39, 136.71, 132.34, 130.05, 





1-Phenyl-1,4,5,6,7,8-hexahydrocyclohepta[d][1,2,3]triazole (6-3ah)  
 
The title compound was prepared according to the general procedure described above in 94% 
yield; 
1
H NMR (500 MHz, CDCl3): δ = 7.56 – 7.45 (m, 3H), 7.43 – 7.39 (m, 2H), 2.99 – 2.94 
(m, 2H), 2.74 (m, 2H), 1.87 (m, 2H), 1.80 – 1.73 (m, 2H), 1.73 – 1.64 (m, 2H); 13C NMR 
(125 MHz, CDCl3): δ = 147.71, 136.92, 136.02, 129.72, 129.55, 125.71, 31.28, 27.59, 27.45, 
27.42, 25.12; HRMS (ESI) calcd for C13H16N3 [M+H]
+
 214.1339, found 214.1342. 
 




The title compound was prepared according to the general procedure described above in 85% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.56 – 7.47 (m, 3H), 7.45 – 7.41 (m, 2H), 3.02 – 2.94 
(m, 2H), 2.75 (m, 2H), 1.89 – 1.71 (m, 4H), 1.54 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 
145.45, 137.06, 134.42, 129.80, 129.70, 125.69, 28.57, 27.87, 25.97, 25.67, 24.85, 22.43; 
HRMS (ESI) calcd for C14H18N3 [M+H]
+
 228.1495, found 228.1494. 
 
4,5-dimethyl-1-phenyl-1H-1,2,3-triazole (6-3aj)  
 
The title compound was prepared according to the general procedure described above in 75% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.57 – 7.49 (m, 3H), 7.49 – 7.44 (m, 2H), 2.36 (s, 3H), 
2.27 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 141.49, 137.27, 130.12, 129.86, 129.59, 125.27, 
10.75, 9.22; HRMS (ESI) calcd for C10H11N3 [M+H]
+
 174.1026, found 174.1024. 
 
4-ethyl-5-methyl-1-phenyl-1H-1,2,3-triazole (6-3ak)  
 
The title compound was prepared according to the general procedure described above in 65% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.58 – 7.49 (m, 3H), 7.46 – 7.42 (m, 2H), 2.69 (q, J = 
7.6 Hz, 2H), 2.39 (s, 3H), 1.09 (t, J = 7.6 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 140.94, 
137.31, 135.78, 129.89, 129.82, 125.76, 16.71, 13.60, 10.89; HRMS (ESI) calcd for C11 
H14N3 [M+H]
+




3-Phenyl-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole (6-3al)  
 
The title compound was prepared according to the general procedure described above in 65% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 8.05 (d, J = 7.4 Hz, 1H), 7.63 – 7.57 (m, 4H), 7.53 (m, 
1H), 7.38 (dd, J = 7.4, 1.9 Hz, 1H), 7.31 – 7.24 (m, 2H), 3.16 – 3.09 (m, 4H).; 13C NMR (125 
MHz, CDCl3): δ 144.58, 137.01, 134.03, 132.81, 130.11, 129.45, 129.05, 128.59, 128.09, 





1,5-Diphenyl-1H-1,2,3-triazole-4-carbonitrile (6-3am)  
 
The title compound was prepared according to the general procedure described above in 95% 
yield. 
1
H NMR (300 MHz, CDCl3): δ 7.52 – 7.41 (m, 6H), 7.36 – 7.32 (m, 4H); 
13
C NMR (75 
MHz, CDCl3): δ 145.5, 135.3, 131.0, 130.2, 129.7, 129.3, 128.9, 125.1, 123.3, 120.5, 112.0. 






The title compound was prepared according to the general procedure described above in 92% 
yield. 
1
H NMR (300 MHz, CDCl3): δ 8.29 (d, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.49 
(t, J = 7.8 Hz, 2H), 7.41 – 7.31 (m, 10H); 13C NMR (75 MHz, CDCl3): δ 187.3, 144.2, 141.8, 
137.8, 136.5, 133.7, 131.3, 130.8, 130.5, 130.1, 130.0, 129.1, 128.9, 126.7, 125.9. HRMS 
(ESI) calcd for C21H15N3O 325.1215, found 325.1212. 
 
Ethyl 1,5-diphenyl-1H-1,2,3-triazole-4-carboxylate (6-3ao)  
 
The title compound was prepared according to the general procedure described above in 90% 
yield. 
1
H NMR (300 MHz, CDCl3): δ 7.45 – 7.36 (m, 6H), 7.33 – 7.28 (m, 4H), 4.39 (q, J = 
7.2 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, CDCl3): δ 161.6, 141.5, 137.6, 
136.5, 130.9, 130.5, 130.1, 130.0, 129.0, 126.4, 125.9, 61.8, 14.8. HRMS  (ESI)calcd for 
C17H15N3O2 293.1164, found 293.1162. 
 
Ethyl 5-ethyl-1-phenyl-1H-1,2,3-triazole-4-carboxylate (6-3ap)  
 
The title compound was prepared according to the general procedure described above in 92% 
yield. 
1
H NMR (300 MHz, CDCl3): δ 7.56 – 7.39 (m, 5H), 4.44 (q, J = 7.1 Hz, 2H), 2.97 (q, J 
= 7.5 Hz, 2H), 1.42 (t, J = 7.1 Hz, 3H), 1.14 (t, J = 7.5 Hz, 3H); 
13
C NMR (75 MHz, CDCl3): 
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δ 161.5, 144.4, 136.0, 135.5, 130.2, 129.6, 125.6, 60.9, 16.9, 14.3, 13.1. HRMS (ESI) calcd 
for C13H15N3O2 245.1164, found 245.1162. 
 
1-Benzyl-5-phenyl-1H-1,2,3-triazole-4-carbonitrile (6-3mm)  
 
The title compound was prepared according to the general procedure described above in 80% 
yield. 
1
H NMR (300 MHz, CDCl3, TMS): δ 7.60 – 7.48 (m, 3H), 7.36 – 7.29 (m, 5H), 5.55 (s, 
2H); 
13
C NMR (75 MHz, CDCl3, TMS): δ 144.5, 134.6, 131.9, 130.2, 129.7, 129.6, 129.4, 
128.0, 123.9, 121.1, 112.6, 53.3; HRMS (ESI) calcd for C16H12N4 260.1062, found 260.1060. 
 
N-(cyclopentyl(pyrrolidin-1-yl)methylene)-4-methylbenzenesulfonamide (6-3na)  
 
The title compound was prepared according to the general procedure described above in 85% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.83 (d, J = 8.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 3.72 
– 3.60 (m, 3H), 3.54 (t, J = 6.5 Hz, 2H), 2.38 (s, 3H), 2.00 – 1.73 (m, 10H), 1.66 – 1.57 (m, 
2H); 
13
C NMR (125 MHz, CDCl3): δ 168.31, 142.49, 141.26, 128.93, 126.01, 50.76, 48.68, 
43.75, 29.58, 26.45, 26.25, 23.80, 21.40; HRMS (ESI) calcd for C17H25N2O2S [M+H]
+
 






The title compound was prepared according to the general procedure described above in 84% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 8.00 (d, J = 8.3 Hz, 2H), 7.92 (d, J = 7.4 Hz, 1H), 7.39 
(d, J = 8.1 Hz, 2H), 7.32 – 7.21 (m, 3H), 3.29 (t,  J = 7.9 Hz, 2H), 3.11 (t, J = 7.9 Hz, 2H), 
2.46 (s, 3H); 
13
C NMR (125 MHz, CDCl3): δ 147.10, 143.68, 133.84, 133.76, 133.48, 130.45, 
128.36, 128.17, 127.33, 127.11, 122.48, 28.05, 21.80, 20.15; HRMS (ESI) calcd for C17 
H16N3O2S [M+H]
+
 326.0958, found 326.0962. 
 
Ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (6-3nq) 
 
The title compound was prepared according to the general procedure described above in 98% 
yield; 
1
H NMR (500 MHz, CDCl3): δ 7.51 (s, 1H), 7.40 (m, 2H), 7.35 (m, 2H), 7.29 – 7.23 
(m, 2H), 4.41 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H).; 
13
C NMR (125 MHz, CDCl3): δ 
160.59, 141.62, 137.55, 136.52, 136.36, 132.56, 131.87, 131.15, 130.51, 130.14, 128.63, 







6.4.4 X-Ray Crystallographic Analysis 
        The configuration of the product 6-3aa was assigned by X-ray crystallographic analysis 
of a single crystal of 6-3aa (Figure 6.1). The configurations of other products were assigned 
by analogy. 
 
Figure 6.1 X-ray structure of 6-3aa 
Table 6.5 Crystal data and structure refinement for 6-3aa 
Empirical formula  C12H13N3 
Formula weight  199.25 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pca2(1) 
Unit cell dimensions a = 8.7281(11) Å a= 90°. 
 b = 20.741(3) Å b= 90°. 
 c = 11.3820(14) Å g = 90°. 




Density (calculated) 1.285 Mg/m3 
Absorption coefficient 0.080 mm-1 
F(000) 848 
Crystal size 0.60 x 0.38 x 0.20 mm3 
Theta range for data collection 0.98 to 27.50° 
Index ranges -11<=h<=11, -20<=k<=26, -14<=l<=14 
Reflections collected 14037 
Independent reflections 4588 [R(int) = 0.0441] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9843 and 0.9538 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4588 / 44 / 290 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0522, wR2 = 0.1195 
R indices (all data) R1 = 0.0602, wR2 = 0.1245 
Absolute structure parameter 0(2) 









1. (a) Hajos, Z. G. & Parrish, D. R. Asymmetric synthesis of optically active polycyclic organic 
compounds. German patent DE 2102623 (1971).; (b) Eder, U., Sauer, G. R. & Wiechert, R. Optically 
active 1,5-indanone and 1,6–naphthalenedione derivatives. German patent DE 2014757 (1971).; (c) 
List, B. Synlett 2001, 1675. (d) List, B. Acc. Chem. Res. 2004, 37, 548. 
2.  (a) Ahrendt, K.A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122,4243.; (b) Baum, J. 
S.; Viehe, H. G.  J. Org. Chem. 1976, 41,183.;  (c)Tchabanenko, K.; Chesworth, R.; Parker, J. S.; 
Anand, N. K.; Russell, A. T.; Adlington, R. M.; Baldwin, J. E. Tetrahedron 2005, 61, 11649.; (d) 
Tchabanenko, K.; Adlington, R. M.; Cowley, A. R.; Baldwin, J. E. Org. Lett. 2005 7, 585.; (e) Baldwin, 
J. E.; Chesworth, R.; Parker, J. S.; Russell, A. T. Tetrahedron Lett. 1995, 36, 9551.; (f)Yamaguchi,  M.; 
Igarashi, Y.; Reddy, R. S.; Shiraishi, T.; Hirama, M. Tetrahedron 1997, 53, 11223.; (g)Yamaguchi, M.; 
Shiraishi, T.; Igarashi, Y.; Hirama, M. Tetrahedron Lett. 1994, 35, 8233.; (h)Ya maguchi, M.; Shiraishi, 
T.; Igarashi, Y.; Hirama, M. Angew. Chem. Int. Ed. 1993, 32, 1176.; (i)Yamaguchi, M.; Shiraishi, T.; 
Igarashi, Y.; Hirama, M. J. Org. Chem. 1996, 61, 3520.; (j)Yamaguchi, M.; Shiraishi, T.; Igarashi, Y.; 
Hirama, M. J. Chem. Soc. Chem. Commun. 1991, 1088.; (k) Kawara, A.; Taguchi, T. Tetrahedron Lett. 
1994, 35, 8805. 
3. (a) Hiemstra, H.; Wynberg, H. J. Am. Chem. Soc. 1981, 103, 417.; (b) Oku, J. I.; Inoue, S. J. Chem. Soc. 
Chem. Commun. 1981, 229. (c) Dolling, U. H.; Davis, P.; Grabowski, E. J. J. J. Am. Chem. Soc. 1984, 
106, 446.; (d) Doyle, A. G.; Jacobsen, E. N. Chem. Rev. 2007, 107, 5713. 
4. (a) Narasaka, K.; Okauchi, T.; Tanaka, T.; Murakami, M. Chem. Lett. 1992, 92, 2099.; (b) Beeson, T. 
D.; Mastracchio, A.; Hong, J.; Ashton, K.; MacMillan, D. W. C. Science 2007, 316, 582.; (c) Jang, H.; 
Hong, J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2007, 129, 7004.; (d) Kim, H.; MacMillan, D. W. C. 
J. Am. Chem. Soc. 2008, 130, 398. 
5. (a) Raheem, I.; Thiara, P. S.; Peterson, E. A.; Jacobsen, E. N. J. Am. Chem. Soc. 2007, 129, 13404.; (b) 
Reisman, S. E.; Doyle, A. G.; Jacobsen, E. N. J. Am. Chem. Soc. 2008, 130, 7198. 
6. (a) Denmark, S. E.; Fu, J. P. J. Am. Chem. Soc. 2000, 122, 12021.; (b) Denmark, S. E.; Fu, J. P. Org. 
Lett. 2002, 4, 1951.; (b) Denmark, S. E.; Stavengr, R. A. Acc. Chem. Res. 2000, 33, 432.; (c) Denmark, 
S. E.; Stavenger, R. A.; Wong, K. T.; Su, X. P. J. Am. Chem. Soc. 1999, 121, 4982. 
227 
 
7. (a) Sigman, M. S.; Vachal, P.; Jacobsen, E. N. Angew. Chem., Int. Ed. 2000, 39, 1279.; (b) Vachal, P.; 
Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 10012.; (c) Vachal, P.; Jacobsen, E. N. Org. Lett. 2000, 2, 
867. 
8. (a) List, B. J. Am. Chem. Soc. 2000, 122, 9336.; (b) List, B. Tetrahedron 2002, 58, 5573.; (c) List, B. J. 
Am. Chem. Soc. 2002, 124, 5656. (d) List, B.; Lerner, R. A.; Barbas, C. F., J. Am. Chem. Soc. 2000, 
122, 2395.; (e) Vignola, N.; List, B. J. Am. Chem. Soc. 2004, 126, 450. 
9. (a) Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243.; (b) Paras, 
N. A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2001, 123, 4370.; (c) Paras, N. A.; MacMillan, D. W. C. 
J. Am. Chem. Soc. 2002, 124, 7894. 
10. (a) Ooi, T.; Kameda, M.; Maruoka, K. J. Am. Chem. Soc. 1999, 121, 6519.; (b) Ooi, T.; Kameda, M.; 
Maruoka, K. J. Am. Chem. Soc. 2003, 125, 5139.; (c) Ooi, T.; Takeuchi, M.; Maruoka, K. Synthesis 
2001, 1716.; (d) Ooi, T.; Tayama, E.; Doda, K.; Takeuchi, M.; Maruoka, K. Synlett 2000, 1500.; (e) 
Ooi, T.; Uematsu, Y.; Kameda, M.; Maruoka, K. Angew. Chem. Int. Ed. 2002, 41, 1551. 
11. Westermann, B. Angew. Chem. Int. Ed. 2003, 42, 151. 
12. Northrup, A. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2002, 124, 2458. 
13. Wilson, R. M.; Jen, W. S.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 11616. 
14. Jen, W. S.; Wiener, J. J. M.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 9874. 
15. Paras, N. A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2001, 123, 4370. 
16. Marigo, M.; Franzen, J.; Poulsen, T. B.; Zhuang, W.; Jorgensen, K. A. J. Am. Chem. Soc. 2005, 127, 
6964. 
17. Kunz, R. K.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 3240. 
18. Yang, J.; Fonseca, M. T. H.; List, B. Angew. Chem. Int. Ed. 2004, 43, 6660. 
19. Yang, J.; Fonseca, M. T. H.; Vignola, N.; List, B. Angew. Chem. Int. Ed. 2005, 44, 108. 
20. The Chemistry of Enamines; Rappoport, Z., Ed.; Wiley: New York, 1994. 
 
21. Kumaragurubaran, N.; Juhl, K.; Zhuang, W.; Bogevig, A.; Jorgensen, K. A. J. Am. Chem. Soc. 2002, 
124, 6254. 
22. Enders, D.; Seki, A. Synlett 2002, 26. 
23. Betancort, J. M.; Sakthivel, K.; Thayumanavan, R.; Barbas, C. F., Tetrahedron Lett. 2001, 42, 4441. 
24. Dalko, P. I.; Moisan, L. Angew. Chem. Int. Ed. 2004, 43. 5138. 
25.  Dalko, P. I.; Moisan, L. Angew. Chem. Int. Ed. 2001, 40, 3726. 
228 
 
26. Gaunt, M. J.; Johansson, C. C. C.; McNally, A.; Vo, N. T. Drug Discov. Today 2007, 12, 8. 
27. Buckley, B. R. Annu. Rep. Prog. Chem. B Org. Chem. 2007, 103, 90. 
28. Lelais, G.; MacMillan, D. W. C. History and perspective of chiral organic catalysts. In: Mikami K, 
Lautens M (eds) New frontiers in asymmetric catalysis. Wiley, Hoboken, 2007, p 3–13. 
29. Pellissier, H. Tetrahedron 2007, 63, 9267. 
30. Denmark, S. E.; Beutner, G. L. Angew. Chem. Int. Ed. 2008, 47, 1560. 
31. Seayad, J.; List, B. Org. Biomol. Chem. 2005, 3, 719. 
32. Palomo, C.; Mielgo, A. Angew. Chem. Int. Ed. 2006, 45, 7876. 
33. Jaroch, S.; Weinmann, H.; Zeitler, K. Chem. Med. Chem. 2007, 2, 1261. 
34. Diels, O.; Alder, K. Justus Liebigs Ann. Chem. 1928, 460, 98. 
35. Corey, E. J. Angew. Chem. Int. Ed. 2002, 41, 1650. 
36. Oppolzer, W. In: Trost B, Flemming I (eds) Comprehensive organic synthesis, vol 5. Pergamon, New 
York, 1991, chap 4.1. 
37. Kagan, H. B.; Riant, O. Chem. Rev. 1992, 92, 1007. 
38. Dias, L. C. J. Braz. Chem. Soc. 1997, 8, 289. 
39. Evans, D. A.; Johnson, J. S. In: Jacobsen EN, Pfalz A, Yamamoto H (eds) Comprehensive asymmetric 
catalysis, 1999, vol 3, chap 33.1. Springer, Berlin Heidelberg New York. 
40. Kano, T.; Tanaka, Y.; Maruoka, K. Org. Lett. 2006, 8, 2687. 
41. Kano, T.; Tanaka, Y.; Maruoka, K. Chem. Asian J. 2007, 2, 1161. 
42. Gotoh, H.; Hayashi, Y. Org. Lett.  2007, 9, 2859. 
43. Pulkkinen, J.; Aburel, P. S.; Halland, N.; Jorgensen, K. A. Adv. Synth. Catal. 2004, 346, 1077.  
44. Halland, N.; Aburel, P. S.; Jorgensen, K. A. Angew. Chem., Int. Ed. 2004, 43, 1272.  
45. Yamaguchi, M.; Shiraishi, T.; Hirama, M. J. Org. Chem. 1996, 61, 3520.  
46. Halland, N.; Hazell, R. G.; Jorgensen, K. A. J. Org. Chem. 2002, 67, 8331.  
47 Hanessian, S.; Pham, V. Org. Lett. 2000, 2, 2975.  
48. Halland, N.; Aburel, P. S.; Jorgensen, K. A. Angew. Chem. Int. Ed. 2003, 42, 661. 
49. Selkälä, S. A.; Koskinen, A. M. P. Eur. J. Org. Chem. 2005, 1620. 
 
50. Ishihara, K.; Nakano, K. J. Am. Chem. Soc. 2005, 127, 10504. 
 
51. Sakakura, A.; Suzuki, K.; Nakano, K.; Ishihara, K. Org. Lett. 2006, 8, 2229. 
52. Sakakura, A.; Suzuki, K.; Ishihara, K. Adv. Synth. Catal. 2006, 348, 2457. 
229 
 
53. Singh, R. P.; Bartelson, K.; Wang, Y.; Su, H.; Lu, X.; Deng, L. J. Am. Chem. Soc. 2008, 130, 2422. 
54. Harmata, M.; Ghosh, S. K.; Hong, X.; Wacharasindhu,; Kirchhoefer, P. J. Am. Chem. Soc. 2003, 125, 
2058. 
55. Tufariello, J. J. In: Padwa A (ed) 1, 3-Dipolar cycloaddition chemistry, vol 2. Wiley,Chichester, 1984, 
p 83. 
56. Torssell, K. B. G. Nitrile oxides, nitrones and nitronates in organic synthesis. VCH, Weinheim, 1988. 
57. Gothelf, K. V.; Jørgensen, K. A. Chem. Rev. 1998, 98, 863. 
58. Pellissier, H. Tetrahedron 2007, 63, 3235. 
59. Coldham, I.; Hufton, R. Chem Rev 2005, 105, 2765. 
60. Huisgen, R. Angew. Chem. Int. Ed. 1963, 2, 633. 
61. Synthetic Applications of 1, 3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural 
Products, (Eds: A. Padwa, W. H. Pearson), John Wiley & Sons, Inc.,Hoboken, 2003. 
62. Braida, B.; Walter, C.;, Engels, B.; Hiberty, P. C. J. Am. Chem. Soc. 2010, 132, 7631. 
63. Hartmann, P.; Manfred, H. Angew. Chem. 1989, 28, 126. 
64. Takahisa, M.; Junko, O.; Junpei, T.; Toshio, H.; Shinichi, Y.;Tsutomu, M. J. Am. Chem. Soc. 2003, 
125, 14446.  
65. Huisgen, R. Pure & Appl. Chem. 1980, 52, 2283. 
66. Curtius, T. Ber. Dtsch. Chem. Ges. 1883, 2230. 
67. Buchner, E. Ber. Dtsch. Chem. Ges. 1888, 2637. 
68. Huisgen, R. Angew. Chem. Intel. Ed., 1963, 2, 565. 
69. Coldham, I.; Hufton, R. Chem. Rev. 2005, 105, 2765. 
70. Gothelf, K. V.; Jørgensen, K. A. Chem. Rev. 1998, 98, 863. 
71. Huisgen, R. J. Org. Chem.1976, 41, 403. 
 
72. Fireston, R. J. Org. Chem 1968, 33, 2285.  
 
73. Houk, K. N.; Gonzales, J.; Li, Y. Acc. Chem. Res., 1995, 28, 81. 
74. Fleming, I. Frontier Orbitals and Organic Chemical Reactions, John Wiley & Sons, 1976. 
75. Sustmann, R. Pure Appl. Chem. 1974, 40, 569.  
76. (a) Sustmann, R. Tetrahedron Lett. 1971, 29, 2717.; (b) Bastide, J.; Henri-Rousseau, N. C. O. 
Tetrahedron Lett. 1972, 41, 4225. (c) Houk, K. N. Accts. Chem. Res. 1975, 8, 361. 
230 
 
77. (a) Barluenga, J.; Valdes, C.; Beltran, G.; Escribano, M.; Aznar, F. Angew. Chem. Int.Ed. 2006, 45, 
6893. (b) Barluenga, J.; Valdes, C.; Beltran, G.; Escribano, M.; Aznar, F. Angew. Chem. Int. Ed. 2006, 
118, 7047. 
78. (a) Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, K. B. Fokin, V. V. J. 
Am. Chem. Soc. 2005, 127, 210.; (b) Bock, V. D.; Hiemstra, H.; van Maarseveen, J. H. Eur. J. Org. 
Chem. 2006, 51. 
79. Karlsson, S.; Högberg, H. E. Tetrahedron Asymmetry 2002, 13, 923. 
80. Karlsson, S.; Hogberg, H. E. Eur. J. Org. Chem. 2003, 2782. 
81. Chow, S. S.; Nevalainen, M.; Evans, C. A.; Johannes, C. W. Tetrahedron Lett. 2007, 48, 277. 
82. Chen, W.; Yuan, X. H.; Li, R.; Du,W.; Wu, Y.; Ding, L. S.; Chen, Y. C. Adv. Synth. Catal. 2006, 348, 
1818. 
83. Vicario, J. L.; Reboredo, S.; Badía, D.; Carrillo, L. Angew. Chem. Int. Ed. 2007, 46, 5168. 
84. Chen, W.; Du, W.; Duan, Y. Z.; Wu, Y.; Yang, S. Y.; Chen, Y. C. Angew. Chem. Int. Ed. 2007, 46, 
7667. 
85. Lee, J. T. D.; Gao, Y. J.; Li, M. G.; Huang, Y.; Wang, J. J. Chem. Eur. J. 2011, 17, 3584. 
86. Selected examples of biologically active pyrazoles: (a) β-Adrenergic blocking activity: Large, M. S.; 
Smith, L. H. J. Med. Chem. 1982, 25, 1417.; (b) antipsychotic activity: Wise, L. D.; Butler, D. E.; 
DeWald, H. A.; Lustgarten, D. M.; Pattison, I. C.; Schweiss, D. N.; Coughenour, L. L.; Downs, D. A.; 
Heffner, T. G.; Pugsley, T. A. J. Med. Chem. 1987, 30, 1807.; (c) Insecticidal activity: Finkelstein, B. 
L.; Strock, C. J. 49 Pestic. Sci. 1997, 50, 324.; (d) Herbicidal activity: Parlow, J. J. J. Heterocycl. Chem. 
1998, 35, 1493.; (e) Cannabinoid receptor agonists and antagonists: Lan, R.; Liu, Q.; Fan, P.; Lin, S.; 
Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769.; (f) 
Review: Elguero, J. in Comprehensive Heterocyclic Chemistry; Katritzky, A. R.; Rees, C. W. E.; 
Scriven, F. V. Eds.: Pergamon Oxford, 1996; Vol 5. 
87. (a) Elguero, J.; Goya, P.; Jagerovic, N.; A.; Silva, M. S. Targets in Heterocyclic Systems–Chemistry and 
Properties, 2002, 6, 52.; (b) Shen, D.; Shu, M.; Chapman, K. T. Org. Lett. 2000, 2, 2789.; (c) Deng, X.; 
Mani, N. S. Org. Lett. 2008, 10, 1307. 




89. (a) Yet L. in Comprehensive Heterocyclic Chemistry III, Vol. 4 (Eds.: A. R. Katritzky, C. A. Ramsden, 
E. F. V. Scriven, R. J. K. Taylor), Elsevier, Oxford, 2008, p. 1; (b) Stanovnik,B.; Svete, J. Science of 
Synthesis, Houben-Weyl Methods of Molecular Transformations, Vol. 12, Thieme, Stuttgart, 2002, 
Category 2, chap. 12.1, p. 15.; (c) Stanovnik, B.; Svete, J. Chem. Rev. 2004, 104, 2433.; d) 
Gerstenberger, B. S.; Rauckhorst, M. R.; Starr, J. T. Org. Lett. 2009, 11, 2097. 
90. Selected examples of pyrazole synthesis by nucleophilic substitution and transition metal catalyzed C-N 
bond formation: (a) Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. J. Org. Chem. 2004, 69, 
5578.; (b) Goikhman, R.; Jacques, T. L.; Sames, D. J. Am. Chem. Soc. 2009, 131, 3042.; (c) Zhu, L.; 
Guo, P.; Li, G.; Lan, J.; Xie, R. You, J. J. Org. Chem. 2007, 72, 8535.; (d) Xi, Z.; Liu, F.; Zhou, Y.; 
Chen, W. Tetrahedron 2008, 64, 4254.; (e) Cristau, H. J.; Cellier, P. P.; Spindler, J. F.; Taillefer, M. Eur. 
J. Org. Chem. 2004, 695. 
91 (a) Kotali, A.; Papageorgiou, V. P. J. Chem. Soc. Perkin Trans. 1 1985, 2083.; (b) Hansen, J. F.; Kim, Y. 
I.; Griswold, L. J.; Hoelle, G.W.; Taylor, D. L.; Vietti, D. E. J. Org. Chem. 1980, 45, 76.; (c) Gnichtel, 
H.; Boehringer, U. Chem. Ber. 1980, 113, 1507; (d) Barluenga, J.; López-Ortiz, J. F.; Gotor, V. J. Chem. 
Soc. Chem. Commun. 1979, 891.; (e) Barluenga, J.; Tomás, M.; López-Ortiz, J. F.; Gotor, V. J. Chem. 
Soc. Perkin Trans. 1 1983, 2273.; (f) Stephanidou-Stephanatou, J. J. Heterocycl. Chem. 1985, 22, 293.; 
(g) Chun, S. Y.; Lee, K. K.; Ko, Y. O.; Shin, H.; Lee, S. Chem. Commun. 2008, 5098.; (h) Manferdini, 
M.; Morelli, C. F.; Veronese, A. C. Heterocycles 2000, 53, 2775. 
92. Bowden, K.; Jones, E. R. H. J. Chem. Soc., 1946, 953. 
93. (a) Kende, A. S.; Journet, M. Tetrahedron Lett. 1995, 36, 3087.; (b) Mass, G.; Gettwert, V. Tetrahedron, 
2000, 56, 4139. 
94. Examples of pyrazole synthesis via Lewis acid or metal catalyzed [3+2] cycloaddition, see: (a) Jiang, N.; 
Li, C. J. Chem. Commun. 2004, 394.; (b) Kende, A. S.; Journet, M. Tetrahedron Lett. 1995, 36, 3087.; 
(c) Maas, G.; Gettwert, V. Tetrahedron 2000, 56, 4139. 
95. (a) Qi, X. B.; Ready, J. M. Angew. Chem. 2007, 119, 3306.; Angew.Chem., Int. Ed. 2007, 46, 3242.; (b) 
He, S.; Chen, L.; Niu, Y. N, Wu, L.Y. Liang, Y.M. Tetrahedron Lett. 2009, 50 2443. 
96. (a) Minoprio, P.; Berneman, A.; Blondel, A. Eur. Pat. Appl., 2272510, 2011.; (b) Skinner, P. J.; 
Cherrier, M. C.; Webb, P. J.; Shin, Y. J.. Gharbaoui, T.; Lindstrom, A.; Hong, V.; Tamura, S. Y.; Dang, 
H. T.; Pride, C. C.; Chen, R.; Richman, J. G.; Connolly, D. T.; Semple, G. Bioorg. Med. Chem. Lett. 
2007, 17, 5620. 
232 
 
97. Rengarajan, B.; Seetharaman, M. Chem. Commun. 2011, 47, 11143. 
98. William, R. M. J. Am. Chem. Soc. 1969, 91, 1135. 
99. Xiang, S. K.; Zhang, B.; Zhang, L.; H.; Jiao, N. Chem. Commun. 2011, 47, 8097. 
100. Armando, C.; Mauro, M.; Chris, N.; Aitor, L.; Karl, A. J. Chem. Commun. 2006, 47, 4928. 
101. Leslie C.; Andrew D. H. J. Chem. Soc. Perkin Trans. 1. 1992, 15, 1929-1937. 
 
102. For reviews and books: see: (a) Dalko, P. I.; Moisan, L. Angew. Chem. 2001, 113, 3840.; Angew. 
Chem., Int. Ed. 2001, 40, 3726.; (b) Benaglia, M.; Puglisi, A.; Cozzi, F. Chem. Rev. 2003, 103, 3401.; 
(c) Berkessel, A.; GrMger, H. Metal-Free Organic Catalysts in Asymmetric Synthesis, Wiley-VCH, 
Weinheim, 2004.; (d) „„Special Issue: Asymmetric Organocatalysis‟‟, Acc. Chem. Res., 2004, 37, 487.; 
e) Dalko, P. I.; Moisan, L. Angew. Chem. 2001, 116, 5248.; Angew. Chem., Int. Ed. 2004, 43, 5138.; (f) 
Mohr, J. T.; Krout, M. R.; Stoltz, B. M. Nature, 2008, 455, 323.; (g) MacMillan, D. W. C. Nature, 
2008, 455, 304; (h) Berkessel, A.; Groger, H. Asymmetric Organocatalysis, Wiley, Weinheim, 2005; (i) 
Dalko, P. I. Enantioselective Organocatalysis, Wiley, Weinheim, 2007.; (j) Reetz, M. T.; List, B.; 
Jaroch, S.; Weinmann, H. Organocatalysis, Springer, 2007.; (k) List, B. Asymmetric Organocatalysis, 
Springer, 2009. 
103. Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Chem. Rev. 2007, 107, 5471. 
104. For selected reports and reviews: see: (a) Kharb, R.; Sharma, P. C.; Yar, M. S. J. Enzyme Inhib. Med. 
Chem. 2011, 26, 1.; (b) Bohacek, R. S.; McMartin, C.; Guida, W. C. Med. Res. Rev. 1996, 16, 3.; (c) 
Meldal, M.; Tornoe, C. W. Chem. Rev. 2008, 108, 2952.; (d) Angell, Y. L.; Burgess, K. Chem. Soc. 
Rev., 2007, 36, 1674.; (e) Pagliai, F.; Pirali, T.; Grosso, E. D.; Brisco, R. D.; Tron, G. C.; Sorba, G.; 
Genazzani, A. A. J. Med. Chem. 2006, 49, 467.; (f) Lee, T.; Cho, M.; Ko, S.Y.; Youn, H. J.; D. Baek, J.; 
Cho, W. J.; Kang, C. Y.; Kim, S. J. Med. Chem. 2007, 50, 585.; (g) Smith, G.; Glaser, M.; Perumal, M.; 
Nguyen, Q. D.; Shan, B.; Arstad, E.; Aboagye, E. O. J. Med. Chem. 2008, 51, 8057.; (h) Yim, C. B.; 
Dijkgraaf, I.; Merkx, R.; Versluis, C.; Eek, A.; Mulder, G. E.; Rijkers, D. T. S.; Boerman, O. C.; 
Liskamp, R. M. J. J. Med. Chem. 2010, 53, 3944.; i) Pisaneschi, F.; Nguyen, Q. D.; Shamsaei, E.; 
Glaser, M.; Robins, E.; Kaliszczak, M.; Smith, G.; Spivey, A. C.; Aboagye, E. O. Bioorg. Med. Chem. 
2010, 18, 6634.; (j) Imperio, D.; Pirali, T.; Galli, U.; Pagliai, F.; Cafici, L.; Canonico, P. L.; Sorba, G.; 
Genazzani, A. A.; Tron, G. C. Bioorg. Med. Chem. 2007, 15, 6748.; k) Carvalho, P.; Andrade, V. L.; 
Campo, P. M. M.; Guedes, R.; Si-Costa, J . S.; Silva, S.; Schenkman, S.; Dedola, L.; Hill, M.; 
Nepogodiev, S. A.; Field,R. A. Bioorg. Med. Chem. 2010, 18, 2412.; (l) Saito, Y.; Escuret, V.; 
233 
 
Durantel, D.; Zoulim, F.; Schinazic, R. F.; Agrofoglio, L. A. Bioorg. Med. Chem. 2003, 11, 3633.; (m) 
Somu, R. V.; Boshoff, H.; Qiao, C.; Bennett, E. M.; Barry, C. E.; Aldrich, III, C. C. J. Med. Chem. 
2006, 49, 31.; (n) Tripathi, R. P.; Yadav, A. K.; Ajay, A.; Bisht, S. S.; Chaturvedi, V.; Sinha, S. K. Eur. 
J. Med. Chem. 2010, 45, 142.; (o) Vatmurge, N. S.; Hazra, B. G.; Pore, V. S.; Shirazi, F.; Chavan, P. S.; 
Deshpande, M. V. Bioorg. Med. Chem. Lett. 2008, 18, 2043.; (p) Phillips, O. A.; Udo, E. E.; Abdel-
Hamid, M. E.; Varghese, R. Eur. J. Med. Chem. 2009, 44, 3217.; (q) Stensbøl, T. B.; Uhlmann, P.; 
Morel, S.; Eriksen, B. L.; Felding, J.; Kromann, H.; Hermit, M. B.; Greenwood, J. R.; Brauner-Osborne, 
H.; Madsen, U.; Junager, F.; Krogsgaard-Larsen, P.; Begtrup, M.; Vedso, P. J. Med. Chem. 2002, 45, 
19.; (r) Harrison, T.; Owens, A. P.; Williams, B. J.; Swain, C. J.; Williams, A.; Carlson, E. J.; Rycroft, 
W.; Tattersall, F. D.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Rupniak, N. M. J.; Hargreaves, R. 
J. J. Med. Chem. 2001, 44, 4296.; (s) Balle, T.; Perregaard, J.; Ramirez, M. T.; Larsen, A. K.; Søby, K. 
K.; Liljefors, T.; Andersen, K. J. Med. Chem., 2003, 46, 265.; (t) Roppe, J.; Smith, N. D.; Huang, D.; 
Tehrani, L.; Wang, B.; Anderson, J.; Brodkin, J.; Chung, J.; Jiang, X.; King, C.; Munoz, B.; Varney, M. 
A.; Prasit, P.; Cosford, N. D. P. J. Med. Chem. 2004, 47, 4645.; u) Fray, M. J.; Bull, D. J.; Carr, C. L.; 
Gautier, E. C. L.; Mowbray, C. E.; Stobie, A. J. Med. Chem. 2001, 44, 1951.; (v) Mohapatra, D. K.; 
Maity, P. K.; Shabab, M.; Khan, M. I. Bioorg. Med. Chem. Lett. 2009, 19, 5241.; (w) Gill, C.; Jadhav, 
G.; Shaikh, M.; Kale, R.; Ghawalkar, A.; Nagargoje, D.; Shiradkar, M. Bioorg. Med. Chem. Lett. 2008, 
18, 6244. 
105. (a) Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-Bakht, S. C.; Obach, R. S.; Donnell, J. P. Chem. Res. 
Toxicol. 2002, 15, 269.; (b) Horne, W. S.; Yadav, M. K.; Stout, C. D.; Ghadiri, M. R. J. Am. Chem. Soc. 
2004, 126, 15366. 
106. Garcia-Moreno, M. I.; Rodriguez-Lucena, D.; Mellet, C. O.; J. Fernandez, M. G. J. Org. Chem. 2004, 
69, 3578. 
107. For selected examples of the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles, see: (a) Spiteri, C.; Moses, 
J. E. Angew. Chem., 2010, 122, 33; Angew. Chem., Int. Ed. 2010, 49, 31.; (b) Zhou, Y.; Lecourt, T. ; 
Micouin, L. Angew. Chem., Int. Ed. 2010, 49, 2607.; (c) Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; 
Agard, N. J.; Chang, P. V.; Miller, I. A.; Lo, A.; Codelli, J. A.; C. R. Bertozzi, Proc. Natl. Acad. Sci. 
USA 2007, 104, 16793.; (d) Agard, N. J.; Prescher, J. A.; Bertozzi, C. R. J. Am. Chem. Soc. 2004, 126, 
15046.; (e) Ramachary, D. B.; Ramakumar, K.; Narayana, V. V. Chem. Eur. J. 2008, 14, 9143.; (f) 
Plass, T.; Milles, S.; Koehler, C.; Schultz, C.; Lemke, E. A. Angew. Chem., Int. Ed. 2011, 50, 3878. 
234 
 
108. Michael, A. J. Prakt, Chem. 1893, 48, 94. 
109. (a) Rodionov, V. O.; Fokin, V. V.; Finn, M. G. Angew. Chem. 2005, 117, 2250.; Angew. Chem., Int. Ed. 
2005, 44, 2210.; (b) Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtesv, V. V.; Noodleman, L.; Sharpless, K. 
B.; Fokin, V. V. J. Am. Chem. Soc. 2005, 127, 210. 
110. (a) Rostovtesv, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. J. Am. Chem. Soc. 2002, 114, 2708.; 
(b) Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057. 
111. a) Gierlich, J.; Burley, G. A.; Gramlich, P. M. E.; Hammond, D. M.; Carell, T. Org. Lett. 2006, 8, 
3639.; (b) Gaetke, L. M.; Chow, C. K. Toxicology, 2003, 189, 147.; (c) Link, A. J.; Tirrell, D. A. J. Am. 
Chem. Soc. 2003, 125, 11164. 
112. (a) Soriano del Amo, D.; Wan, W.; Jiang, H.; Besanceney, C.; Yan, A. C.; Levy, M.; Liu, Y.; Marlow, 
F. L.; Wu, P. J. Am. Chem. Soc. 2010, 132, 16893.; (b) Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, 
V. V. Org. Lett. 2004, 49, 2853. 
113. Shu, H.; Izenwasser, S.; Wade, D.; E. Stevens, D.; Trudell, M. L. Bioorg. Med. Chem. Lett. 2009, 19, 
891. 
114. Warmuth, R.; Makowiec, S. J. Am. Chem. Soc.2005, 127, 1084. 
 
 
 
 
 
 
 
 
 
 
 
 
